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Abstract
The oxidation of low density lipoprotein (LDL) is one mechanism by 
which serum cholesterol may deposit in the arterial wall causing coronary heart 
disease (CHD). Epidemiological studies have provided evidence to suggest an inverse 
relationship between the dietary intake o f flavonoids and the risk o f CHD. O f the 
many groups of flavonoids present in foods, chiefly in vegetables, fruit, tea and wine, 
the polyphenols are especially important since they have been shown to express potent 
antioxidant activities in vitro. They are particularly abundant in red wine, a high 
consumption of which has been implicated in the low mortality from CHD in 
countries such as France, giving rise to the ‘French paradox’. Despite intense interest 
in the potential health benefits of dietary polyphenols, the outcome o f studies 
addressing this issue have been largely inconclusive. The overall aim o f this study was 
to determine whether the putatively protective effects of red wine are mediated 
through an in vivo antioxidant action o f extracted red wine polyphenols and related 
foods and whether alcohol affects their biological activity. The initial objective of this 
study was to develop methods for assessing the oxidative status o f plasma and 
oxidative susceptibility of LDL. Once established, these assays were used to test a 
range of different polyphenols | for |their antioxidant potential in vitro for a
human ‘intervention trial’. The selected polyphenol supplements were then used as 
dietary supplements in a 2 week dietary intervention in healthy male volunteers. 
Measures of oxidation status and polyphenol content in plasma and LDL were 
determined before and after dietary supplementation. Supplementation with red wine 
and extracted red wine polyphenols either alone or in combination with white wine, 
alcohol, or vitamin E was associated with a significant increase in total antioxidant 
status of plasma and decrease in the oxidative susceptibility of LDL and lipid 
peroxides. It was also shown to increase the polyphenol content o f plasma and LDL, 
and total plasma TGF-B levels. From these data it can be concluded that the 
polyphenols contained within red wine and similar beverages are powerful inhibitors 
o f LDL oxidation and that alcohol promotes pro-oxidation changes in these 
parameters.
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CHAPTER 1 
Introduction
INTRODUCTION
1.1 General Introduction
In 1953, Ancel Keys, one o f the pioneers in the investigation of 
coronary heart disease (CHD), wrote, “Clinical coronary disease usually represents the 
cumulative effect o f a factor, or factors, operating over a period o f years.” He also
recognised that the major problem in prevention was “ the question o f predicting
the threat o f coronary disease” (McGill et al 1994).
Coronary heart disease (CHD) and atherosclerosis have been linked to 
diet, the excessive consumption of dietary fat, particularly saturated fatty acids, and 
serum cholesterol. This was first shown through the Seven Countries Study (Keys et 
al 1957) and later confirmed by other cross-cultural comparisons. Other dietary 
constituents have also been implicated in the initiation and development o f 
atherosclerosis and the severity of CHD. A balanced diet rich in foods o f plant origin 
can significantly retard the development o f CHD (Amtzenius et al 1985, Omish et al 
1990, Watts et al 1992). Special diets, mainly those o f vegetarian, and thus mostly low 
in fat, have been shown to lower the concentration o f atherogenic plasma lipoproteins, 
and promote the regression of CHD (Amtzenius et al 1985, Omish et al 1990). A 
Mediterranean diet with more cereals, vegetables, fruit and less saturated fats has 
recently been shown to confer rapid and exceptional protection from recurrences and 
death from CHD. In most countries there is a positive correlation between the 
consumption o f saturated fat and mortality from CHD. However, in certain parts of 
France mortality from CHD was found to be low despite a relatively high intake of 
saturated fat and semm cholesterol levels similar to the UK and USA where CHD was 
more prevalent (Renaud et al 1992). The relationship between diet and CHD is thus 
very close, but complex, because of additional nutrients, such as alcohol, natural 
antioxidants and an appropriate balance between fatty acids all o f which influence the 
development o f CHD.
Atherosclerosis can affect coronary, cerebrovascular and peripheral 
arteries. The Office of Population Censuses and Surveys (1984) reported the level of
cardiovascular related mortality as 49% of total mortality in England and Wales. In 
addition, cerebrovascular related mortality accounted for 13% and peripheral vascular 
disease 4%. However, present risk factors can only account for approximately 60% of 
CHD (Salonen et al 1981). Thus, with such a large proportion of the overall 
atherosclerosis related mortality rate unaccounted for, it is clear that alternative factors 
need to be explored.
1.2.1 Aetiology of atherosclerosis
Atherosclerosis is not merely a disease in its own right, but a process 
that is the principal contributor to the pathogenesis o f myocardial and cerebral 
infarction, gangrene and loss of function in the extremities. During their development, 
the lesions of atherosclerosis contain all o f the cellular responses that define 
inflammatory-fibroproliferative response to “injury”. Elements o f inflammation 
followed by repair in the highly specialised environment of the artery wall. The 
formation of the different lesions may be modified by the specific local characteristics 
of the artery wall, including the overlying endothelium and the ability o f the smooth 
muscle cells in the media and intima to respond to causive agents associated with the 
risk factors that result in the lesion formation. Thus, the process o f atherogenesis is not 
a degenerative one, but rather is an active process involving the specialised elements 
of chronic inflammation associated with those o f repair in the artery wall.
The following inter-related pathological processes involve a complex 
series o f interactions between the constituents o f blood, blood flow and the vessel 
wall:
a) Inflammation with increased endothelial permeability, endothelial activation and 
monocyte recruitment (on exposure of the subendothelial connective tissue, platelets 
and macrophages are able to attach to the injury site).
b) Growth with smooth muscle cell (SMC) proliferation, migration, and matrix 
synthesis (SMC proliferation is thought to be caused by the release o f platelet and 
macrophage derived growth factor. SMC seem to change from showing purely 
contractile properties to exhibiting secretgy potential).
c) Degeneration with lipid accumulation.
d) Necrosis, possibly due to cytotoxic effects of oxidised lipid.
e) Calcification/ossification that may be an active rather than a dystrophic process.
f) Thrombosis with platelet recruitment and fibrin formation. This is usually 
considered a complication of the atherosclerotic process.
1.2.2 A therosclerosis m orphology
In 1958 WHO defined atherosclerosis as “a variable combination of 
changes in the intima of arteries consisting of a focal accumulation o f lipids, complex 
carbohydrates, blood products, fibrous tissue and calcium deposits.”
The striking feature of atherosclerosis is the massive accumulation of esterified 
cholesterol that forms the core of the arthermatous plaque. In fact the name 
“atheroma” itself stems from the Greek word meaning gruel; which was first used by 
pathologists in the 18th century to describe a thickened area in the wall of a major 
artery that on sectioning exuded a yellow gruel like lipid that we now know to be 
nearly pure cholesteryl ester (Goldstein et al 1977).
Fig. 1.1: Distribution of LDL across arterial wall
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Although diverse factors, such as smoking, high blood pressure, 
diabetes mellitus, and elevated blood lipid can accelerate the development of 
atheromata in man, in each case the advanced pathologic lesion is remarkably similar. 
It consists o f plaque like thickening of the intima and media, the innermost and 
middle of the three layers of artery wall. This intimal-middle thickening is due to an 
accumulation of proliferating smooth muscle cells surrounded by interstitial substance 
that includes collagen, elastin, glycosaminoglycans and fibrin. However, the substance
that gives the atheroma its menacing character is the lipid, chiefly cholesteryl ester, 
which deposit in massive amounts both in the interstitial space surrounding the 
smooth muscle cells; and within smooth muscle cells themselves (See Fig. 1.1). Many 
of the latter are so swollen with droplets o f cholesteryl esters that their cytoplasm 
appears vacuolated and they are termed as “foam” cells. Animal observations have 
shown that fatty streaks precede the development o f intermediate lesions, which are 
composed of layers o f macrophages & smooth muscle cells and in turn, develop into 
the more advanced, complex, occlusive lesions called fibrous plaques. The fibrous 
plaques increase in size and by projecting into the arterial lumen, may impede the flow 
o f blood. They are covered by a dense cap of connective tissue with embedded smooth 
muscle cells that usually overlay a core of lipid and necrotic debris. The fibrous 
plaques contain monocyte-derived macrophages, smooth muscle cells and T- 
lymphocytes, many o f which are activated. The key process in the formation of the 
fibrous plaque seems to be the proliferation of smooth muscle cells in the intima 
which are originally derived from the media (Castellot et al 1982).
1.2.3 Outcome of Atherosclerosis
Atherosclerosis produces alterations in the size o f the arterial lumen. 
Vessels such as the aorta widen as a result of their walls being weakened. Widening 
can result in elongation, bending and twisting of the vessels or even bulging at weak 
spots producing an aneurysm. Smaller vessels, such as the coronaries, narrow due to 
the bulging out of the lesions into the lumen space. This may not be deleterious if  the 
development is slow enough for the collateral circulation to extend its vessels into the 
area of the oxygen deprived tissue. However, if  severe it can lead to angina and 
ischaemic heart disease (IHD).
Thrombosis can occur in severely atherosclerotic arteries. When a 
small and flat thrombus forms in a large artery over the surface o f an atheromatous 
lesion there is no serious interference with the flow o f blood. If the thrombi are large 
enough to occupy the entire lumen, for example in the coronary artery, then blockage 
causes disastrous tissue necrosis and results in the clinical condition called myocardial
infarction, which is often fatal. Extensive damage to the arterial wall may result in its 
rupture, leading to haemorrhage into the surrounding body cavity.
1.3 Risk factors for Atherosclerosis
A risk factor is defined by common usage as any measurable trait or 
characteristic of an individual that predicts that individual’s probability o f developing 
clinically manifest disease. The definition is broad and does not necessarily imply a 
casual relationship. A number o f factors have emerged consistently from experimental 
and epidemiological studies as predictors o f IHD morbidity and mortality (See Fig. 
1.2). The main factors include blood lipids, age, hypertension, genetic influences, 
diabetes, abnormal BCG (electrocardiographs), smoking, and lack o f exercise 
(Hopkins et al 1981).
Figure 1.2: Risk factors
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Complex mathematical models such as logistical & multivariate 
analyses are required to untangle the effect o f independent factors such as serum 
cholesterol level, triglyceride levels, fatty acid intake, hypertension, diabetes mellitus, 
and smoking, when all are having an effect at the same time. Consequently risk factors 
are helpful but cannot be seen to tell the whole story (Shaper et/at\^%l').
1.3.1 Diabetes
Diabetes in both men and women o f any age increases susceptibility to 
IHD. A multivariate analysis of the other atherogenic traits indicates that diabetes is an 
important factor with a doubling of mortality risk when present. The risk o f IHD is 
inherently greater in the presence o f glucose intolerance and independent o f the levels 
of total cholesterol and its components, body weight, cigarette smoking and systolic 
blood pressure.
The nature o f CHD risk in diabetes is not fully understood. However, 
glucose intolerance has been shown to result in damage to small blood vessels and 
impairment o f myocardial function. Raised atherosclerotic lesions in the aorta, 
coronary, and cerebral arteries were originally shown to be more extensive in 
hypertensive and diabetic persons than in those without hypertension and diabetes in 
all populations (Robertson et al 1968). These results were later confirmed by WHO 
(Matova et al 1976, Zdanov et al 1976), by Reaven et al (1988) and Zavaroni et al 
(1989).
1.3.2 Hypertension
High blood pressure has been shown to be directly involved with the 
incidence o f IHD and stroke. Re-evaluation of the Framingham and other study data 
points to high blood pressure having an association that is five times greater than 
previously found (Macmahon et al 1990). In addition to contributing potentially to 
cardiovascular mortality, hypertension is a common precursor o f cardiovascular 
disease (Kannelp / j f 1976).
1.3.3 Alcohol
Possible pathophysiological mechanisms for the effect o f alcohol on 
CHD were explored in the Lipid Research Clinics (LRC) study (Langer et al 1992). 
These data suggested that the beneficial effect of alcohol on CHD was in part 
mediated through high density lipoprotein (HDL) cholesterol, low density lipoprotein 
(LDL) cholesterol and systolic blood pressure. Systolic blood pressure gained more
support as a better predictor of coronary heart disease and stroke (Fisher et al 1985). 
Both excess alcohol and the use of contraceptives are known to increase levels of 
triglycerides (TG) in blood. Raised serum TG and its related abnormalities in 
lipoproteins provides the most coherent metabolic link between blood pressure, 
smoking, diet, and BMI to CHD risk. More recently it has been suggested that raised 
serum TG and its related abnormalities in serum lipoprotein provides link to CHD 
(Austin et a l \9 9 \ ,  Kesaniemi et al 1998) (see Fig. 1.4).
1.3.4 Blood lipids
Results from the Multiple Risk factor Intervention Trial relating 10 
year mortality rates from CHD to plasma cholesterol concentrations were included in 
the 1990 National cholesterol Education program and serves as a “gold standard” for 
predicting CHD mortality. More recently, Gronbaek et al (1995) found that the ‘U 
shape’ mortality curve persisted after correction o f the effects o f other risk factors, 
such as smoking and obesity. Serum cholesterol measurements are very useful in 
predicting heart disease risk. In Britain the concentration o f serum total cholesterol in 
middle aged men is considerably higher than that found in middle aged Americans 
(Shaper et al 1985), placing the former at considerably higher risk. Those such 
concentrations carry a twofold risk of IHD compared with lower concentrations. The 
development o f precipitation methods for measuring HDL and LDL cholesterol, 
(Rudel et al 1977) facilitated measurement o f lipoprotein cholesterol in large 
populations. In longitudinal studies, LDL cholesterol was shown to be directly 
associated with CHD, whilst HDL cholesterol was inversely associated with CHD 
(Davis et al 1990, Grundy 1991). Miller et al (1998) evaluated long-term 
predictors o f coronary events in men and women in their ‘BCOLTS’ study (Baltimore 
Coronary Observational Long-Term Study). They showed that the mean HDL 
cholesterol was significantly lower (P= 0.002) and TGs higher (P=0.03) in case 
patients than in control. Risk factors for elevated levels o f oxidised LDL are not well 
established and may be important in identifying individuals who may benefit from 
antioxidant supplementation or intervention to reduce oxidant stress. Mosca et al 
(1997) evaluated the relation between clinical parameters and oxidised LDL in 45 
non-smoking, nondiabetic patients with CAD, data shows a positive correlation
between the two. In recent years, many investigations in experimental animals and in 
vitro systems have provided insights into the mechanisms whereby elevated serum 
LDL promotes atherogenesis. Data from the LRC follow-up study demonstrated that 
TG related to 12-year CAD mortality in both men and women. The Scandinavian 
Simvastatin Study (4S 1994) was the first trial to show that effective treatment o f 
hypercholesterolemia decreases total and CAD mortality without affecting 
noncardiovascular mortality. Recent, clinical trials (Sacks et al 1996, Ericcson et al 
1996) documented that use o f drug therapy to decrease levels o f serum LDL markedly 
decreases the incidence o f CAD. Shepherd et al (1995) in their ‘WOSCOPS’ study 
demonstrated the effectiveness o f ‘Pravastatin’(cholesterol lowering drug), in reducing 
cholesterol levels thereby reducing risk of coronary events in asymptomatic subjects 
with hypercholesterolemia. Thus, LDL cholesterol is the major serum cholesterol 
fraction linked to coronary atherosclerosis.
A positive relationship exits between serum triglyceride levels and risk 
of CHD by univariate analysis (Austin et al 1991). Meta analysis o f data from 
population based prospective studies has demonstrated that plasma TG is an 
independent risk factor for CAD (Hokanson et al 1996). Recently, Austin et al (1998) 
confirmed that increase TG was associated with a 32% in men and 76% in women 
increase in risk of CVD. After adjustment for HDL cholesterol and other risk factors, 
these risks were decreased to a 14% & 37% increase in men and women respectively, 
and remained statistically significant.
1.3.5 Smoking
Cigarette smoking is one o f the strongest predictors o f coronary disease
and occlusive peripheral arterial disease ( S h a p e r 1987). The association between 
CHD and cigarette smoking could also be the result o f a direct influence on 
thrombosis or on the myocardium and its neuromuscular system (Bekheit et al 1976). 
A clinical intervention trial with a normotensive, high risk group in the Oslo study 
(Hijermann et al 1981), showed that a change in diet and reduction in smoking led to 
serum cholesterol lowering.
Fig. 1.3: Consequences of cigarette smoking on the plasma
Cigarette
smoking
Hypoxia
Accelerates
atherosclerosis
Increases LDL 
oxidation
Enhance platelet 
aggregation
Inhibits prostacyclin 
synthesis
Decreases plasma 
antioxidant vitamins
After five years, the morbidity and mortality of CHD was significantly 
lower in the intervention group than in the control group. The mortality from CHD has 
been reduced in the United States during the last 10-15 years; at the same time, serum 
cholesterol levels and smoking have declined.
The nicotine content o f cigarettes enhances the oxidation o f LDL and 
decreases plasma antioxidant vitamins. Increased platelet adhesion, injuries to arterial 
endothelium and lowering o f HDL cholesterol are additional effects that have been 
shown to be associated with smoking ( M c G i l l 1979). Smoking also produces 
nutritional differences which are more powerful than the effects o f social class such as 
intake of fibre and polyunsaturated fatty acids (Fulton et al 1988).
1.3.6 Body Mass Index
Obesity is one of the most plausible, yet inconsistent, o f all the 
suspected risk factors for CHD. Results from both longitudinal and case-control 
studies have demonstrated a positive and independent relationship between weight and 
CHD, a univariate relationship which disappears when hypertension, diabetes, and 
serum cholesterol levels are included in a multivariate analysis. Body mass index does 
not emerge as an independent risk factor, but it is linked to increased blood pressure, 
serum cholesterol and development of diabetes (Shaper et^qt 1987). Exercise o f even 
moderate degree has been found to have a protective effect against CHD in young and 
old men, as shown by data from the Framingham Cohort (Karmel et al 1979). In WHO 
study obese people had more coronary atherosclerosis, coronary stenosis, and 
myocardial lesions than thin people (BMI<30)(see Fig. 1.4).
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1.3.7 Genetic factors
CHD occurring in younger persons, has long been recognised as a 
familial problem. Genes may contribute up to 50% of the variation in the incidence 
of CHD. The first step in explaining the physiological basis of familial aggregation 
was the identification of individuals with very high serum cholesterol levels, a 
syndrome transmitted as an autosamal dominant trait that became known as familial 
hypercholesterolemia. This condition was ultimately traced to a defect in the LDL 
receptor gene (Brown et al 1975). Diseases with a multi-factorial aetiology arise as a 
result of interactions between different genes (gene-gene) and the environmental (diet- 
gene) (Cullen et al 1998).
1.3.8 Physical activity and exercise
Moderate physical activity has favourable affects on HDL cholesterol, 
blood pressure, body weight, and insulin resistance, all mechanisms by which it may 
reduce risk of CHD. Exercise may also protect against myocardial infarction directly, 
as it is important in the regulation of cardiac function by increasing cardiac output and 
overall cardiopulmonary efficiency (Powell et al 1987).
Fig.1.4 Link between risk factors and CHD.
Triglycerides 
Reverses ALP i
Physical activity or exercise
LDL size ^
[rriglyceridesi^
LDL particle N'
Very high risk of CHD
\
(Smokin^
Atherogenic lipoprotein phenotype, - |— (^ H D ljjl
\Small, dense oxidatively susceptible LDI
Insulin resistant dyslipidaemia I
Increased synthesis 
o f  lipoproteins
B M I^, saturated fatty
Genes major determinant^ (  Diabetes) (^ypertensic^
acids, alcohol
of inter resistance 
dislipidaemia
■ Oxidised LDL
( ~ \ t  Nitric oxidM 
\re lease /
11
1.4 Blood lipids and the Lipid hypothesis
The lipid hypothesis proposes that dietary fat promotes an increase in 
serum lipid levels and LDL which causes disease. In cross-cultural studies, migrant 
Japanese have also been employed to show the increased in IHD mortality with 
respect to lipids. Japanese from Japan, Hawaii and California show successively 
higher IHD mortality rates together with raised plasma total cholesterol (Robertson et 
al 1977). Recently, however a number o f papers have questioned the hypothesis and 
brought to light some disturbing facts. Cliff et al (1987) details a number of instances 
where the diagnosis of IHD had an error of 50% or more. Intervention studies 
(Hijermann et al 1981) where a successful reduction in smoking, serum cholesterol 
and hyper tension were achieved but not a reduction in the mortality or morbidity of 
IHD and subsequent publications of the data failed to mention these inconsistent 
findings.
1.5 Lipoprotein B iochem istry  
1.5.1 The structure of LDL
Fig. 1.5: Structure of LDL
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LDL, the main earrier of cholesterol in the body, 
is a spherical particle with a diameter o f about 
22nm and an average molecular weight of 2.5 
million. LDL is composed of: 
phospholipids 20-40%,
free cholesterol 9-10%,
cholesteryl esters 40-44%,
triglycerides 3-5%, and
protein 21-26%.
The neutral lipids (Cholesteryl esters, triglycerides) form a hydrophobic core which is 
surrounded by a surface monolayer coat of phospholipids and cholesterol. The only 
protein present in LDL is apolipoprotein B-100. Embedded in the monolayer is a large 
protein, apolipoprotein B-100, with a molecular weight of about 550kDa. The outer 
monolayer on average consists of 700 molecules of phopholipids and 600 molecules 
of cholesterol, whereas the interior core is composed of 1600 molecules of cholesteryl 
ester and 100 molecules of triglyceride. The total number of fatty acid molecules
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bound in the different lipid classes is 2700 on average, of which about half are 
polyunsaturated fatty acids (PUFAs).
Serum levels of LDL depend on the metabolism of apo B (Fig. 1.6). Three 
parameters of apo B metabolism affect LDL levels. These are 
A rate of product and secretion (VLDL),
A fractional conversion rate VLDL —> LDL, and
4 fractional catabolic rate (LDL receptors + other mechanisms {non-receptor 
mediatry}).
Another factor affecting LDL-cholesterol levels is the amount of 
cholesterol carried in each LDL particle. Only one molecule of apo B is present per 
LDL particle, but the quantity of cholesterol per particle can vary considerably. 
Normal people have about 1.5 times the mass of cholesterol per LDL particle as apoB. 
Fig. 1.6: The metabolism of chylomicrons and VLDL, LDL, IDL.
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Cholesterol is completely insoluble in aqueous solutions, so it is 
complexed with other polar lipids and apoproteins, forming macromolecular 
complexes called lipoproteins. There are several major classes of lipoproteins that 
traditionally distinguished by their densities. In normal healthy persons, about two- 
thirds of the total cholesterol is carried in LDL.
1.5.2 LDL anti-oxidants
In general, lipid composes 75% of the mass of the LDL particle and 
protein makes up 25%.
13
L i p i d  C o m  p o n e n t
Ç h o i e s t e r o l  e s t e r s P h o s p h o l i p i d s
p h o s p h a t i d y l c h o l i n e  S p h i n g o m y e l i n
L i n o l e a t e  O l e a t e  P a l m  i t a t e  S t e a r a t e  P a l m  i t o l e a t e  A r c h i d o n a t e
LDL contains several lipophilic endogenous antioxidants which protect 
its PUFA from oxidation (Esterbauer et al 1992). On a molar basis the major 
antioxidant in LDL is a-tocopherol (1.03 pg/mg of LDL), the most biologically active 
tocopherol isomer, which is found in the outer phopholipid monolayer of LDL. The 
other antioxidants are present in smaller quantities and include y-tocopherol, 
carotenoids, oxycarotenoids and ubquinol-10 (Esterbauer et al 1990). On average 
there are seven antioxidant molecules per LDL particle, six of which are a-tocopherol 
with one other antioxidant, which have to protect 1200 PUFA, giving an average 
anti oxidant to PUFA ratio of 1:170.
Fig. 1.7: The lipid composition of plasma lipoproteins fractions.
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excess o f PUFA in LDL 
compared to the amount of 
endogenous antioxidants. 
When LDL is subjected to 
oxidative stress, 
peroxidation does not
immediately occur because of the presence of these endogenous antioxidants. The 
onset of peroxidation occurs once these endogenous antioxidants have been consumed 
(Jessup et al 1990, Dieber-Rotheneder et al 1991). The order o f antioxidant depletion 
in the lipoprotein occurs in the order: a-tocopherol first, followed by y-tocopherol, 
cryptoxanthin, other carotenoids and lastly P-carotene (Esterbauer et al 1989,1992).
Vitamin E operates as a potent antioxidant in cell membranes by 
breaking the chain reaction of lipid peroxidation and preventing the accumulation of 
lipid hydroperoxides. Vitamin C acts within the water soluble cellular components and 
also in the regeneration of vitamin E and glutathione.
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Within plasma, albumin, uric acid and even glucose can act 
as antioxidants (Halliwell et al 1990). The antioxidant vitamins A, E, C, 13-carotene, 
and the metal cofactors (copper, selenium) for the major antioxidant enzymes 
(glutathione peroxidase, super-oxide dismutase) are provided by dietary intake. Hence, 
to optimise the body’s antioxidant defence mechanism an adequate intake of 
appropriate nutrients is necessary. In animal models severity o f atherosclerosis as 
measured by a reduction in the number o f the lesions has been achieved by 
supplementation with vitamin A, C or E (Gey et al 1986).
1.6 LDL oxidation
The chemical events which occur when LDL is oxidised are complex 
(see Fig. 1.9). Oxidation begins when a reactive radical abstracts a hydrogen atom 
from a PUFA on the LDL particle. Lipid peroxyl and alkoxyl radicals are formed, 
which in turn can initiate oxidation in neighbouring fatty acids. In the absence of 
sufficient concentrations of antioxidants, this results in the propagation of lipid 
peroxidation. Although this process presumably begins in the PUFA of surface 
phospholipids, it then spreads to involve the bulk o f lipids in the core o f the LDL 
particle, including fatty acids in cholesteryl esters and triglycerides.
This process, leads to the formation o f highly reactive aldehydes, 
ketones, and other products, which in turn may bind to lysine and anginine residues of 
the apolipoprotein B moiety o f LDL. These lipid-lysine adducts change the charge on 
the LDL and believed to form the epitopes that are recognised by scavenger receptors 
on macrophages. All o f these reactions lead to a marked alteration in the structure of 
LDL. They also generate a variety of new compounds, many o f which are sufficiently 
polar to leave the LDL particle and which appear to have atherogenic properties.
LDL is able to penetrate the endothelium o f arterial walls and may 
become oxidised in the space between the endothelial layer and the smooth muscle 
layer, known as the intima (subendothelial space), away from the protection of 
circulating antioxidants (see Fig 1.8).
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Fig. 1.8: The oxidation and uptake of LDL.
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Oxidation of LDL may occur as a result o f low antioxidant defences in 
this microenvironment, where water soluble antioxidants could be destroyed by 
oxygen radicals released from inflammatory cells (Esterbauer et al 1992) and potent 
intracellular antioxidants such as glutathione peroxidase are probably denied access to 
the lipoprotein. The oxidation of LDL appears to be essential before its uptake by 
monocyte-derived macrophages via scavenger receptor circulating antioxidants (see 
Fig. 1.8). Such oxidation of LDL appears to be essential before uptake by 
monocyte-derived macrophages via scavenger receptor-mediated endocytosis.
Oxidised LDL is believed to play a major role in the formation of fatty 
streaks, the earliest lipid deposits which is believed to form just beneath the 
endothelium of the aorta and other major arteries (Fig. 1.10). These lipid deposits are 
formed when blood monocytes (macrophages) migrate through the endothelium, 
engulf lipid and become engorged (“foam cells”). Oxidised LDL is taken up by 
macrophages 3-10 times more rapidly than is native LDL and, unlike native LDL can 
lead to foam cell formation. Once formed, oxidised LDL has many other potential 
atherogenic effects. Oxidised LDL increases the adherence and migration of 
monocytes, induces endothelial cell damage, and stimulates cytokine and growth 
factor release from cells present in the arterial wall.
Figure 1.9: Chemical events in LDL oxidation
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LH is a lipid containing a PUFA; the main LH species in LDL is cholesteryl linoleate. 
X* is any reactive radical able to abstract a hydrogen atom from LH; L* is a carbon 
centred lipid radical, (e.g.-CH=CH-CH=CH-*CH-); LOO’ and LO* are lipid peroxyl 
radicals and lipid alkoxyl radicals: LOOH are lipid hydroperoxides; in their 
decomposition to LO* and LOO* metal ions in both valency states (e.g., Cu^^/CiL or 
Fe^^^/Fe^^) can take part, but reaction with Cu^ or Fe^^ is thermodynamically 
favoured
There is also a growing body of evidence to show that the oxidative 
modification of LDL does indeed occur in vivo with LDL becoming 'seeded’ with 
traces of lipid peroxides (LDL 'seeded’ with lipid peroxides). Oxidised LDL has been 
identified in atherosclerotic lesions, and circulating autoantibodies to epitopes of
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oxidised LDL have been detected in the serum of patients with atherosclerosis 
(Witztum et al 1991). In addition, lipid peroxide concentrations have been found to be 
higher in subjects with atherosclerosis (Stringer et al 1989).
Fig. 1.10: Early events in the development of atherosclerosis.
GAGS: glycosaminoglycans.
M  o  n  o  c  V t e
a d h e s i o n
D  i f f e  r e  n t i t a  t i c  n
C h e m  o  t a  X IS
GAGS
M  a e r o  p h a g e
LDL
o x i d a t i o n
. F o a m  c e l l
G A G S  -  L D L
-  C  y  t o  t o  X i c  i l y
E x t r a c e l l u l a r  ^
m,  S m o o t h  m u s c l e
^  c e l l  p r o l i f e r a t i o n
Oxidation of LDL appears to influence atherogenesis by several mechanisms. 
Potential mechanisms by which oxidised LDL may be atherogenic are:-
i) Shows enhanced uptake by macrophages leading to cholesteryl ester enrichment and 
foam cell formation.
ii) Is chemotactic for circulating monocytes and T-lymphocytes (recruiting monocytes 
and T-lymphocytes into the arterial wall).
Hi) Inhibits the motility of tissue macrophages (trapping macrophages and their return 
to plasma)
iv) Is cytotoxic, (may contribute to disruption of endothelial cell integrity, 
and metalloproteinases released by activated macrophages may result in matrix 
degradation and disorganisation)
V)  Can alter gene expression of neighbouring arterial cells such as induction of 
monocyte chemoattractant protein (MCP-1 ) and monocyte colony stimulating factor 
IL-1 by cells. These cytokines will both attract monocytes to the subendothelium and 
affect their growth and differentiation into macrophages.
vi) Induces a variety of pro inflammatory genes and their products such as 
hemoxygenase (possibly mediated by nuclear factor-kB-mediated signal transduction 
pathways), and ceruloplasmin.
vii) Immunogenicity; can elicit autoantibody formation and reactive T-cells.
viii) Oxidationt renders LDL more susceptible to aggregation, which independently
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leads to enhanced macrophage uptake.
ix) Alters coagulation pathways, such as by induction of tissue factor and alteration of 
platelet aggregation.
x) Adversely effects vasomotor responses of coronary arteries (Nitric oxide-inhibitor 
release).
Thus, minimally modified forms o f LDL, (lipid is oxidised but apo-B is 
not oxidised) which are insufficiently modified to have accelerated macrophage 
uptake, may still be highly injurious to the arterial wall and proatherogenic. It is 
possible that by the time LDL becomes so extensively modified that it is recognised 
by macrophage scavenger receptors, it may have adversely affected the artery wall. 
From this perspective, uptake by macrophages may now be seen as protective, albeit 
at the expense of increased foam cell formation (Witztum et al 1994). If  this formation 
is correct, then it implies that preventing oxidation o f LDL in the first place will be of 
primary therapeutic importance.
1.6.1 Atherosclerosis and oxidised low-density lipoproteins (LDL)
The concept that oxidised lipoproteins are involved in the development 
o f atherosclerosis was formulated from the following: LDL can injure cells under 
certain conditions (Henriksen et al 1979, Hessler et al 1979), which were later shown 
to be conditions that facilitated oxidation o f the lipoprotein (Hessler et al 1983, Morel 
et al 1983); LDL modified by malondialdehyde, a product o f the oxidation of 
unsaturated fatty acids, was taken up by monocyte/macrophages via scavenger 
receptors (Schechter et al 1981); and macrophage will also take up via scavenger 
receptors LDL that was modified by cultured endothelial cells (Hemiksen et al 1981). 
Endothelial modification o f LDL was later shown to be via oxidation, mediated by 
reactive oxygen species produced by the cells (Morel et al 1984, Steinbrecher et al 
1984). Cultured smooth muscle cells, stimulated monocytes, neutrophils, and 
macrophages were shown to oxidise LDL (Parthasarathy et al 1986).
Mechanisms for LDL oxidation have been explored in depth.
Numerous products (lipid peroxides, lysolecethin and modification o f apolipoprotein- 
B) of the oxidation process have been partially identified, and their effects on oxidised 
LDL on cultured cells have been described.
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Fig. 1.11: Postulated linkage between the lipid-infiltration hypothesis and the
endothelial injury hypothesis
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The congruence of the actions o f oxidised LDL on cells with the known 
features of atherosclerotic lesions and the evidence that LDL in lesions is oxidised 
suggests strongly an atherosclerotic role for the altered lipoprotein. The most 
compelling data derives from a growing number o f studies showing that 
administration of antioxidants retards the progression o f atherosclerosis. The 
administration of a wide variety o f antioxidants in experimental and clinical studies 
has been associated with ‘reduced’ atherosclerosis, including probucol, a-tocopherol, 
butylated hydroxytoulene (BHT), P-carotene, quercetin, catechin. The principal 
explanation o f this lies in the prevention o f (LDL) lipoprotein oxidation.
The main focus is on oxidised lipoproteins because L D L  serves as the 
principal carrier o f cholesterol in normal human plasma and because o f the strong 
correlation’s between small, dense LD L oc LD L oxidation or cholesterol levels and 
increased atherosclerosis risk.
1.6.2 Supporting evidence for the LDL oxidation hypothesis
A wide range of biochemical and biological assays, including 
fluorescence, electrophoretic mobility and thiobarbituric acid-reactive substance's (see 
Chapter 2, section 2.4), have been used in conjunction with compositional studies of 
native and aortic plaque LDL, to investigate and test the LDL oxidation hypothesis 
(Esterbauer et al 1992). Atherosclerotic lesions have been shown to contain LDL
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derived and modified from plasma LDL (Shaikh et al 1988). Using immunostaining 
techniques, Rosenfeld and colleague showed the presence of malondialdehyde and 4- 
hydroxynonenal-modified lysine residues in vitro in copper-oxidised LDL, and in vivo 
in LDL obtained from the arterial wall o f Watanabe heritable hyperlipidaemic rabbits 
(an animal model for familial hypercholeaterolaemia) (Rosenfeld et al 1990). The 
presence o f these residues, which were most probably derived from apoprotein B, 
indicated that this apoprotein undergoes aldehydic modification in atherosclerosis in 
rabbits and in the in vitro copper oxidation model o f oxidation involving copper 
catalysis.
1.7 Atherosclerosis and Transforming growth factors
The regulation o f growth of smooth muscle cells stimulated early 
interest in the role of growth factors in atherogenesis. Growth factors, cytokines and 
other chemicals, including lipids and small molecules such as nitric oxide, induce and 
regulate numerous critical cell functions. These have the potential to act on cell 
recruitment and migration, cell proliferation and the control o f lipid and protein 
synthesis in the atherogenic process. In the genesis o f lesions, the endothelium can 
interact with macrophages, platelets, and smooth muscle as well as T-lymphocytes. 
The principal products of platelets, macrophages, and smooth muscle that may affect 
the endothelium are shown in Fig. 1.12. Endothelial mitogens produced by 
macrophages include vascular endothelial growth factor (VEGF), fibroblast growth 
factor (FGF), and transforming growth factor-a,p (TGF-a, TGF-p) as well as 
interleukin-1 (IL-1), and tumour necrosis factor-a (TNF-a) all o f which can inhibit 
endothelial proliferation. Furthermore, these three molecules can induce secondary 
gene expression of other growth regulatory molecules, such as platelet-derived 
growth factor (PDGF), by the endothelium. TGF-B can also induce endothelial 
synthesis and secretion o f connective tissue matrix.
Oxidised LDL produced by endothelium or macrophages can have a 
profound effect in furthering the injury to the endothelial cells. Similarly platelets can 
provide not only PDGF but TGF-a and TGF-B as well. Several of the molecules
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expressed by macrophages and platelets can also be generated by smooth muscle cells 
in the arterial wall or in atherosclerotic lesions that underlie the endothelium.
Fig. 1.12 Endothelium in atherosclerosis
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In turn, the endothelial cells have the capacity to express genes for and 
synthesise a number of growth regulating molecules (see Fig. 1.12), including 
molecules that can induce connective tissue proliferation, such as PDGF, bFGF. and 
TGF-B or IL-1 and TNF-a, which can induce secondary gene expression for PDGF in 
endothelium and smooth muscle. The endothelial cells can also be a major source of 
mitogenic and activating factors for the underlying macrophages through monocyte 
colony-stimulating factor (M-CSF), or oxidatively modified LDL. Similarly, the 
endothelial can participate in leukocyte chemotaxis by providing chemotactic factors 
such as oxidised LDL or MCP-1. Through their capacity to form nitric oxide (NO) and 
PGI2, endothelial cells can profoundly affect the state of dilation or constriction of the 
artery. The endothelial cell represents the first potential site o f oxidation of LDL as it 
transports the LDL into the arterial wall.
1.7.1 Effects o f TGF-B on atherosclerosis
The development of clinically significant atherosclerosis is correlated 
with a variety of risk factors identified through population studies (Syekowski et al 
1990). Evidence suggests that, transforming growth factor-13 (TGF-p) may regulate 
atherogenesis (Grainger et al 1995). TGF-p is a member of a family of structurally 
related polypeptides that regulate cell growth and differentiation. In humans, three
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closely related TGF-Ps (pi ,  P2, P3) have been isolated. TGF-p is now recognised to 
be a multifunctional cytokine that circulates in plasma as a latent complex and an 
activated form. Increasing evidence from both clinical and animal research suggests 
that low levels o f active TGF-p are linked to the development of atherosclerosis 
(Grainger et al 1994, 1995). Patients with severe CAD have low levels o f active TGF- 
p compared to individuals with angiographically normal arteries. Also transgenic mice 
with hyperlipidaemia have low levels of TGF-p, and develop fatty streak lesions. 
Atherosclerotic lesions o f the coronary vessels are thought to originate from injury or 
dysfunction of the endothelium (Ross et al 1976), although the mechanisms 
responsible for the initial injury are not well defined. In response to various agents 
acting at the site o f injury including platelet-derived groAVth factor, other mitogens and 
chemotactic agents, the underlying vascular smooth muscle cells (VSMCs) migrate in 
to the lumen and proliferate to form an intima (Ross et al 1993). TGF-P inhibits both 
the migration (Kojima et a l \9 9 \)  and proliferation o f VSMCs in cell culture. Human 
VSMCs produce TGF-P in a latent, inactive form which is activated proteolytically by 
the serine protease, plasmin (Kirschenlohr et al 1993, Lyons et al 1990). The plasmin 
is produced proteolytically from plasminogen activator (tPA) and the risk factors PAI- 
1 and Lp(a) block the activation o f latent TGF-p by competitively inhibiting tPA. 
PAI-1 and Lp(a) therefore promote human VSMC proliferation in culture by relieving 
the inhibition caused by TGF-P (Fig. 1.13).
Fig. 1.13; Model relating active TGF-p to atherogenesis.
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TGF-B also increases the production o f cell matrix components such as 
collagen and fibronectin and decreases metalloptoteinase activities. The component of 
Lp(a) that acts an inhibitor of plasminogen activation is apolipoprotein(a) {apo(a)},
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which has 80% amino-acid sequence homology with the corresponding domains in 
plasminogen (McLean et al 1987). Evidence from transgenic mouse model o f 
atherosclerosis in which human apo(a) is expressed, has provided in vivo support for a 
relationship between the accumulation of apo(a) on the vessel wall and inhibition of 
TGF-B activation. At the sites o f apo(a) accumulation, the VSMCs are activated and 
vascular lesions subsequently develop.
1.8 Antioxidant Hypothesis
The antioxidant hypothesis stipulates that; “health requires 
protection against free radical injury which may be caused either by endogenous...,
exogenous..., or the secondary propagated radicals...................” (Gey 1986).
Within the body there is multiple levels of protection against free radicals, which 
comprises o f : (i) Métallo enzymes (e.g. Superoxide Dismutase, and Glutathione 
peroxidase), (ii) Essential endogenous antioxidants (B-carotene, Vitamin A, E, C), (iii) 
Nono-essential endogenous antioxidants (e.g. Glutathione, Uric acid)(Fig. 1.14).
In a completely peroxide-free lipid system, initiation of peroxidation 
occurs by the attack of a species capable of abstracting hydrogen atoms from fatty acid 
side chains.
Fig. 1.14: Antioxidant protection in the cell.
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Species capable o f doing this include peroxy radicals, such as trichloromethyIperoxy 1. 
If the fatty acid side chain is designated as L-H (L for lipid), the reaction may be 
written as
CCljO^’ + L-H ---------y CCI3O2H + L"
Hydroxyl radicals are also effective
OH* + L-H -► L* + H2O
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Hydrogen atom abstraction is facilitated by the presence o f double bonds in the carbon 
chain, so that the order of susceptibility to attack is first polyunsaturated fatty acid 
(PUFA) side chains, which are more susceptible than monounsaturated, which are 
much more susceptible than saturated. The hydroperoxy radical, the protonated form 
of superoxide (O2*),
+ O2 i * HOj'
can abstract hydrogen from isolated PUFAs
HO2' +L- H -------- ► L* + H2O2
Reaction of heme proteins, such as myoglobin or haemoglobin with H2O2 
generates heme ferryl species together with protein associated amino acid radicals that 
can initiate lipid peroxidation. The identity o f the protein radicals is uncertain, but 
tyrosine peroxyl radicals are frequently suggested. Reactions involving haemoglobin 
and possibly other heme proteins, such as cytochrome c released from damaged 
mitochondria, could be relevant in advanced atherosclerotic lesions, in which bleeding 
(a potential source of free haemoglobin) can take place and there is much cell death.
LOOH + (Cu^"")  ► (Cu"") + LO;' +
In addition to heme-protein-stimulated peroxidation, if  exposed to excess H2O2, 
myoglobin, haemoglobin, and cytochrome c can break down to release “free" iron 
that is catalytic for free radical reactions.
LOOH + Fe^* (Cu"")  ► Fe’'"(Cu^’") + LO" + OH'
The most likely fate of carbon-centred (L*) radicals generated from PUFA side chains 
is to undergo molecular rearrangement to conjugated diene structures (which have the 
characteristic absorbance at 234nm, {Chapter 2, section 2.5}) followed by reaction 
with oxygen to give conjugated diene peroxy radicals
L- + 0 2  ► LO2'
Oxygen is a lipophilic molecule, so it tends to be concentrated in the hydrophobic 
regions of membranes and lipoproteins. Peroxyl radicals can damage proteins, deplete 
antioxidants, and react with adjacent PUFA side chains to propagate lipid 
peroxidation. Hence, once initiated, peroxidation of pure (antioxidant-free) lipids 
accelerate in an autocatalytic manner until radical termination reactions consumes a 
significant percentage of the propagating peroxyl radicals.
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L*+ LO2' -------- ► LOOL
LO2' + LO2' -------- ► LOOL + O2
Peroxidation will cease when the substrate (e.g., PUFAa and /or oxygen) is exhausted.
Chain-braking antioxidants (AH) delay the autocatalytic phase o f lipid 
peroxidation by competing with PUFAs for propagating radicals:
LO2' +  A H  ----------► A* 4- LO2H
Some o f the evidence put forward to support the lipid hypothesis now 
underlies antioxidant theory. The replacement o f saturated fats with vegetable oils 
(PUFA) is thought to necessitate the need for increased vitamin E (tocopherols) 
intake.
Therefore an antioxidant nutrient is a compound present naturally in the diet, 
or added to it, which lowers the rate of production o f deleterious changes by free 
radical reactions without significantly impairing the essential reactions involved for 
bodily functions (Harman et al 1995).
1.8.1 Dietary Antioxidants
The potent antioxidant activity o f polyphenols has been studied. 
Flavonoids which occur naturally in vegetables, fruits, tea and wine inhibit the 
oxidation and cytotoxicity of oxidised LDL in vitro. The Zutphen Elderly Study 
showed an inverse relation between flavonoid intake and CHD (Hertog et al 1993).A 
strong body of evidence indicates that lowering LDL cholesterol levels will reduce 
risk for CHD by curtailing atherogenesis. LDL filters into the arterial wall where it 
participates in the development of atherosclerotic lesions. However, the precise 
mechanism by which LDL promotes atherosclerosis, is not understood. Most 
investigators believe that LDL must be modified in some way to become atherogenic. 
At the present time, the LDL-oxidation theory o f atherogenesis is just that-a theory. 
But growing evidence supports this theory, which if correct, could lead to the 
development o f new therapeutic approaches to the prevention of atherosclerosis.
The findings of the MONICA project, a world-wide monitoring system 
for cardiovascular diseases organised by WHO (1989), confirmed that the mortality 
rate from CHD is much lower in France than in other industrialised countries. France
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is varied and characterised by low consumption of butter and high consumption of 
bread, vegetables, fruit, cheese, vegetable fat, and wine (a Mediterranean diet). One of 
these approaches might be the use of antioxidants to prevent the formation of oxidised 
LDL. Hayek et al (1997) demonstrated that dietary consumption of red wine or its 
polyphenolic flavonoids quercetin and, to a lesser extent, catechin leads to attenuation 
in the development of the atherosclerotic lesion in apoE, and this effect was associated 
with a reduced susceptibility of their LDL to oxidation and aggregation. The diet, 
contains several antioxidants that have the potential to inhibit the oxidation of LDL. 
Three of these are vitamins; vitamin C, vitamin E, and B-carotene. Miyagi et al (1997) 
showed that red wine or grape juice can inhibit LDL oxidation. However, both animal 
studies and clinical trials will be required to prove that these antioxidants actually 
prevent the development o f atherosclerosis. If the studies reveal benefit in retarding 
atherogenesis, the antioxidant vitamins could become an adjunct to cholesterol- 
lowering therapy for prevention o f atherosclerosis. Their use would be another 
important step in the dietary prevention of CHD.
1.9 Relevance of flavonoids
Investigations into the ability o f flavonoids such as quercetin and the 
catechins, the most important polyphenolic compounds in tea and wine, to inhibit 
LDL
oxidation in vitro may give some indication of their potential in vivo effects if  
ingested and absorbed. The antioxidant ability of these compounds has been assessed 
in several in vitro LDL oxidation studies. Several flavonoids including quercetin could 
inhibit modification of LDL as measured by its uptake by macrophage scavenger 
receptors (De Whalley et al 1990). Quercetin and catechin was shown to inhibit 
peroxidation of LDL induced by ultraviolet radiation and its subsequent toxicity 
towards cultured lymphoid cells, and to directly protect against the cytotoxic effects o f 
previously oxidised LDL (Negre-Salvayre et al 1992 and 1991). Plant phenolics can 
interact with metal ions to exert pro-oxidant effects in vitro (Laughton et a l \9 9 \ ,  
Shahidi et al 1992). The oral feeding o f polyphenolic fraction isolated from green tea 
for 30 days to hairless mice followed by irradiation with ultra-violetB (900mJ/cm^) 
resulted in significant protection against UVB (P<0.0005) and depletion o f the
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antioxidant-defence system in epidermis (P<0.005) (Agarwal et al 1993).
1.9.1 W ine
An intriguing controversy has developed around the issue as to whether 
all alcoholic beverages are equivalent in their ability to protect against CHD. Several 
epidemiological studies based on questionnaires designed to assess drinking 
preferences have concluded that beverage type does not affect outcome (Yano et al 
1977, Klasky et al 1986). Other publications, based upon equally indirect analyses of 
per capita CHD mortality and wine consumption on a country-by-country basis, have 
shown an inverse correlation between these demographic variables (St. Leger et al 
1979, Hegsted et al 1988). The fact that the French, who as a race follow a lifestyle 
more inclusive of risk factors for CHD than ‘clean living’ North Americans, have a 
much lower incidence of CHD. There is evidence to suggest that, the French are 
protected against CHD mortality by dietary factors which may include more fresh 
produce; fruit and vegetables, garlic and consume vast amount of wine, particularly 
red wine (flavanols). The only consistent difference between the red wine and white 
wines is that the red contains more phenolic compounds; among these phenols, the 
major difference is in the flavonoids, the antioxidant properties o f which may have an 
important role.
1.10 Phenolic com pounds
Phenolics naturally present in foods are heterogeneous compounds 
showing increasingly interesting nutritional, biochemical, pharmacological 
characteristics. The term ‘phenolic’ or ‘polyphenol’ can be defined chemically as a 
substance which possesses an aromatic ring bearing one or more hydroxy substituents, 
including functional derivatives. The most important and diverse group of 
polyphenols known as flavonoids is responsible for the colour and flavour o f foods. 
Over 4,000 flavonoids have been identified in plants. The role o f flavonoids in foods 
has been extensively reported, and several comprehensive reviews have been 
published (Markakis et al 1974, Kuhnau et al 1976, Timberlake et al 1980, Jackman et 
a / 1987).
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Flavonoids are present in fruits, vegetables, grains, nuts, stems, leaves, 
flowers (Hertog et al 1992) in amounts which vary depending on factors such as 
growing conditions, fruit size, degree of ripeness, plant maturity and variety (Hermann 
et al 1976). Foods o f plant origin contain traces to several grams o f flavonoids per 
kilogram fresh weight (Singleton et al 1981). In addition other beverages such as tea, 
coffee, beer, wine contains significant amounts. Flavonoids include catechins (flavan- 
3-ols), proanthocyanidins (condensed tannins, also known as anthocyanogens or 
polymeric leucoanthocyanidins), anthocyanins, flavones, flavonones flavanones 
(reduced flavonones), flavanonols, flavonols and their glycosides. Many flavonoids 
are present in the form of glycosides. It is estimated that the daily average 
consumption of flavonoids may range from 50mg to about Ig per person. Nearly half 
of the total flavonoid intake is anthocyanins, catechins and 4-oxoflavonoids (Kuhnau 
et al 1976).
1.10.1 Flavonoid structure
Polyphenols by definition are those which contain a number of 
phenolic groups in the molecule. There is a general consensus that anything greater 
than three phenolic groups counts as a polyphenol. Those with one to three phenolic 
groups are called non-polyphenols.
Flavonoids belong to a group of phenolics having the basic skeleton of 
diphenylpropanes (C^ + C3 + C^) with a different oxidation level o f the central pyran 
ring. They are 2-phenylbenzo-y-pyrone derivatives with important differences in 
number and position of hydroxyl groups (Beretz et al 1978, Laughton et a l \9 9 \ ,
Myra et al 1993). The basic structural feature of flavonoid compounds, the flavone 
nucleus, is comprised of two benzene rings (A & B) linked by a heterocyclic six- 
member ring (C) (see Fig. 1.15). A carbonyl group at position 4 gives a flavone while 
a methyl^(CH2) group gives a flavane.
Flavonoids are usually present in the cell vacuoles o f plants as 
glycosides with a sugar moiety linked through an OH group (known as O- 
glycosylflavonoids) or through carbon-carbon bonds (known as C- 
glycosylflavonoids), which are broken down to their corresponding aglycones and
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sugars by enzymes or acid and heat treatment. The sugar moiety can be D-glucose, 
galactose, arabinose,
Fig. 1.15: The core structure of flavonoids
L-rhamnose or glucorhamnose and is generally bound at 
position C3 or C7 (Havesteen et al 1983). Other forms 
of conjugation such as méthylation, sulphation, and 
malonylation are also found (Harbome et al 1986).
Flavonoids commonly found in foods o f plant origin are 
monomeric flavanols (catechins, leucoanthocyanidins), proanthocyanidins, 
anthocyanidins, flavones, flavonols, flavanones and chalcones. The presence or 
absence of a hydroxyl group at position 3 allows the distinction between the two main 
flavonoid sub-groups: 3-hydroxyflavonoids (flavonols, catechins{flavan-3-ols}and 
flavanonols), and 3-deoxyflavonoids (flavones and flavanones). Another 
differentiation is the presence of a carbonyl group at position C4; these compounds are 
called 4-oxoflavonoids and include flavonols, flavanones, flavanonols and flavones 
but not catechins.
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1.10.2 Inhibition o f  lipid peroxides by flavonoids.
Several flavonoids are potent inhibitors o f lipid peroxidation (Terao et 
al 1994, Laughton et al 1989, Salvayre et al 1988, Ratty et al 1988), and some 
including quercetin, (+)catechin and chrysin also have metal chelating capacity 
(Thompson et al 1976). Evidence for a relationship between the chemical structure 
and anti-oxidant ability o f polyphenols derives from spectral and kinetic data on the 
formation and decay o f the flavonoid aroxyl radicals. A relationship between 
flavonoid structure and their antioxidant activity can be seen (Fig. 1.16). The 
structural groups are important determinants for radical scavenging and/or 
antioxidative potential: a) The ortho dihydroxy (catechol) structure in the B ring, 
which is the obvious radical target site for all flavonoids with a saturated 2,3-bond, 
which gives the most stable phenoxyl radicals due to electron delocalisation.
Fig. 1.16: Structural groups for radical scavenging.
b) the C2-C3 double bond in 
conjugation with a C4 
carbonyl group on the C ring 
which are responsible for 
electron delocalisation from the B ring.
c) the additional presence of both C3 and C5 hydroxyl groups and a carbonyl group at 
C4 for maximal radical scavenging potential and strongest radical absorption.
1.11 A ntioxidant properties o f phenols.
Autoxidation of polyunsaturated lipids in food involves a free radical 
chain reaction which is generally initiated by exposure of lipids to light, heat, ionising 
radiation, metal ions or metalloprotein catalysts. Enzyme lipoxygenase can also 
initiate oxidation. The route of autoxidation includes initiation (production o f lipid 
free radicals), propagation and termination (production o f non-radical products) 
reactions.
Antioxidants can interfere with the oxidation process by reacting with free radicals, 
chelating catalytic metals, and also by acting as oxygen scavengers.
Initiation RH -------► R* + H* (1)
Propagation R* + O2 ' ► ROO* (2)
,0H
Hi
(b)(a )
Hi
(c)
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ROO’+ R H  ------ ► R’ + ROOH (3)
Termination R* + R* — i
R* + ROO' I ---- ► Non-radical products (4)
ROO' + ROO'— I
Phenolic antioxidants function as free radical terminators and may serve as metal 
chelators. Antioxidants are regarded as compounds capable of delaying, retarding or 
preventing autoxidation processes.
According to their mode o f action, antioxidants may be classified as 
free radical terminators, chelators of metal ions, or as oxygen scavengers that react 
with oxygen in closed systems. Thus, primary antioxidants react with high energy 
lipid radicals to convert them to thermodynamically more stable products. Secondary 
antioxidants, also known as preventive antioxidants, function by retarding the rate of 
chain initiation by breaking down hydroperoxides. Phenolic antioxidants are included 
in the category o f free radical terminators. Phenolic antioxidants (AH) interfere with 
lipid oxidation by rapid donation of a hydrogen atom to lipid radicals (reaction 5 & 6). 
The latter reactions compete with chain propagation reactions (3) & (9).
ROO' + AH -------- ► ROOH + A ' (5)
RO' + AH  ► ROH + A ' (6)
ROO' + A" -------- ► ROOA (7)
R O ' + A ' ------ -► ROA (8)
RO" + RH -------- ► R 0 ( ^ H + | R V ;  (9)
The above reactions are exothermic in nature. The activation energy increase with 
increasing A-H and R-H bond dissociation energy. Therefore, the efficiency o f the AH 
increases with decreasing A-H bond strength. The resulting phenoxy radical itself 
must not initiate a new free radical or be subject to rapid oxidation by a chain reaction. 
In this respect, phenolic^oxidants are excellent hydrogen or electron donors and, in 
addition, their radical intermediates are relatively stable due to resonance 
delocalisation and lack of suitable sites for attack by molecular oxygen (Sherwin et al 
1978).
The phenoxy radical formed by reaction o f a phenol with lipid radical 
is stabilised by delocalisation of unpaired electrons around the aromatic ring as 
indicated by the valence bond isomers (reaction 10).
3 4
( 1 0 )M
Phenol itself is inactive as an antioxidant. Substitution o f the hydrogen 
atoms in the ortho and para positions with alkyl groups increases the electron density 
o f the OH moiety by an inductive effect and thus enhances its reactivity towards lipid 
radicals. Substitution at the para position with an ethyl or «-butyl group rather than a 
methyl group improves the activity o f the phenolic antioxidant, but in presence o f 
chain or branched alkyl groups in this position the antioxidant activity decreases.
The stability o f the phenoxy radical is increased by bulky groups at the 
ortho positions as in 2,6-di-tertiary-butyl, 4-methoxyphenol or butylated 
hydroxyanisole (BHA). Since these substituents increase the steric hindrance in the 
region o f the radicals, they further reduce the rate of possible propagation reactions 
that may occur (reaction's 11,12,&13) involving antioxidant free radicals.
A" + O2 ------ ► AOO* (11)
AOO" + RH ------ ► AOOH + R" (12)
A ' + RH ------ ► AH + R ' (13)
The introduction o f a second hydroxy group at the ortho or para position o f the 
hydroxy group o f a phenol increases its antioxidant activity. The effectiveness o f a 
1,2-dihydroxybenzene derivative is increased by the stabilisation of the phenoxy 
radical through intramolecular hydrogen bond (reaction 14)
Reaction 14 ^he antioxidant activity o f dihydroxybenzene derivatives is partly
due to the fact that the semiquinoid radical, produced initially, can be 
further oxidised by reaction with another lipid radical. It can also 
form a quinone or hydroquinone molecule (reaction 15). The activity o f 2- 
methoxyphenol is much lower than that o f catechol which possess two free hydroxy 
groups. This is because 2-methoxyphenols are unable to stabilise the phenoxy radical 
by hydrogen bonding as in reaction 14. It has been established that the position and 
degree of hydroxylation is of primary importance in determining antioxidant activity 
o f flavonoids. The o-dihydroxylation of the B-ring contributes to the antioxidant 
activity, hence all flavonoids with 3’, 4 '-dihydroxy configuration possess this activity.
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Robinetin and myricetin have an additional 
j? hydroxy at their 5’position, leading to 
J  ^  O  enhanced antioxidant activities over those
[ j ,  K a ) R u i  RÜO R o a i o
of their corresponding flavones which 
Fig. 1.17: Forms of copper complexes with flavones and flavanones group
3-hydmx^av.ne 5-hy<toxyfiavo„e do not possess the 5’-hydroxy group namely
fisetin and quercetin. Other important features 
+ o \ ^ o  include a carbonyl group at position-4 and a
B-hydroxyfla^^none 5-hydroxyfla^one h"ee hydroxy group at position-3 and/or 5. The
ability o f flavonoids to form complexes with
0 Cu cupric ion has also been demonstrated by UV
spectral studies. Such complications may contribute to the antioxidative action of 
flavonoids (Fig 1.17). Chelation of metal ions renders them catalytically inactive.
Chalcones, the natural precursors o f flavones and flavanones, have also been 
shown to possess potent antioxidant activity. It has been mentioned that at least two, 
and three neighbouring phenolic hydroxy groups (catechol or pyrogallol structure) and 
a carbonyl group in the form of an aromatic ester or lactone or chalcone, flavone or
V
flavanone are essential molecular features required to achieve a high level of 
antioxidant activity.
1.11.1 Polyphenolic com position o f  tea, cocoa and wine.
Popular beverages in the world include tea, cocoa, coffee, beer, wine 
and fruit juices. All o f these beverages contain phenolic compounds. The content of 
phenolics in beverages depends on species, degree o f maturity and/or processing.
1.11.1.1 Tea
Tea, a water infusion prepared from the dried leaves of Camellia sinensis, is 
one of the most popular beverages in the world. Basically, tea can be classified 
into three types by manufacturing techniques: black tea, oolong tea, and green tea.
Black tea: In the preparation o f black tea, the leaves are allowed to ferment 
under high humidity so as to ensure a high degree o f enzymatically catalysed aerobic 
oxidation of the leaf polyphenols. About 1-2% of the total dry matter o f black tea are
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theaflavins, theaflavin-3-O-gallate, theaflavin-3’-0-gallate and theaflavin-3,3’-0 - 
digallate.
Green tea: The primary goal in manufacture of green tea is the preservation of 
Fig. 1.18: Structure of (-)Epicatechin-3-gallate, the leaf catechins. The steps 
(-)EpigaIlocatechin-3-gallate include plucking, rapid enzyme
(-)E p ica tech in -3 -galla te  (-)E pigallocatech in-3-galla te  inactivation by Steaming or pan 
^ firing, rolling, and high
OH temperature air drying to prevent
° OH oxidation of the polyphenol
components and changes o f leaf colour (Graham et al 1992). This tea has almost the 
same composition as the fresh leaf except for the few enzymatically catalysed changes 
which occur very rapidly after plucking. Green tea contains polyphenols, which 
include flavanols, flavandiols, flavonoids, and phenolic acids, these compounds may 
account for up to 30% of the dry weight. Most o f the green tea polyphenols are 
flavanols commonly knovm as catechins. The catechins are colourless, astringent, 
water soluble compounds. They are readily oxidisable, although their oxidation 
potentials vary. Some major green tea catechins are (-)epigallocatechin-3-gallate 
(EGCG), (-)epigallocatechin (EGC), (-)epicatechin-3-gallate (EGG), (-)epicatechin 
(EC), (+)gallocatechin, and (+)catechin (Yang et al 1993) (Fig. 1.18).Carotenoids are 
present at low levels but they important precursors o f tea aroma. Violaxanthine, 13- 
carotene, neoxanthin, and lutein are among those identified (Venkatakrishna et al 
1976).
Tea polyphenols possess strong antioxidant activity (Wang et al 1989, Ozawa 
et al 1987 via three mechanisms.
1) Metal ion chelations because of the presence of the “catechol” structure. They can 
bind and thus decrease the level of free cellular ferric and ferrous ions, which are 
required for the generation of reactive oxygen radicals.
2) Free radical scavenging, as EGCG, EGC, and ECG are strong scavengers against 
superoxide anion radicals and hydroxy radicals-two major reactive oxygen species that 
can damage DNA and other cellular molecules and can initiate lipid peroxidation 
reactions.
3) Terminateers o f lipid peroxidation chain reactions. Reactive oxygen species
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may play important roles in carcinogenesis through damaging DNA, altering gene 
expression, or affecting cell growth and differentiation (Cerutti et al 1989).
1.11.1.2 Cocoa
Cocoa beans are seeds found in woody plants. The manufacturing of 
cocoa involves fermentation, drying, cleaning, roasting, and milling. 12-18% of whole 
dry bean weight are phenolic compounds, which give the characteristic flavour and 
colour o f fermented cocoa. Fermentation and drying bring about complex changes in 
cocoa polyphenolic compounds. The enzymic oxidation of (-)epicatechins and 
leucocyanidins results in the formation of brown colour characteristic of chocolate 
caused by the production of melanin and melanoproteins. Also anthocyanins are 
hydrolysed to anthocyanidins, which polymerise along with simple catechins to form 
complex tannins.
1.11.1.3 W ine
Phenolic compounds in wine contribute to the sensory characteristics 
such as colour, flavour, astringency, and hardness o f wine directly or by interaction 
with proteins, polysaccharides, or other phenolic compounds. The phenolic content 
varies greatly depending on the variety of grape used, environmental factors in the 
vineyard, nature o f crushing, possible inclusion or elimination o f crushed grape skins, 
pulp, and seeds prior to fermentation, procedures employed for wine making and the 
chemical reactions that occur during the ageing of wine. A longer fermentation period 
of skins, pulps and seeds allows more phenolics to be extracted in to the wine as the 
ethanol produced acts as extraction medium for phenolics. Wines with higher levels of 
Fig. 1.19 iCyanidin & Malvidin-3-glucose phenolics are more astringent and
therefore require a longer maturation than those
0,1 «I
lûT' ci/vA iüC li. with lower contents o f phenolics. Phenolics of
wine include derivatives o f hydroxybenzoic and
«I
hydroxycinnamic acids, flavonoids such as flavan-3-ols {(+) catechin, (-)epicatechin, 
(+)gallocatechin, (-)epigallocatechin}, flavan-3,4-diols, anthocyanins and 
anthocyanidins, flavonols, flavones and condensed tannins. Phenolic content o f red 
wines is more and a larger amount and variety of flavonoids compared to white wines
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(Pierpoint et al 1986). Gallic acid is the most abundant phenolic acid in wine, the 
amounts of this and caffeic acid present in red wine greatly exceed those in white. The 
majority of the colour in red wine is due to anthocyanins such as cyanidin and 
malvidin-3 -glucoside (Fig. 1.19), the latter being present at higher concentrations 
(Frankel et al 1995).
Anthocyanins are present in red wine at concentrations up to 500mg/l, 
but they are absent from white wine. During the ageing o f red wine, the content of 
anthocyanins decreases progressively and irreversibly. More stable polymeric 
pigments are formed that are less sensitive to changes o f pH and resistant to 
decolorization by sulphur dioxide. O f the low molecular weight phenolics found in 
wines, catechin, epicatechin, procyanidin B2, B3 and B4, quercetin and gallic acid are 
predominant (Singleton et al 1981). The total content of phenols expressed in mg of 
gallic acid equivalents may range from 50mg/l in some white wines to 6500mg/l in 
certain types of red wine.
1.11.2 Biological effects o f  flavonoids
Flavonoid drugs are widely used in medical practice chiefly for 
disorders of the peripheral circulation. Quercetin, among others, has been reported to 
give local pain relief to patients with bee stings, headaches and in oral surgery. 
Furthermore, the use of flavonoids instead of aspirin in the treatment o f stomach 
ulcers, and instead o f glucocorticoids in inflamed joints has been recommended as 
bleeding, the main side effect associated with these original treatments, is absent with 
flavonoids. Clinical application o f flavonoids to treat disorders o f the peripheral 
circulation (Jaeger et al 1988), to prevent or aid recovery from frostbite, myocardial 
infarction, thrombophlebitis (inflammation o f veins), scalding, bruising in contact 
sports and irradiation damage has stemmed from reports o f the beneficial effects of 
these compounds in experimental conditions (Singleton et ût/ 1981).
1.12 Evidence for the ‘cardio-protective’ effects o f  w ine
Recent studies suggest that people consuming diet usually called 
the “Mediterranean diet” (Willett et al 1995) show a low incidence o f CHD, and
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an epidemiological link between flavonoid intake and a decreased risk o f CHD 
(Hertog et al 1993). In certain parts of France mortality from CHD was found to be 
low despite a relatively high intake of saturated fat and raised serum cholesterol levels 
similar to the UK and USA where CHD was more prevalent (Renaud et al 1992). This 
anomaly could not be explained by differences in other risk factors for CHD such as 
blood pressure, smoking or body mass index. It has thus been postulated that French 
people may be protected against CHD risk as a result o f the larger amounts o f wine , 
particularly red, they drink as compared to North European or Americans. Moreover, 
there is evidence o f gradient o f decreasing CHD risk on moving from the north to the 
south of the country (Ruidavets et al 1993). An inverse association between moderate 
alcohol consumption and CHD is well established. Evidence for this association 
comes from over 60 epidemiological, case control studies with men and women who 
drink one to two drinks a day having the lowest risk o f CHD (Gazino et al 1993, 
Klatsky et al 1992, and 1993, Leger et al 1979, Langer et al 1992, Stampfer et al 
1988, Suh et al 1992, Yano et al 1977).
Studies have shown that alcohol consumption is positively associated 
with serum HDL cholesterol and that reduced or low HDL cholesterol is predictive 
o f CHD in men and women (Moore et al 1986). Hence, the mechanism responsible for 
the protective effect o f alcohol was thought to act through HDL. The main role of 
HDL is to transport cholesterol from arteries to liver for subsequent excretion, thus 
preventing accumulation of cholesterol and hence atherosclerosis (reverse cholesterol 
transport) (Renaud et al 1992).
The protective effect o f alcohol against CHD was also suggested to 
arise through beneficial effects on haemostasis such as decrease in blood platelet 
activity, thereby reducing thrombotic tendency. It has been shown that platelets from 
men with premature CHD are larger and aggregate more rapidly in response to 
platelet agonists particularly adrenaline (McGill et al 1994). Increased aggregability 
with ADP and thrombin has been observed in CHD patients compared to healthy 
controls (Buczynski et al 1993), and there is evidence of an association between 
platelet concentration and aggregability (induced by ADP but not by collagen or 
adrenaline) and long term incidence of fatal CHD (Thaulow et al 1991). This indicates
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that platelets play a role in the formation of the localised obstructive lesions in the 
coronary arteries and subsequent acute coronary events (Hjemdahl et al 1995).
The first experiments investigating the effects of alcoholic beverages 
on atherosclerosis and CHD were carried out in 1981(Klurfeld et al 1981). After 3 
months of a high cholesterol diet, rabbits consuming equal dose o f water with glucose 
or beer developed atherosclerotic lesions in the aorta and other major blood vessels, 
whereas ethanol and water, whisky, white wine or red wine reduced the incidence of 
lesion formation to 75%, 83%, 67% and 40%, respectively. These results provided the 
first indication that absorption of compounds from red wine might occur in vivo and 
have favourable effect on atherosclerosis.
The possibility of protective factors being present in wine but not in 
beer or spirits was also alluded to in a recent study by Gronbaek et al (1995).
Klasksky and co-workers (1993) in the United States who had published extensively 
on this topic had not been able to show any difference between wine and other types 
o f alcohol. They claimed that the effect was completely due to alcohol alone. Renaud 
and Lorgeril (1992) were in agreement with this idea and claimed that the alcohol 
content of wine intake can reduce mortality by 40% and suggested the effect was due 
to changes of platelet aggregability and thrombosis. However this does not explain the 
huge reduction in mortality in France and in other Mediterranean countries.
This issue was resolved by Frankel et al (1993) who showed that the 
alcohol content o f wine was not the sole explanation for the French Paradox. By 
studies in vitro he found that phenolic substances in red wine inhibits the copper 
catalysed oxidation of LDL. Evidence for the hypothesis that a change in fibrinolytic 
activity may be an important mechanism whereby moderate alcohol consumption 
decreases risk of heart disease has been provided by Ridker et al (1994). These 
workers found a positive association between alcohol intake and the plasma 
concentration of endogenous tissue type plasminogen activator (t-PA) a serine 
protease that plays a critical role in the regulation o f intravascular fibrinolysis. This 
association was independent of HDL cholesterol and various non-lipid cardiovascular 
risk factors including age, body mass index and exercise frequency.
Flavonoids, present chiefly in vegetables, fruit, tea, and wine are
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known to possess antioxidant activity in vitro (Robak et al 1988), though investigation 
on the study of wine polyphenols in relation to CHD are limited. In 1995 Furhman et 
al studied the effect o f red and white wine on LDL. They revealed that red wine 
consumption resulted in 34% increase in the propensity o f plasma to undergo lipid 
peroxidation. On the other hand de Rijke et al (1996) could not repeat these results 
using de-alcoholised wine.
There are many negative effects associated with excessive alcohol 
consumption. There is evidence to suggest that it may increase the risk of 
subarachnoid haemorrhage in women (Stampfer et al 1988) and pharyngeal cancers in 
the United States, the cancer risk being higher among people drinking sprits or beer 
rather than wine (Blot et al 1988). The increased risk of death from non- 
cardiovascular causes (liver cirrhosis, unnatural death and tobacco related cancers) in 
heavier drinkers has also that been documented. Furthermore, it is evident that high 
ethanol intake is associated with hypertension, an increased risk o f stroke and 
cardiomyopathy (Leak et al 1995).
1.13 Study Aim s and objectives
In view of the obvious concern over promoting alcohol consumption as 
a means o f acquiring the health benefit associated with moderate drinking, the 
increased consumption of the non-alcoholic cardioprotective components o f red wine 
would be a more appropriate means of coronary prevention.
The aim of this study was to determine whether the putative 
cardiovascular protective effect of red wine is brought about by an action o f extracted 
red wine polyphenols and related foods in vivo, or by the effect o f the alcoholic 
component, or through an additive or even synergistic effect of the two.
The objectives o f this study were :
1) To develop methods for evaluating the susceptibility o f LDL to
oxidative modification.
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2) To establish the most suitable and effective technique for removing the 
excess EDTA in LDL preparations by comparing tube dialysis (with 
and without EDTA), and with a novel column method, and to validate 
theses techniques for their effect on the oxidation of LDL.
3) To screen a wide range of compounds for their antioxidant potential in
vitro, and to select from these compounds those with the greatest 
antioxidant potential for testing as dietary supplements in a human 
intervention trial.
4) To test the effects of these selected compounds on the polyphenolic 
content o f plasma and LDL, and antioxidant status o f plasma and LDL.
In order to achieve these objectives the following assays were set-up, validated and 
optimised prior to the supplementation trial, details o f which are provided in chapter 2.
Chapter 2 contains general method for taking blood, sample storage, isolation of 
LDL, desalting techniques, and following assay procedures:
*  conjugated dienes,
4, total polyphenol concentration in plasma and LDL,
*  lipid peroxides in plasma and LDL,
4» thiobarbituric acid reacting substances in LDL,
4. total antioxidant status in plasma,
4" total growth factor-B, active and latent form in plasma.
The polyphenolic compounds chosen for assessment in the human 
intervention trial were selected on the basis of data obtained from in vitro experiments. 
Thus, the in vitro studies provided a means of grading the antioxidant potency of a 
wide range of screened compounds. Phenolic supplements were given to human 
volunteers over 2 week period. Polyphenol content and antioxidant activity was 
measured in total plasma and purified LDL at base line and after 2 weeks. The results 
-show that that red wine and extracted red wine polyphenols are strong antioxidants 
and very powerful inhibitors of LDL oxidation, and this is due to polyphenolic
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species. This study demonstrated that consumption of extracted red wine polyphenols
and red wine increases in vivo protection of LDL from oxidation.
Chapter 3 : deals with screening compounds for their antioxidant potential in vitro.
Chapter 4 : validation o f methods for removing excess EDTA, and its effect 
on antioxidant parameters after 2 weeks of supplementation with 4 
different compounds.
Chapter 5 : intervention study design and results of polyphenols in plasma and LDL 
before and after 2 weeks of supplementation with 15 different 
supplements.
Chapter 6 : effects of 15 dietary polyphenol supplements on antioxidant parameters 
before and after 2 weeks o f consumption.
Chapter 7 : general discussion and conclusions.
CHAPTER 2 
Material and methods.
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2.1 Collection and storage o f blood and plasm a
Blood samples were drawn into labelled K3 EDTA (1 mmol/1) tubes. 
Samples were centrifuged at 2000 x g for 15 minutes at 4^C using MSE Mistral 30001 
refrigerated centrifuge to obtain plasma. Aliquots of plasma were taken, using plastic 
disposable pasteur pipette, into labelled 1.8ml Nunc freezer tubes at -70^C for analysis 
of total antioxidant status (TAS) and total growth factor-B (TGF-B). The remaining 
plasma was collected into labelled 7ml flat-base plastic tubes with stopper (Sarstedt, 
Germany) for the rest o f the analysis. Isolation of LDL and all the analyses except 
TAS and TGF-B were commenced on the same day, and the separated plasma was 
kept at 4^C before analysis.
Sample collection is known to be the most critical factor in the analysis 
of antioxidant status (LDL oxidation susceptibility). Hence, to avoid contamination, 
plasma was carefully aspirated avoiding buffy coats and red cells. Disposable pipettes 
and clean, correctly labelled tubes were used to avoid cross contamination.
2.2 Isolation o f plasm a low density lipoproteins (LDL)
There are number of alternative procedures for the preparation o f LDL, 
by far the most common being ultracentrifugation. The classical methods o f 
ultracentrifugation require the sequential stepwise isolation of lipoprotein fractions in 
increasing order of density, a process lasting days. Chung et al (1980) devised a 
single- step method of isolation of LDL. One of the problems encountered is smearing 
of VLDL down the side o f the tube in the vertical rotor in triglyceride-rich samples. 
This can be reduced with a near vertical rotor (Puhl et al 1993, Gieseg et al 1993).
For this study an alternative procedure involving a two-step isolation 
of LDL was employed, using a Beckman bench top ultracentrifuge (model Optima 
TLX, Beckman, Palo alto, CA) and a fixed angle rotor TLA 100.4 (Beckman). This 
bench top ultracentrifuge reaches high ‘g’ rapidly, reducing the time required for
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centrifugation. This two-step method provided rapidity o f isolation thus minimising 
peroxide formation during the isolation of LDL.
All the chemicals used were of highest grade (from Sigma or Merck) 
and all the reagents were prepared using reverse osmosis water treated with an ion- 
exchange resin column to remove trace elements (Elga, High Wycombe, UK).
The rotor TLA( 100.4) and all polycarbonate tubes were kept at 4^C 
over night, prior to the isolation of LDL. The ultracentrifuge was cooled to 4°C before 
each run. The density o f plasma was adjusted by the addition o f sodium bromide 
(NaBr-Sigma). Sodium bromide was added to 24ml plasma and gently mixed until the 
salt dissolved thereby adjusting the density o f plasma to 1.3g/ml (see fig. 2.1)
Fig. 2.1: LDL isolation procedure 1 (0.443g NaBr/ml o f plasma).
P l a s m a  + Na Br ( 1 . 3 ] i ,  
1 m I
I
u n d e r l a y e d  on 
2m I of  ( 1 . 0 06 ) N  aB r
1 m I of  LD L+ 1 m i 1 . 1 5 4  N a B r  
+ 1 m 1 1 . 0 6 3  N a B r
Pur e  LDL  r e m o v e d
‘P i g m e n t e d ’ LDL band  
rem oved
C e n t r i f u g e  1 0 0 , 0 0 0  g 
20 m ins.
C e n t r i f u g e  1 0 0 , 0 0 0  g 
30 m ins.
Aliquots of 1ml plasma were underlayed very carefully, to avoid 
mixing, with 2ml o f 0.15 mol/1 (1.006g/ml) sodium chloride (NaCl) containing 2pM
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EDTA, in cooled thick walled polycarbonate tubes (3.2 ml) without cap (Beckman). 
This was designed to create a density gradient within which pigmented LDL migrated 
to approximately one-third from the top o f the tube. The tubes were placed into the 
cooled rotor and centrifuged at 100,000 x g for 20 minutes at 4®C. The LDL which 
formed a yellow/orange band 50% down the two gradients, was carefully aspirated 
from each tube using a disposable plastic 1ml syringe (Plastipak, Becton &
Dickinson), and pooled in pre-cooled, labelled 7ml flat-base plastic tubes with stopper 
(Sarstedt, Germany). From the pooled LDL, aliquots o f 1ml were added to 1ml of 
1.154g/ml NaBr and 1ml o f 1.063g/ml NaBr density gradients (both contained 
2pmol/l EDTA) in pre-cooled polycarbonate tubes and centrifuged for 30 minutes at
100.000 X g at 4°C. The top yellow isolated LDL was removed carefully (using 
syringe) from each tube and pooled in 7ml plastic labelled tubes. The isolated LDL 
was then processed
immediately.
2.2.1 Subsequent treatm ent o f LDL
All reagents were prepared using reverse osmosis water, treated with 
an ion exchange resin column to remove trace elements. All the chemicals used were 
high grade from Sigma (UK. Ltd).
The removal of EDTA from LDL was achieved by three different 
methods as shown below:-
1) final dialysis without EDTA,
2) continuous dialysis with EDTA,
3) column (EcNo-pac lODG desalting column (No. 732-2010 Bio-Rad Labs, UK)). 
Method (1) (final dialysis without EDTA) was used exclusively fbr:-
a) Red wine (RW), b) White wine (WW), c) White wine containing 1 g red wine 
polyphenols (WP), d) Red wine polyphenols as a powder Ig (PP), g)
Vodka+lemonade (AL), h) Vodka lemonade+lg red wine polyphenols (AP), i )
Sefacal drink (SD), j) French paradox capsules (FP), k) Endotelon tablets (EN), 1)
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Green tea extract (TC), m) Chocolate (CH) treatments. All three methods (l,2,3)(fmal 
dialysis without EDTA, continuous dialysis with EDTA, and column) were used for:- 
e) Red wine polyphenols as powder 2g (PT), f) Polyphenol drink (PD), 
n) Vitamin E capsules (VE), o) Vitamin E+lg polyphenol powder (EP) for 
comparison of methods.
A ‘Slide-A-Lyzer’ dialysis cassette was used (See Fig.2.2) as an 
alternative to normal dialysis tubing. This method was more convenient, since no 
preparation was required prior to use (Pierce Slide-A-Lyzer perstorp Biotec Company, 
USA). The introduction and removal of sample was easily accomplished by 
penetrating the silicone gasket with a hypodermic needle. The cassette consists of 
hermetically sealed chamber which maintained the highest possible sample integrity. 
Fig. 2.2: Dialysis cassette
G uide ports
M em brane w indow
►  Plastic frame
G uide ports
The cassette was removed from its protective pouch by holding the 
plastic frame, making sure that the membrane was not touched, to prevent 
contamination. The LDL sample was collected into a 20ml plastic syringe (Plastipak, 
Beckton & Dickinson). The silicone gasket was penetrated with the needle through 
one of the syringe ports at the corner of the cassette, LDL was injected, and the comer 
of the cassette was marked with permanent marker (only the beveled portion o f the 
needle was penetrated as overextending the needle into the cavity can potentially 
puncture the membrane). With the syringe needle still inserted in the cassette cavity, 
air was excluded by drawing up the syringe piston, which compresses the membrane 
windows. Thus, LDL contacts the greatest window surface area, and is not in direct
48
contact with air. This helps in preventing the possible oxidation o f LDL during the 
overnight dialysis. The silicone imparts resealability to the needle puncture, ensuring 
that no sample was lost from the cassette during dialysis. The cassette was placed into 
the groove o f a ‘Buoy’ that floats in the dialysis buffer. Buoy was made up o f silicone 
5cm in length, 3cm in width, with a groove in the middle for holding the cassette. The 
buoy ensures the dialysis cassette will float during the overnight dialysis.
After overnight dialysis the LDL was removed by filling the syringe 
with a small amount of air and penetrating the silicone gasket with the needle through 
another, unused, syringe guide port. Air was discharged into the cassette cavity. To 
avoid the penetration o f the membrane by needle, air was used to further separate the 
membrane. Each guide port was only penetrated once, to avoid coring of the silicone 
and subsequent loss of the LDL. The syringe piston was drawn back slowly to aspirate 
the dialysed LDL within the syringe barrel. Syringe was removed from the cassette, 
and LDL was taken out into a 7ml flat-base labelled tube. Dialysis cassette was 
discarded.
2.2.2 (1) Final dialysis w ithout EDTA.
The dialysis cassette containing 2.5 ml o f LDL was placed into a 5 1 
beaker, containing 51 of lOmmol/1 sodium phosphate buffer saline (PBS) with 2pmol/l 
EDTA, pH 7.4. A magnetic stirrer was added to the beaker, which was covered with 
tin foil, and kept at 4^C, ensuring that cassette was floating. After Ih  the buffer was 
discarded, and the cassette was removed and added to another beaker with a magnetic 
stirrer containing lOmmol/1 PBS, pH 7.4, and dialysed over night ensuring that the 
cassette was rotating, and floating. Both buffers were degassed by vacuum and 
subsequent purging with argon.
2.2.3 (2) Continuous dialysis w ith EDTA.
The dialysis cassette containing 2.5 ml o f LDL was placed in a 51 
beaker containing 51 of 1 Ommol/1 sodium phosphate buffer saline (PBS) with
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10|imol/l EDTA, at pH 7.4, stirred and dialysed as described previously (section 
2 .2 .2( 1)).
Tin foil
Beaker
Buoy
Dialysis cassette 
Buffer
Magnetic stirrer
2.2.4 (3) Colum n treatm ent.
For this treatment a method published by Leonhardt et al (1996) was 
adapted. LDL was passed through an EcNo-pac lODG desalting column (No. 732- 
2010 Bio-Rad Labs, UK). The column was washed twice with 60ml o f 1 Ommol/1 
PBS, pH 7.4, pH was adjusted with sodium hydroxide (NaOH) solution. Prior to use, 
PBS buffer was treated as follows:-
Chelating, chelex-100 resin, sodium form (Bio-Rad, UK) was added to 
buffer to bind traces of heavy metal ions. 5 grams of chelex-100 resin was placed in a 
21 beaker, to which 11 of PBS 1 Ommol/1 buffer was added. The beaker was covered 
with tin foil and stirred for Ih (Ikameg, UK.). The resin in the buffer was stored at 
4°C. After 24h, chelex was removed by careful decanting. The buffer was 
deoxygenated by vacuum degassing and subsequent purging with argon.
600pl of LDL was loaded onto the top of a 10 DG size exclusion 
column. PBS buffer (3ml) was added at a rate of 0.6 ml/min. using a peristaltic pump 
(Ismatec, Weston super Mare, UK). The first 3ml of eluate was collected and 
discarded. Another 1.2 ml o f PBS was added at the same rate for elution of LDL.
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This yellow colour fraction, of LDL was collected in 7ml flat-base plastic tube 
(Sarsted, Germany). EDTA was shown to be completely separated from LDL, since it 
eluted 4-8 ml after LDL. The PD-IODG column was then rinsed with further 60ml of 
PBS buffer. 3 mis o f treated 1 Ommol/1 PBS buffer was added to the column, which 
was covered with the plastic lid provided by manufacturer and stored at 4^C for 
further use. The same column was re-used at least four occasions for removing excess 
EDTA.
EDTA- free LDL from all three methods 1, 2, and 3 was then 
filtered through 0.22pm sterile filter (Sartorius A.G., Germany), using a plastic 
disposable syringe (Plastipak, Becton & Dickinson) in 7ml flat-base plastic tubes 
(Sarstedt, Germany). LDL was kept at 4°C before analyses.
2.3 Protein Analysis
Protein analysis was carried out using Bradford method (Bioquant Reagent- 
1.10306, Merck, Germany). This method is rapid, sensitive, relatively inexpensive, 
and specific for protein.
2.3.1 Principle of assay:
The determination of total protein in plasma and LDL is based on the 
property o f Coomassie brilliant blue G-250 to bind to proteins (reagent contains 
phosphoric acid and methanol). The dye binds primarily to  basic (especially arginine) 
and aromatic amino acid residues.
The mechanism of dye binding can be explained by the existence of 
three absorbing species: a red cationic species, a green neutral species, and a blue 
anionic species. Colour changes are due to successive protonations. Binding o f the 
dye to protein stabilises the blue anionic dye form, detected at 595nm. In doing so, its 
absorbance maximum is shifted from 465nm to 595nm. The absorption o f sample 
solution at 595nm is proportional to the concentration.
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2.3.2 Protein assay procedure
The protein standard (Pierce, Sigma), was diluted in distilled de­
ionised water in the range 0.01 to 0.1 mg/ml. Plasma was diluted so that the 
abosorbance value was in the middle of the standard curve. 125 pi o f LDL or diluted 
plasma was taken into plastic semi-micro cuvettes (Sarstedt, Germany) to this, 1.25ml 
of Bradford reagent solution was added, mixed thoroughly and measured against 
reagent blank after two minutes at 595 nm using a M-350 double-beam ultra violet 
visible spectrophotometer (Camspec, Cambridge, UK). The optical density o f the 
standards was plotted against the standard protein concentrations (0.01-0.1 mg/ml). 
The protein concentration o f plasma or LDL was measured from the standard curve 
and multiplied by the dilution factor, and expressed as milligram/ml of protein.
2.4 LDL oxidation
Com parison o f  m ethods for m onitoring LDL oxidation
Several techniques, including spectophotometric, fluorescence, electrophoretic 
mobility has been used to investigate the LDL oxidation.
2.4.1 Conjugated dienes
The conjugated diene assay is a very convenient assay for the 
continuous monitoring o f the oxidation process by U L T R A  V IO LET spectrophotometry, 
usually at 234nm. Most high grade spectrophotometers (usually dual beam), with an 
automatic cell changer equipped with six cell cuvette holders are suitable. The 
measurement can be translated into a number o f parameters, the most important of 
which is the lag time measurement (when Cu^^ is used as a pro-oxidant catalyst) 
devised by Esterbauer et al (1989). An alternative is the time required to produce 50% 
o f maximum oxidation which may be helpful if  samples are very susceptible to 
oxidation. The lag time is measured by the intersection o f tangent . . . .  =
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o f the slope o f the absorbance curve in the [ propagation phase (see fig. 2.3) 
with the baseline. i The assay itself is relatively simple and gives reproducible
data.
2.4.2 A nion-exchange chrom atography
LDL oxidation can also be monitored by anion-exchange 
chromatography (FPLC using Mono Q HR5/5) utilising multi-step NaCl gradient 
elution (Vedie et al 1991). This method detects five fractions o f LDL, with the more 
negative forms representing the more oxidised species. This technique allows the 
extent of LDL oxidation to be assessed by comparing the relative sizes o f the different 
peaks, but requires specialist equipment.
2.4.3 E lectrophoresis
2.4.3.1 A garose gels
LDL normally has a net negative change, with an isoelectric point of
5.4 (Hurt-Camejo et al 1992). Upon oxidation, LDL acquires a greater net negative 
charge, partly due to the neutralisation of the positive charges o f the arginine(+), lysyl 
residues of apo B-lOO as aldehydes react with these. This provides an easy and 
reliable way to measure the extent of oxidation o f LDL, particularly if an indication of 
the modification o f apo B-lOO is required. The entire LDL band migrates towards the 
anode faster when it is oxidised, rather than one band being seen for native LDL and 
one for oxidised LDL (Henriksen et al 1983), probably due to the formation o f 
aggregates. The Relative Electrophoretic Mobility (REM) of the oxidised LDL can be 
calculated, i.e. the distance migrated by the oxidised LDL divided by the distance 
migrated by the native LDL. There is usually a lag period of several hours with 
macrophages or Cu^^ before the electrophoretic mobility is increased (Carpenter et al 
1994). The mobility then increases and remains stable, in contrast to the measurement 
o f lipid hydroperoxides which increase after a lag period, peak and then decrease. The 
relative electrophoretic mobility is therefore a valuable measure o f the later stages of 
LDL oxidation (closer to ‘biological a s s a y L D L  protein modification).
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2.4.3.2 Polyacrylam ide gel electrophoresis
Apo B-lOO in LDL is fragmented during its oxidation into a large 
number o f polypeptides due to oxidative stress (Fong et al 1987). LDL oxidation can 
therefore be fbllo^ved by the disappearance o f the apo-BlOO band o f Mr 513000 and 
the appearance o f bands o f lower Mr by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis. However, this is a time consuming way to measure LDL oxidation.
Mr of apo B-lOO can increase, as well as decrease, during oxidation, due to the 
covalent cross linking o f apo B-lOO molecules in two or more LDL particles (Meyer 
e ta l\9 9 5 ).
2.4.4 LDL oxidation by fluorescence
The fluorescence of LDL increases when it is oxidised and the 
fluorescence spectra are similar for LDL oxidised by copper, iron or cells (Jurgens et 
al 1987). The fluorescence can be measured at an excitation wavelength o f 360nm and 
an emission wavelength o f 430nm and at these wavelengths is probably due to the 
reaction of 4-hydroxynonenal or similar aldehydes with apo B-lOO and the generation 
o f an unknown fluorophore (Cominacini et al 1991). An advantage o f this technique is 
that the increase in fluorescence o f the LDL upon oxidation can be measured 
continuously, as in the case with conjugated dienes. The fluorescence increases, after 
a lag period, at about the same time as the conjugated dienes increase but it continues 
to increase after the conjugated dienes have peaked, presumably because the 
conjugated diene lipid hydroperoxides fragment to form aldehydes which then react 
with the apo B-lOO to form fluorophores (Esterbauer et al 1990). Unlike the 
conjugated diens, which peak and then decrease, the fluorescence will eventually 
plateau; this would be an advantage over measuring the conjugated dienes if  only a 
single time point is taken.
2.4.5 L ipid hydroperoxides
2.4.5.1 Fox assay
The ‘Fox’ or xylenol orange assay is a sensitive spectrophotometric 
assay (Jiang et al 1992, Nourooz-Zadeh et al 1994). Hydroperoxides oxidise ferrous
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to ferric ion in dilute acid and the resultant ferric ions are determined using ferric 
sensitive dyes as an indirect measure of hydroperoxide concentration. Xylenol orange 
binds fenic ion with high selectivity to produce a coloured (blue-purple) complex 
with an extinction coefficient o f 1.5 x lO'^M*’ cm"' with an absorbance maximum of 
560nm.
2.4.5.2 Tri-iodide assay
Lipid hydroperoxides can also be measured easily in LDL using a tri- 
iodied assay (El-Saadani et al 1989). The lipids o f LDL are dispersed by the detergent 
used in an enzymatic cholesterol kit and the hydroperoxides oxidise ^ T  to I2 which is 
detected spectrophotometrically.
2.4.5.3 High pressure liquid chrom atography (HPLC)
The HPLC procedure for detecting lipid hydroperoxides has the 
advantage that the identity and mass o f specific lipid peroxides may be determined 
down to very low concentrations, well below that available by the colorometric 
methods. This sensitivity is dependent on the availability of chemiluminescence 
detection (Stocker et al 1991).
2.4.6 Uptake o f oxidised LD L by m acrophages
The extent of oxidation of LDL can be assessed by measuring its rate 
o f uptake by macrophages, which is a type of bioassay. This assay was in fact, the 
principal method by which cell modified (oxidised) LDL was discovered (Henriksen 
et al 1981 ), and the rapid uptake of oxidised LDL may be the process for the 
modification of macrophages into cholesterol-laden foam cells in atherosclerotic 
lesions.
2.5 Determ ination o f conjugated diene
LDL was diluted to a protein concentration of 0.05mg/ml in the 
spectrophotometer cuvette (Merck Cell, semi micro, with stopper, u.v. Silica, path 
10mm, Merck, Germany) with PBS buffer. The cuvettes had a 1cm path length and
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accuracy was increased by using the stopper to prevent evaporation during the 
analysis. Oxidation was promoted by the addition o f CUSO4 (Analar grade copper 
sulphate-5-hydrate, BDH, UK Ltd.) to give a final concentration o f 5pmol/l. The 
cuvettes were placed in an automatic six-cell changer that was thermostatically 
controlled at 37^C by water. Immediately upon addition o f Cu^^ (CUS04 ) the cuvettes 
were placed in Cecil 9000 spectrophotometer and a zero time reading was taken. 
Absorbance readings were taken at 5 minute intervals over 390minutes (634 hrs.), a 
maximum run time imposed by the limitations o f the computer software. The 
spectrophotometer was controlled by an IBM compatible personal computer installed 
with Cis-scan kinetic personnel software. The output from the spectrophotometer was 
converted into ASCII file format and imported into the spreadsheet program EXCEL 
(Microsoft Corporation, Redmond, WA, USA). Each test measurement was run in 
parallel with air and in parallel with a separate control of LDL without Cu"^ .^ All the 
test samples were analysed in duplicates.
Assay conditions which were important for the reproducibility, and 
consistency of measurement :-
1) The concentration o f LDL.
2) The purity o f LDL.
3) The final concentration of metal ions.
4) The temperature at which the oxidation was performed.
5) Cleanliness o f the cuvettes.
6) The nature o f the buffer, its pH, and the presence of trace amounts o f metal
ions in the buffer or in water since this can change the rate o f LDL oxidation.
7) The level o f EDTA in the final concentration of LDL in relation to the
copper concentration applied.
Thorough cleaning o f cuvettes between assays was very important to obtain good 
between batch precision. The explanation for this observation may be that trace 
amounts of residual oxidised lipids in the cuvette could accelerate peroxidation by 
‘seeding’ the reaction.
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The dienes formed during LDL oxidation produced an absorption 
spectrum with a distinct peak at 234nm with essentially no inter-individual variation; 
the initial absorbance at 234nm was taken as the baseline.
The absorbance curve at 234nm was divided into three phases- 
1) a lag phase. 2) a propagation phase, and 3) a decomposition phase (see Fig. 2.3).
2.5.1 M easurem ent o f lag phase
Fig. 2.3: The method for determination of lag phase
S l o p e  o f
t i m  e
T i m e  i n m i n u t e s
The lag time is defined as the interval between the intercept of the 
tangent of the slope of the absorbance curve in the propagation phase with the 
baseline, and was expressed in minutes.
2.5.2 C alculations for m easuring total conjugated dienes
The maximal increase in absorbance was read from the absorbance 
curve as the difference in absorbance found at the beginning of the decomposition 
phase minus the absorbance found at the start of the lag phase. From this value, the 
total amount of conjugated dienes (in nanomoles) formed per milligram of LDL 
protein were calculated, i.e. maximal increase in absorbance divided by the molar 
absorptivity of conjugated dienes 8=2.95 x lO"^  (moles/L)’' cm'' .
Absorbance = c x Cone, x light path length
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Hence,
Cone. = A/s
Cone. X dilution factor of LDL = nmoles of dienes/ mg LDL protein.
The lag phase represents the progressive depletion o f antioxidants in 
LDL, with a-tocopherol as the first and P-carotene as the last. During this period, the 
lipophilic antioxidants protect the polyunsaturated fatty acids against oxidation and 
thus prevent LDL entering into a propagating chain reaction (propagation phase).
In the propagation phase the polyunsaturated fatty acids are rapidly 
converted to conjugated lipid hydroperoxides, with about three molecule's lipid 
hydroperoxides being formed in each LDL particle every minute. The transition from 
the lag phase into the propagation phase and the exponential increase o f the oxidation 
rate is mediated by copper ions catalyse the decomposition of the lipid hydroperoxides 
formed during the lag phase to lipid radicals (LO*, LOO*). These radicals initiate, by 
chain branching, a series o f free radical chain reactions. The lipid hydroperoxides 
generated in the LDL particle during the propagation phase are labile intermediatery 
products, their concentration rises within about 60-80 min to a maximum value. The 
transition from the lag phase to the propagation phase is not abrupt, but continuous. 
The rates of the diene formation during the two phases differ widely enough to obtain 
from the curve the length o f the lag phase. In addition to the lag time, the curve also 
allows the determination o f the maximum rate of oxidation and the maximum 
amount of conjugated dienes formed in LDL.
The third phase is the ‘decomposition’ phase, and is marked by a 
decrease in lipid hydroperoxides and conjugated dienes. Both phases temporarily 
overlap and cannot be fully dissociated from one another.
2.6 Determ ination o f  total polyphenols in plasm a and LDL
2.6.1 Principle of polyphenol assay
Plasma and LDL polyphenols were measured by the Folin-Ciocalteu 
reaction using the method of Singleton et al (1965). This method is based on the
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capacity of Folin-Ciocaiteu reagent to oxidise the phenolates. The heteropoly acid 
becomes partially reduced resulting in the production of complex molybdenum 
tungsten blue.
2.6.2 A ssay m odification
In the Singletons method the final assay volume was 20ml. which 
consisted of 2ml of diluted sample + 10ml diluted Folin-Ciocalteu reagent + 8ml of 
Na^CO] (20% soln.), incubated for 120min. Optical density was then measured at 
765nm.
The total assay volume was reduced by 25%, and a centrifugation step 
was introduced before measuring the optical density of the supernatant. All other 
conditions of temperature and incubations remained the same. This assay procedure 
saved on expensive glassware and reagents, and although more care was required, the 
time per analysis was decreased. The additional centrifugation step facilitated the 
provision of a clear supernatant.
2.6.3 Assay procedure
The gallic acid (Sigma. UK. Ltd) (3,4,5 trihydroxy benzoic acid) was 
used as the standard, the stock (1 mg/ml) was prepared in distilled de-ionised water, 
and kept at 4^C. Fresh working stock solution of 250pg/ml was prepared from this 
stock solution every day. Standards were prepared in the range of 0-125pg/ml using 
distilled de-ionised water. 500pi of diluted plasma or LDL or standard was taken in a 
labelled 7ml flat-base plastic tube (50 x 60mm) with stopper (Sarstedt, Germany). 
Folin-Ciocalteu reagent 2.5 ml 1/10 aqueous diluted (V/V) was added and mixed, 
after 30seconds and before 8 mins. 2 ml of Na2C03, 75g/l (w/v) was added, and mixed 
by shaking the tube. Tubes were kept at room temperature (RT) for 150minutes 
(2!6hrs.), centrifuged for lOmins. using the MSB Mistral 30001 centrifuge at RT. The 
supernatant was carefully aspirated using disposable plastic pasteur pipette, and added
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to plastic semi-micro cuvettes (10 x 4 x 45 mm) (Sarstedt, Germany). The cuvettes 
had a 1cm path length. Optical density was measured at 765nm using Campspec 
M-350 double beam UV spectrophotometer (Cambridge).
Fig. 2.4 Assay procedure of total polyphenols in plasma and LDL
0.5ml dil. Plasm a or 
LDL sam ple, or 
Standard
+ 2.5ml Folin reagent 
(1+9) diluted
2 .0ml o f  N azC O s
(75g/L)
Incubation at R.T. 
for 214 hrs.
O.D. at 765nm ^ ------ supernatant ^ ------
Centrifuge at 2000 x g
for lOmins.
2.6.4 Calculations for plasma and LDL polyphenols
The polyphenol concentration o f plasma and LDL was calculated from 
the gallic acid standard curve multiplied by the dilution factor and divided by its 
protein concentration. Results were expressed as the milligrams o f polyphenol/g of 
protein.
2.6.5 Reproducibility of polyphenol assay
Table 2.1 shows results obtained from 35 separate assays with the above procedure. 
Reducing the assay volume and addition o f the centrifugation 
step in this procedure clearly improved the reproducibility.
Table 2.1: Reproducibility of total phenolics assay, results are shown for conc. 
of Gallic acid ,O.D., and 95%CI
Gallic acid standards (jig/ml) Mean O.D. ± S.D. 95%C1 of Mean 
Minimum Maximum
6.25 0.17 ± 0 .0 2 0.16 0.18
12.5 0.34 ± 0.02 0.33 0.34
25.0 0.67 ±0 .01 0.67 0.68
50.0 1.21 ± 0 .0 6 1.18 1.23
75.0 1.76 ± 0 .0 7 1.73 1.79
100.0 2.26 ± 0.08 2.23 2.29
125.0 2.68 ±0.13 2.63 2.73
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2.7 Determ ination o f lipid peroxides
2.7.1 Plasm a lipid peroxides
Plasma lipid peroxides were estimated using the method of Gorog et 
al ( 1993). This method uses the reagent of a commercially available test kit for 
cholesterol estimation. Half way through the project Merck ceased production of this 
reagent on its own. Hence, it was prepared ‘in house’ in the laboratory for further 
estimations. A spectrophotometric scan (200 - 800nm) was carried out on both the 
reagents (commercially available CHOD-iodide reagent & own) for comparison and 
validation. Both scans were similar, at 404.5nm Merck-CHOD reagent gave the OD 
of 0.053 compared to 0.052 OD of in house reagent. The only disadvantage of the in 
house laboratory reagent was its reduced stability. The latter was stable for 3 weeks at 
4°C compared to 8 weeks for the commercially available reagent. As such, it was 
necessary to prepare and scan the reagent every 3 weeks. Comparison of the scan with 
the commercially available reagent provided a measure of the quality and 
reproducibility of the reagent.
In addition, commercially available sodium chloride for injection 0.9% 
(Phenix Pharmaceuticals LTD. Glouster, UK) was used, since the impurities in 
prepared NaCl gave high blank OD value (0.06, ' ).
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2.7.1.2 Principle o f  assay
The principle o f this assay is based on the oxidative activity o f lipid 
peroxides that will convert iodide to iodine, which is then detected 
spectrophotometrically.
2.7.1.3 Preparation o f  C H O D -iodide reagent
Reagents: Potassium phosphate 0.2 mol/1 pH=6.2 (Analar, BDH), Potassium iodide 
0.12 mol/1 (Analar, BDH), Sodium azide 0.15 mol/1 (Analar, BDH), Triton X-100 
peroxide and carbonyl free 2 g/1 (Sigma), Benzalkonium chloride 0.1 g/1 (Sigma), 
Ammonium molybdate lOpmol/1 (BDH).
All reagents were weighed, and mixed in a glass volumetric flask, with 
de-ionised water giving a final volume of 250ml. Precaution was taken not to mix 
vigorously to avoid the formation o f a foam.
2.7.1.4 Procedure o f  plasm a lipid peroxide assay
All plasma lipids and lipoproteins were removed selectively by PHM- 
L-liposorb absorbent (Calbiochem-Novabiochem, UK). This absorbent is designed to 
selectively remove virtually all lipids and lipoproteins from plasma or serum. It does 
not adversely affect the antibody content or coagulation factors, and can be used 
directly with no further additions, affording improved plasma stability.
Dry 20 ± lm g PHM-L-liposorb was weighed into an amber-coloured 
conical screw-top 2.0ml microcentrifuge tube (Fison, UK), and 240pl o f 150mM 
sodium chloride (50ml injection by Phenix Pharmaceuticals LTD. Glouster, UK) 
containing lOmM sodium citrate (Analar, BDH) was added to form a gel. The 
contents of the tube were whirlimixed and allowed to equilibrate for 5 minutes at RT, 
500pl of plasma or saline (blank) was then added to the prepared liposorb suspension.
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stirred and kept in Camlab Microtherm shaker (model no. CVS 748, Cambridge) at 
RT for 15 minutes. 1.0ml o f saline was then added to the plasma-lipsorb mixture, 
mixed and centrifuged at 12,000 x g for I minute using Camlab ALC microcentrifuge 
(NO. 4214). The clear supernatant was removed carefully using a glass pipette (Volac 
disposable glass pipettes, 150mm, John Poulten Ltd., Barking Essex, UK) and 
discarded. The liposob gel was washed twice by 1.5ml o f saline followed by stirring 
and centrifugation. The washed liposorb gel was then suspended in 1.2ml o f CHOD- 
iodide (BDH-Merck) reagent and placed in the Camlab shaker for 60 minutes at RT. 
Tubes were then centrifuged at 12,000 x g for 3 minutes at RT 1.0ml o f clear 
supernatant was carefully aspirated using glass pipette (making sure there were no 
traces of liposorb) and transferred into disposable plastic semi-micro cuvette 
(Sarstedt, Germany). The optical density o f the clear supernatant was measured in a 
M-350 double beam ultraviolet, visible spectrophotometer (Campsec, Cambridge, 
UK) at 405nm against distilled water.
A saline blank was subtracted from the sample value and 
concentrations o f lipid peroxides were calculated by using the molar absorptivity of 
13:2.46 X 10"^ M'^  X cm’*. Results were expressed as pmolar lipid peroxides in plasma. 
Fig. 2.5: Assay procedure of plasm a lipid peroxide
20mg of + 0.24ml of
Equilibrate 5min RT 0.5ml of
PHM-L- liposob Citrated saline saline or plasma
gel+1.5ml saline
In shaker 
15min. at RT
gel+1.5ml saline + 1ml saline
I
gel+1.2ml 
CHOD-reagent
Mixed, centrifuged 
12,000xg for 1 min. 
supemant dicarded
Mixed, centrifuged 
12,000xg for 1 min. 
supemant dicarded
Incubated at RT for Ihr
Mixed centrifuged 
12,000xg __
for 3 mins.
Supernatant OD at
in cuvette 405nm
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2.7.2 LDL lipid peroxides
2.7.2.1 Principle o f  assay
The major initial reaction products o f lipid peroxidation are lipid 
peroxides and their quantitation serves as a direct index o f oxidative status o f LDL. 
CHOD-iodide reagent was used to measure the lipid peroxides. The principle is based 
on the oxidative activity o f lipid peroxides that will convert iodide to iodine. Iodine is 
then simply measured by spectrophotometry (El-Saadani et al 1989). This method is 
quick, for the direct measurement of lipid peroxides, and allows the study o f a larger 
number of samples.
2.7.2.2  Procedure o f  LD L lipid peroxides assay
CHOD-iodide reagent was prepared as described above (section 
2.7.1.3). Dialysed or column treated LDL was diluted to a protein concentration of 
0.05mg/ml in labelled 7ml plastic flat-base tubes with stopper (50 x 16mm, Sarstedt, 
Germany).
Fig. 2.6: Assay procedure of LDL lipid peroxide
Incubated at 37°C 
for 414 Hrs
0.05mg/ml LDL ± 5nmolar Cu ---------------------►► + EDTA + CHOD Reagent
OD at Supernatant
405nm in cuvette
tRT for 1 Hr
Centrifuged 
2500xg for 8mins
For each LDL sample two tubes were prepared. In one tube oxidation was initiated by 
the addition of CuS04(Analar, BDH) to give a final concentration o f 5pmol/l, whereas 
in the other tube there was no Cu^^ (blank). The final volume in both tubes was made 
up to 1ml by phosphate buffer (pH=7.4). Tubes were incubated in water bath at 37*^ C 
for 270minutes (4% hrs). The tubes were then removed from the water bath and kept 
at 4**C for 10 mins. The reaction was terminated by the addition o f EDTA
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(final conc. 0.1 mmol/1). CHOD-iodide reagent was added, mixed thoroughly, and kept 
at RT for Ihr. Tubes were then centrifuged at 2500 x g using MSE Mistral centrifuge 
(model no.3000i) for 8 mins. Supernatant was aspirated into plastic semi-micro 
cuvettes (Sarstedt, Germany), and the optical density was measured at 405 nm against 
the blank.
2.7.2.3 C alculations for LDL lipid peroxides
The concentration of lipid peroxides was calculated using the molar 
absorptivity o f 2.46 x lO'^  x cm'*, which was then divided by protein concentration. 
Results were expressed as pmol lipid peroxide/g o f LDL protein.
2.8 D eterm ination o f  th iobarbituric acid reactive substances m easurem ent 
(TEARS)
2.8.1 Principle o f  assay
This assay is based on the reaction o f malondialdehyde, a break-down 
product o f lipid peroxides, with thiobarbituric acid (TEA). The measurement o f so- 
called thiobarbituric acid reactive substances (TEARS) has been used traditionally to 
monitor lipoproteins for products of lipid peroxidation. This method provides a 
convenient index for determining the extent o f peroxidation. In this assay, the 
lipoprotein is precipitated by tri-chloroacetic acid to give a red species absorbing at 
535nm, and only the water-soluble malondialdehyde present in the supernatant is 
estimated.
2.8.2 Procedure o f  TEA R S assay
Dialysed or column treated LDL was diluted to a protein concentration 
o f 0.05mg/ml in labelled soda glass rimless test tubes (75 x 12mm, Saxco). Two tubes 
were prepared for each LDL sample. In one tube oxidation was initiated by the 
addition o f CUSO4 5H2O (Analar, BDH) to give a final concentration o f 5pmol/l,
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where as in other tube there was no Cu^^ (as a control). Test tubes were closed by 
rubber stoppers. The final volume in both tubes was made up to 1ml by phosphate 
buffer (pH=7.4). Tubes were incubated in water bath at 37**C for 4!4 hrs. Then, tubes 
were removed from water bath and kept at 4®C for 10 mins. Reaction was terminated 
by the addition o f EDTA (final conc. 0.1 mmol/1). To this, 2ml o f TCA-TBA-HCl 
reagent was added and mixed thoroughly (15%w/v tri-chloroacetic acid (Sigma) + 
0.375% w/v thiobarbituric acid (Sigma)+ 0.25 N hydrochloric acid (Analar Sigma)). 
Fig. 2.7: Assay procedure of TEARS
0.05mg/ml LDL ± 5pmolar Cu
Incubated at 37°C 
for 4*4 Hrs Cooled
+
EDTA + TCA-TBA-HCl Reagent 
In water bath
OD at Supernatant
535nm ^ ------ in Cuvette
Centrifuged 2500xg 
for lOmins
for 15mms
Cooled
Tubes were then kept in boiling water bathe for 15 mins. After cooling, the 
fluocculent precipitate was removed by centrifugation at 2500 x g for lOmins using 
MSE Mistral centrifuge (model no. 30001) at 4^C. The supernatant was aspirated into 
plastic semi-micro cuvettes (Sarstedt, Germany), the absorbance of the sample was 
measured at 535 nm against the blank which contained all the reagents except the 
LDL. The optical density o f the sample was subtracted from the control.
2.8.3 C alculations o f  TEARS
The malondialdehyde concentration o f the sample was calculated using 
an extinction coefficient of 1.56 x lO^M’* cm’*, which was then divided by the protein 
concentration of LDL. Results were expressed as pmols TBARS/g of LDL protein.
2.9 D eterm ination o f  Plasm a Total A ntioxidant Status (TAS)
The published chemical methods for estimating the antioxidant 
capacity o f a solution all measure the inhibition o f an artificially generated
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oxidative process (Rice-Evans et al 1994). A free radical species is generated in a 
solution containing an oxidation target; antioxidants in the added sample quench the 
target response by interaction with the reactive oxygen species. The method differ in 
the choice of free radical generator, target and type o f measurement used to detect the 
oxidised product. Table 2.2 summarises the characteristics of six recently published 
methods.
Table 2.2: Methods of determining antioxidant capacity
Reference Free radical 
generation
Target Measurement Sample (pi) Time 
quantity required
Wayner Peroxyl radicals Lipid O2 consumption 30 Up to 2
(1985) (ABAP) peroxidation hrs.
Nakamura H202/peroxidase o-Phenylene A430nm 500 2hrs
(1987) diamine
DeLange Peroxyl radicals Phyco- Fluorescence 250 50min
(1989) (AAPH) erythrocin 540/565 nm
Arshod Cu^/H202 Thiobarbituric Assonm 2000 2hrs
(1991) acid
Miller Ferryl ABTS A 7 3 4 8 6min
(1993) metmyoglobin
Maxwell HRP/H2O2 Luminol Chemilumin- 2 lOmin
(1992) esscence
ABAP=2,2’-azobis(2-amidinopropane) hydrochloride; AAPH= 2,2’azobis(2- 
amodinopropane) dihydrochloride; ABTS=2,2’azinobis(3-ethylbenzothiazoline-6- 
sulphonate); HRP= Horse radish peroxidase.
2.9.1 Modification of method
Plasma total antioxidant status was measured using the commercially 
available kit (Randox Laboratories Ltd., Crumlin, UK). Since, this kit was very
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expensive, the analysis a d ^ té d  was modified to suit microwell plates rather than 
cuvettes. This helped to reduce the quantity of reagent used during the analysis. The 
time required for measuring the optical density was also reduced to less than a minute 
for several samples, as the microtiter plate reader measures the optical density of 96 
wells at a time. For the kit to achieve exactly 3 minute readings after the addition of 
substrate, it was necessary to have a time course, which made analysing large number 
o f samples difficult. The optical density of each sample was measured in each cuvette 
individually and manually. This made the whole procedure time consuming and 
labour intensive. As the substrate in the kit did not produce the satisfactory results, 
probably because of instability, the substrate for the assay was prepared in the 
laboratory for accuracy and reproducibility. Randox total antioxidant control was used 
to validate the assay.
2.9.2 A ssay principle
ABTS*^ (2,2’-Azino-di-[3-ethylbenzthiazoline sulphonate])is incubated 
with a peroxidase (metmyoglobin) and H2O2 to produce the radical cation ABTS*^^. 
This has a relatively stable blue-green colour, which is measured at 600nm. 
Antioxidants in the added sample cause the suppression of this colour production to a 
degree which is proportional to their concentration.
HX-Fe^ + H2O2  ► - [Fe^ = O ] + H2O
ABTS*^ +»X - [Fe^ = O ] -------- ► ABTS*^^ + HX - Fe^
HX - Fe^ = Metmyoglobin 
X - [Fe"* = O ] = FerryImyoglobin
ABTS*^ = 2,2’-Azino-di-[3-ethylbenzthiazoline sulphonate
2.9.3 O ptim isation and validation o f  assay
Recovery within the assay (see Table 2.3) was 98%, (For 1.5 mmol/L 
recovery was 1.47 ± 0.02 and 95% Cl was 1.45-1.48). Recovery between assays
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was 98.5%. Thus, the modified method for total antioxidant status proved satisfactory. 
Table 2.3 : Absorbances and recovery (mmol/1) for Total Antioxidant Status (TAS)
Sample Abs.l
[Al]
Abs.2
[A2]
Change in 
abs.
Blank[A2-Al]- 
[sample A2-A1]
Recovery
mmol/L
Blank 0.021 0.659 0.638 - -
For factor
Std. 2.5 0.038 0.149 0.110 0.528 F= 4.73**
Recovery o f standard 1.5 mmol/L
1 0.036 0.363 0.327 0.311 1.471
2 0.034 0.361 0.327 0.311 1.471
3 0.030 0.359 0.329 0.309 1.461
4 0.032 0.362 0.330 0.308 1.456
5 0.035 0.359 0.324 0.314 1.485
6 0.036 0.361 0.325 0.310 1.466
7 0.038 0.365 0.327 0.311 1.471
8 0.036 0.358 0.322 0.316 1.494
9 0.036 0.361 0.325 0.313 1.480
10 0.032 0.361 0.329 0.309 1.460
11 0.030 0.365 0.335 0.303 1.433
12 0.029 0.366 0.331 0.307 1.452
13 0.034 0.356 0.322 0.316 1.494
14 0.031 0.368 0.337 0.301 1.423
Factor =
Conc. o f standard
2.9.4 A ssay procedure | A blank - ^  A standard)
Plasma samples were thawed at RT no later 
than 14 days after freezing. 5pi o f distilled de-ionised water or sample or standard 
was added to each well (in triplicate) in a 96 well microplate (Life technologies, 
Glasgow). To this, was added 250pl o f chromogen in phosphate buffer, pH=7.4 
(containing metamyglobin 6.1pl/l final concentration in assay, and ABTS*^610pl/l 
final concentration in assay). Optical density was measured on a microtiter plate 
reader (Model No. 96F, Life Technologies, Glasgow). The plate reader was 
controlled by an IBM compatible personal computer installed with “Genesis” soft 
ware. The output plate reader was converted into ASCII file format and imported into 
the spread sheet program Excel (Microsoft Corporation, Redmond, WA, USA). With 
the genesis software it was possible to pre-programme the starting time o f mixing, and
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the length of time required to mix the contents in the wells. Optical density was 
measured against air (A l). Then, 50pl of substrate was added to each well (40pl of 
HiO? made up to 100ml with distilled de-ionised water. 1 ml o f diluted H2O2 was 
added to 1.5 ml of phosphate buffer which made the working substrate). The 
microtitreplate was then transferred to a theromostatically controlled shaker, at 37^C 
for 3 minutes (Camlab., Microtherm shaker model No. CVS 748, Cambridge.). 
Optical density was measured again after 3 minutes at 600nm (A2).
Fig. 2.8: Assay procedure of TAS
5 pi of water or 
Standard or sample +
250plof
Chromogen
Shake for 20 sec.
OD at 600n
In shaker for 
3 mins. at 37°C
OD at oOOnm
50pl of substrate 
mix.
2.9.5 C alculations o f TAS
A2 - A 1 = A A of sample/standard/blank 
Total antioxidant status:
Conc. of standard
Factor =
(^ A blank - a  a  standard)
Total Antioxidant ^  Factor x (a  A blank - A A standard) 
status mmol/1
2.9.6 Norm al reference range for Plasm a-TAS
A normal reference range was established in 55 healthy male 
volunteers age (40-65) who has no previous history of major illness. Blood samples 
were collected and plasma was separated as described before (section 2.1). The 
normal range obtained was 1.16-1.94 mmol/1 (Mean was 1.609 ± 0.21 SD) and 95% 
Cl of mean was minimum 1.55 & maximum 1.66. This range was similar to the range
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obtained by Randox Laboratories (1.33-1.77 mmol/1). The total antioxidant status of 
the plasma samples was less than 2.5 mmol/1. Hence, neat plasma was used for the 
determination of total antioxidant status.
Fig. 2.9 Reference range for plasma TAS in 55 healthy male volunteers.
REFERENCE RANGE FOR PLASMA-TAS
1.16 1.29 1.42 1.55 1.68 1.81
PLASMA TAS mmol/L
1.94
2.10 Transform ing grow th factor B (TGF-B) in Plasm a
2.10.1 M easurem ent o f plasm a total (Latent + Active) TGF-B
Plasma total (latent + active) TGF-B was measured by a Quantikine ® 
human TGF-beta immuno assay kit supplied by R&D systems (Abingdon, Oxford, 
UK). This is a quantitative enzyme-linked immunosorbent assay (ELISA) which uses 
two polyclonal antibodies against TGF-B. This assay rapidly determines the amount of 
active plus acid-activatable, latent TGF-B forms ((a+1) TGF-B) present in human 
serum and plasma. TGF-B soluble receptor type II binds TGF-B 1 (recombinant human 
TGF-B soluble receptor type II). When samples or standards are in contact with this 
pre-coated receptor, the TGF-B 1 present is bound by the immobilised receptor. After 
washing away any unbound substances, an enzyme-linked polyclonal antibody 
(conjugated to horseradish peroxidase, with preservative) specific for TGF-B 1 was
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added to sandwich the TGF-Bl immobilised during the first incubation. The soluble 
receptor binds TGF-B 1, TGF-B3, and TGF-B5 with similar affinities. The selectivity 
o f the immunoassay was provided by the polyclonal antibody which is specific for 
TGF-Bl. The soluble receptor also binds TGF-B2 but with an affinity at least 100 
times lower which had been precoated on a microtiter plate.
2.10.1.1 Plasma sample activation
Samples were acid-activated prior to assay, to activate latent TGF-Bl 
to immunoreactive TGF-Bl detectable by the Quantikine immunoassay. lOOpl o f 
plasma was taken into labelled Nunc tubes (Sigma) to it lOOpl o f 2.5 N acetic acid 
containing lOM urea (Sigma) was added, mixed on rota mix, and incubated at RT for 
10 minutes. lOOpl o f 2.7N NaOH with IM  HEPES was further added to the tubes to 
neutralise the sample and mixed. Then, 50pi o f neutralise sample was transferred to 
Nunc tube containing 450pl o f calibrator diluent (animal serum with preservative).
2.10.1.2 Assay procedure
Standards TGF-Bl (lyophilised, recombinant human TGF-Bl in 
buffered protein base) were prepared in a dilution series 0-2000 pg/ml using 
calibrator diluent (animal serum with preservative).
Fig. 2.10: Assay procedure of plasma total (latent+active) TGF-B 
Incubate at RT
200|il o f  V  ^ Aspirated & washed ^  200pl o f
standard or san --------  ►  3 times with wash I Conjugate
buffer
Incubate at RT
Incubate RT 
for 1.5 hrs.
Read OD ^ d d  50|ii
for 20 mins
at 450nm ^stop so lu t i^
Add 200pl oi[ ^  Aspirated & washed 
substrate j  3 times with wash buffer
200pl o f standard or sample was added to each well (in duplicates), 
covered with the adhesive strip, and incubated at RT for 3 h. The contents o f the well
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were aspirated using a multi-channel pipette. Each well was washed three times by 
adding the 400pi o f wash buffer and aspirating, making sure all the contents of the 
well were removed each time. This was achieved by inverting the plate and blotting it 
against a clean paper towel. Removal o f all the reagent was important to achieve good 
results. Then, 200pl o f TGF-Bl conjugate (TGF-Bl conjugated to horseradish 
peroxidase) was added to each well. The plate was covered with new adhesive strip 
and incubated at RT for a further 1.5 h. The plate was then washed three times with 
buffer (as described above). 200pl of substrate (stabilised hydrogen peroxide 
containing stabilised chromogen) was added and the plate was incubated at room 
temperature for a further 20 minutes. 50 pi o f stop solution (2N sulphuric acid) was 
added to each well and the plate was gently taped to ensure thorough mixing.
Optical density was measured at 450nm using the microtiter plate 
reader (Model No. 96F, Life Technologies, Glasgow). The plate reader was 
controlled by an IBM compatible personal computer installed with “Genesis” soft 
ware. This software was capable o f generating a four parameter logistic (4PL) curve 
fit. A 4PL graph was plotted for standards, and the concentration o f TGF-B for 
samples were measured against the standards. The values obtained were multiplied 
by the dilution factor and the results were expressed as ng/ml.
Both TGF-B assays were carried out simultaneously.
2.10.2 M easurem ent o f  active TGF-B in plasm a
Maxisorp 96-well ELISA plates (Gibco; Uxbridge, UK) were used for 
the assay. Standard TGF-Bl 2pg lypholised protein, (R&D Systems, Oxon, UK) was 
reconstituted with 400pl of 4mM HCl in distilled de-ionised water containing 1 mg/ml 
fatty acid free BSA to give a TGF-Bl stock solution of 5pg/ml. From this stock 
solution, aliquot’s o f lOpl were transferred to labelled micro-centrifuge tubes. Tubes 
were stored at -20^C until required for the analysis. Prior to analysis, stock solution 
was defrosted at room temperature and diluted to give 50ng/ml working stock, with 
Tris-buffered saline (TBS; NaCl 137mmol/l, Tris/HCl 50mmol/l, pH=7.4) containing
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3% fatty acid free bovine serum albumin (BSA, Sigma). Standards were prepared in 
the range of a 0-50ng/ml dilution series with TBS containing 3% BSA.
Fig. 2.11: Assay procedure of active TGF-B
Plate in shaker at
^ n ,iln fR D A i^  RT overnight Aspirated & washed 
per well J  ^ ™ S
Aspirated & washed 
3 times with TBS
+
Incubate at RT
^ j^OOpi o f  sa m f^
[ o r  standard J
50pl o f first 
k^ntibody BDA
Plate in shaker 
"at RT for 1 hr~*
Aspirated & washed 
3 times with TBS +_  
0.1%NP-40
Incubât at RT
350pl of] for 1 hr.
Aspirated & washed 
3 times with TBS
+
j^OOpl of se c o n d  
anti-body against 
R abbit IgG y /
Read OD 
at 450 Nm
Add 50pl 
2M H 2S0d
Incubate at RT 
for 20 mins
Plate in shaker 
at RT for 1 hr
Aspirated & washed 
3 times with TBS 
+0.1%NP-40
Add 200pl 0 
K-Blue , 
\  /
Maxisorp, 96-well plates were coated 12h prior to assay, with the 50pl 
of antibody BDA 19 anti-TGF-6 chicken IgY (40pg/ml) diluted in tris-buffered saline. 
The plate was covered with pre-cut transparent microplate sealer (Greiner 
Labortechnik Ltd., Dursely, UK), and kept in a shaker (Camlab Microtherm shaker 
model No. CVS 748, Cambridge, UK) for 12 h at RT, until dry by evaporation. Then, 
the plate was washed three times quickly with TBS. This was achieved by aspirating 
the reagents by multi-channel pipette, and adding the TBS-buffer (making sure that all 
the contents of the well were removed each time by inverting the plate and blotting it 
against a clean paper towel). This step proved to be important for the maintaining 
accuracy, and reproducibility of the results.
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To block the wells, 350pl of TBS containing 3% fatty acid free bovine 
serum albumin (FAF-BSA) was added, and the plate incubated for 1 h at RT. The, 
plate was then washed three times with TBS, and 200pi of standard or sample was 
added to each well. The plate was then covered with transparent sealer and incubated 
for 2 h at RT, on the bench top.
After the binding of the samples, the plate was again washed three 
times with TBS and incubated for 1 hour in a shaker at room temperature with 50pl of 
detection antibody BDA 5 (0.5pg/ml, reconstituted in millique water, and stored at 
4^C, R& D systems, UK). BDA5 is a TGF-B antibody which recognises both native 
and SDS-denatured human and porcine TGFBs. The plate was rinsed three times with 
TBS+0.1% NP-40 and incubated with lOOpl o f an anti-body against rabbit IgG 
conjugated to horseradish peroxidase (Sigma A-6154) at 1: 5000 dilution in TBS+ 3% 
fatty acid free BSA for 1 h in a shaker at RT.
After washing three times with TBS + 0.1% NP-40, 200pl o f 
K-blue the substrate (Elisa Technologies, UK) was added. The plate was covered with 
transparent seal and incubated for exact 20 minutes at RT (K-blue substrate is an 
chromogenic substrate orthophenylenediamine). The reaction was terminated by the 
addition o f 50pl of 2 M H2SO4 to the plate and the absorbances were read at 450nm 
using the microtiter plate reader (Model No. 96F, Life Technologies, Glasgow).
CHAPTER 3 
Determination of the antioxidant potential of wine 
and related foods: In Vitro Experiments.
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“Screening” of compounds for their antioxidant potential in vitro.
Recent research has sparked considerable interest in natural food 
antioxidants such as phenolic flavonoids. Since flavonoids in the diet have been 
shown to be inversely associated with deaths from CHD (Hertog et al 1993). 
Flavonoids are found in high concentration in grapes, wines and grape products. These 
phenolics may act as antioxidants. Some of these compounds may act selectively at 
very low concentrations to inhibit LDL oxidation in vitro (Frankel et al 1993). In view 
of the concern about promoting alcohol consumption because of its toxicity when 
taken in excessive amounts (Scuckit et al 1987), it has been suggested that the 
increased consumption o f the non-alcoholic cardioprotective compounds of red wine 
would be a more appropriate measure for coronary prevention.
3.1 In vitro experim ents
Having developed and optimised methods to assess the oxidative 
susceptibility of LDL, it was important at the outset to screen the antioxidant potential 
o f a range of compounds in vitro using this LDL oxidation system. The rationale for 
this approach was based on the following. In vitro experiments are more manageable 
to obtain precise results in a shorter time. In vivo experiments are time consuming, 
labour intensive, expensive, require ethical approval and human volunteers.
Therefore, it was deemed more practical to eliminate inactive compounds by testing 
their capacity to protect LDL from oxidation by studying compounds in vitro prior to 
their use as dietary supplements in vivo.
3.1.1 In vitro assay
Before examining the effects of each compound on LDL, the total 
polyphenol concentration o f each compound was first measured using the method 
described in Chapter 2 (section No. 2.6). Stock gallic acid {3,4,5 trihydroxy benzoic 
acid} (Sigma) 500pg/ml was prepared in distilled deionised water. Standards were
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made in the range o f 0-500 gg/20ml in distilled deionised water. The compound 
under evaluation was diluted sequentially to various concentrations and analysed. 
Optical density was measured at 765nm, against a standard curve. Results were than 
expressed as milligrams of gallic acid.
Fig.3.1: Assay procedure o iin  vitro expt.
2ml of standard 
or sample +
10 ml Folin ciocalteu’s 
reagent (1+9) diluted
+ 8 ml Na2 CO 3
Incubated at 
room temp. 
2.3 hrs.
O.D. measured ^ supernatant taken in ----- Centrifuged
at 765 nm. plastic cuvette at 2000 rpm
(Folin and Ciocalteu’s phenol reagent (Sigma) 2N, sodium carbonate anhydrous 
(Analar), plastic semi micro cuvettes (Sarstedt. Germany)).
The amount of compound required to provide a polyphenol content in 
the range between 0.1 to 4pg was calculated and the copper diene assay carried out.
+23.1.2 Cu diene assay procedure
The required amount of solution, containing 0.1pg-4.0pg of polyphenol 
of compound under investigation, was added to the semi-micro cuvette containing 
LDL (O.OSmg LDL protein/ml) and mixed gently. lOOpl of CuSO^ solution (50pM) 
was added to give a final concentration of copper ions of 5pM, in a total volume of 
1ml. The rest o f the procedure was identical to that described in Chapter 2, section 
2.5). From the output data, a line graph was plotted for each individual sample, and 
the lag time in minutes was calculated (as described in Chapter 2, section 2.5.1).
To standardise the LDL in the assay in terms of its oxidative potential 
at different concentrations of test compounds, the same pooled LDL was used for each 
run. Five different concentrations of each compound were analysed along with a 
negative control (without the compound) to obtain dose-response curves. Hence, it
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was then possible to measure the lag time for the compound by taking the difference 
between the negative control and the compound.
Fore.g.:-
Cuvette 1 - LDL + Cu^^ + Buffer = X (lag time for LDL)
Cuvette 2 - LDL + Cu^^ + Buffer + S (comp. 0.1 pg) = Y (lag time for LDL+Comp.)
Calculation
Y - X = Inhibition o f lag time in minutes for 0.1 pg of S (compound)
Lag time was calculated as described previously (Chapter 2 section 2.5.1).
Tabic 3.1 Polyphenol concentration of different compounds studied for vitro 
experiment.
No. Compound Abbrevi
ation
Polyphenol
Conc.
1 Red wine-Cabemet sauvignon RW 1.6 g/L.
2 White wine- Vin ordinaire WW 0.2 g/L
3 White wine + lg  Polyphenol powder WP 1.8 g/L
4 Red wine Polyphenol powder PP 450 mg/g
5 Anthocyanins-grape skin extract- 
Sefacal Drink extract conc.
SD 49.0 mg/ml
6 Grape seed proanthocyanidins- 
Endotelon tablets
EN 105.65 mg/tablet
7 Green tea catechin- 
Polyphenon capsules
TC 96.0 mg/tablet
8 Grape skin residue after wine making- 
French Paradox capsules
FP 51.8 mg/capsule
9 Alcohol (vodka)+ 1 g PP AP 1.2g/L
10 Polyphenol powder as drink PD 1.17mg/ml
11 Chocolate CH 4.88mg/g
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The amounts of total phenolic flavonoids in each compound was 
determined and are shown in Table 3.1. The antioxidant activities o f the following 
compounds were studied in vitro (see Table 3.1). Various wines (red and white), 
anthocyanins (grape skin), proanthocyanidins (grape seed), grape skin residue after 
wine making, red wine polyphenols (PP) (Preparation of polyphenol powder as 
described in Chapter-5, section No. 5.3):- in powder form (PP), drink (PD), in 
capsules (PT), or along with an alcoholic drink (AP) (10%v/v), and chocolate (CH).
Since there was such a large variation in the amount o f phenolic 
material within different test compounds, the LDL oxidation assay was carried out 
over a range of different concentrations of total phenol equivalent as determined by 
the Folin-Ciocalteu assay. For the purpose of comparison lag phase results obtained 
for total phenol concentration 0.2pg in assay were selected for all the compounds 
tested, which were compared with the lag phase obtained for red wine.
The kinetic software incorporated on the computer was able to process 
only 390 minutes, hence the 0.2 pg results were chosen. The propagation phase 
extended beyond 390 minutes for the following preparations, at the higher polyphenol 
concentrations in the following assays: tea catechin (Polyphenon capsules), endotelon 
tablets, sefacal concentrated extract.
3.1.3 Results
The effect of different compounds on the kinetics o f copper-initiated 
LDL oxidation is shown in (FigJ3.2, 3.3 and 3.4).
For all compounds tested, the susceptibility o f LDL to oxidation was 
inhibited in a concentration-dependent manner, the higher the polyphenolic 
concentration, the greater the inhibition of LDL oxidation. Red wine and white wine- 
containing polyphenol powder showed very similar results (at Q.2pg polyphenols 
inhibition o f 14min & 17 min respectively) (see Table 3.2).
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+2Table 3.2: Effect of different concentrations of polyphenols in Cu diene assay 
Propagation times, and lag time in minutes for all tested compounds.
Compound Polyphenol conc. 
in assay (pg)
Lag time 
(mins.)
Lag time of  
comp..(mins)
Red wine (RW) 0
0.2
0.4
0.8
1.2
2.0
56
70
82
93
138
231
14
26
37
82
175
White wine (WW) 0 83
0 .2 86 3
0.4 105 2 2
0 .8 135 52
White wine + lg 0 70
polyphenol powder (WP) 0.19 87 17
0.38 100 30
0.76 163 93
Polyphenol powder 0 50
0 .2 85 35
0.42 115 65
1.05 245 195
2.1 ** **
4.2 * * **
Anthocyanins- 0 51
Sefacal conc. (SD) 0 .2 86 35
0.41 117 66
0.82 196 145
1.22 * * **
2.04 * * **
Proanthocyanidins- 0 47
Endotelon (EN) 0.25 79 32
0.5 109 62
1.0 203 156
1.5 275 228
2.5 ** **
Green tea catechins- 
Polyphenon caps. (TC)
0
0.26
0.51
1 .02
1.54
2.56
38
79
135
268
**
**
41
97
230
**
**
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Compound Polyphenol conc. 
in assay (pg)
Lag time 
(mins.)
Lag time of  
comp, (mins)
Grape skin residue- 0 59
French paradox caps. 0.2 56 -3
0.4 77 18
0.8 104 45
Aicohol+lg 0 65
polyphenol powder 0.22 90 25
0.44 95 30
0.88 155 90
1.33 210 145
2.22 ** **
Red wine polyphenol- 0 65
as drink (PD) 0.19 74 19
0.39 83 28
0.78 95 30
Chocolate (CH) 0 51
0.18 70 19
0.37 70 19
0.73 72 21
1.09 80 29
1.83 86 35
(** Propagation phase not completed after six and half hours.)
In a descending order of magnitude (at 0.2 pg of polyphenols in assay), 
polyphenol powder and sefacal drink showed the greatest inhibition o f lag time, then 
polyphenon caps. > endotelon tabs. > alcohol with polyphenol powder > chocolate > 
polyphnol drink > white wine containing polyphenol powder > red wine > white wine. 
Only one compound (french paradox caps.) showed a potentially pro-oxidant effect, 
with a decrease in lag phase of 3 minutes (see Table 3.3).
All o f the tested compounds showed antioxidant activity, but the rate of 
conjugated diene formation varied for each substance. Despite the differences in 
response of the individual polyphenols, in combination they gave a curve very similar 
in shape to that produced by red wine (Fig. 3.2, 3.3. and 3.4 ).
8 1
Table 3.3: Effects of phenolic substances on the Cu^  ^- catalysed oxidation of 
LDL; change A in the lag time of test substances relative to red wine 
(100%).
Compound Lag phase in 
mins.
Change A in lag time 
relative to red wine = 100%.
Red wine (RW) 14 100.0
White wine (WW) 3 21.4
White wine + lg  PP (WP) 18 128.6
Polyphenol powder (PP) 35 250.0
Sefacal conc. (SD) 35 250.0
Endotelon (EN) 26 186
Polyphenon caps. (TC) 32 228
French paradox caps. (FP) -3 -21.4
Alcohol + lg  PP (AP) 25 178
Polyphenol drink (PD) 19 135.7
Chocolate (CH) 20 142.9
(0.2pg polyphenol concentration was taken for each compound, incubated with Cu^^ 
for 390 minutes, lag time was compared with red wine as 100%).
3.1.3.1 Total conjugated dienes
Total conjugated dienes were calculated as described in Chapter 2 
(section 2.5.2), at 0.2pg/ml o f polyphenol content in assay. The results are shown in 
Table 3.4. French paradox and tea catechin produced the most conjugated dienes, 
(similar to white wine), an increase of 40% and 37% respectively compared to red 
wine, where as chocolate produced the leas t. Red wine and white wine coupled with 
polyphenol powder produced the identical conjugated dienes (583 nmoles/mg o f LDL 
protein). Total conjugated dienes formed for polyphenol powder and polyphenol drink 
were similar.
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Table 3.4 Effect of different polyphenol containing compounds on the formation 
of total conjugated dienes expressed as nmoles/g of LDL protein (0.2pg 
of polyphenol/assay).
C o m p o u n d T o ta l c o n ju g a te d  d ie n e s  
[n m o le s /m g  L D L  p r o te in ]
Red wine (RW) 583
White wine (WW) 793
White wine + lg  PP (WP) 583
Polyphenol powder (PP) 644
Sefacal cone. (SD) 773
Endotelon (EN) 636
Polyphenon caps. (TC) 800
French paradox caps. (FP) 814
Alcohol + lg  PP (AP) 690
Polyphenol drink (PD) 732
Chocolate (CH) 515
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Fig. 3.2: Effects of polyphenol-containing compounds on the formation of 
conjugated dienes on LDL as measured by Cu+2 catalysed oxidation 
of LDL in vitro
F ig . 3 .2 (a )
VITRO EXPT. RED WINE (RW)  LDL+CU
 LDL+0.2M9
RW
LDL+0.4pg
RW
 LDL+0.8pg
RW
 LDL+1.2|jg
RW
 LDL+2.0pg
RW
Time In minutes
F ig. 3 .2 (b )
VITRO EXPT. WHITE WINE (WW)
1.40
 LDL+CU
1.20
 LDL+0.2|ig WW
C 0.80
0.60
0.40
LDL+0.8(ig WW
0.20
0 .0 0  -L Time in minutes
Fig. 3 .2 (c)
VITRO EXPT. WHITE WINE WITH POLYPHENOLS (WP)
LDL+CU0.9
0.8
0.7  LDL+0.19|jg WP
i:
0.3
— — LDL+0.38|jg WP
0.2
0.1
Time in minutes
F ig. 3 .2 (d )
VITRO EXPT. POLYPHENOL POWDER (PP)  LDL+CU1.20
1.00 LDL+CU+0.21|jgPP
0.80
 LDL+CU+0.42|jgPP
■eo.60
LDL+CU+1.052|jgPP
0.40
 LDL+CU+2.104(jgPP0.20
Time in minutes
Inhibition of LDL oxidation induced by Copper sulphate at 37°C with 
different conc. o f polyphenolic content ranging from 0.2 to 2.0 pg/ml.
Fig 3.2(a) for red wine, Fig. 3.2(b) for white wine,
Fig.3.2(c) for white wine+polyphenols. Fig. 3.2(d) for polyphenol powder
84
Fig. 3.3: Effects of polyphenol-containing compounds on the
formation of conjugated dienes on LDL as measured by Cu+2 
catalysed oxidation of LDL in vitro 
F ig . 3 .3 (a ) ______________________________________________________________
VTRO EXPT. SEFACAL CONC.{SD)
0.00 «
— LDL+CU
—  LDL+0.2pg SD 
LDL+0.4(jg SD
—  LDL+0.8|jg SD 
LDL+1.2pg SD
—  LDL+2.04gg 
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1 ime in minutes
F ig . 3 .3 (b )
VITRO EXPT. ENDOTELON TABS. (EN)
B 0.60
■fi
°  0.50
<  0.40 
0.30 
0.20 
0.10 
0.00
 LDL+CU
 LDL+0.25|jg
EN
 LDL+0.5(jg
EN
LDL+1 .Opg 
EN
 LDL+1.5|jg
EN
LDL+2 5pg 
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Time in minutes
F ig . 3 .3 (c)
ViTRO EXPT. POLYPHENON CAPS. (TC)1.40 LDL+CU
1.20
 LDL+0.26gg TC
1.00
1.40
0.00 -■
Time in minutes
4)20
F ig . 3 .3 (d )
ViTRO EXPT. FRENCH PARADOX (FP)
1.3 -r
LDL+CU
I  0.7
0.5
0.3
0.1
Time in minutes
4)1
Inhibition of LDL oxidation by copper sulphate at 37 °C with 
different conc. o f polyphenolic content from 0.2 to 2.0 pg/ml.
Fig. 3.3(a) for sefacl drink, Fig. 3.3(b) for endotelon tabs.,
Fig. 3.3(c) for tea catechin, and Fig. 3.3 (d) for french paraadox caps.
Fig. 3.4: Effects of polyphenol-contaming compounds on the
formation of conjugated dienes on LDL as measured by Cu+2 
catalysed oxidation of LDL in vitro
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Flg.3.4(a)
VITRO EXPT. ALC0H0L(V0DKA)+1g PP (AP)
1.4 T  LDL+CU
1.2 / T
f  0.8
0.6
0.4
0.2
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Flg.3.4(b)
VITRO EXPT. POLYPHENOL DRINK (PD)
LDL+CU1.40 T
1.20
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0.40
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Flg.3.4(c)
VITRO EXPT. CHOCOLATE (CH) LDL+CU
1.0
0.9
0.8
0.7
 LDL+0.73|jg
CH
LDL+1.iOpg 
CH
 LDL+1.83|jg
CH
0.6
0.5
0.4
0.3
0.2
0.1
Inhibition of LDL oxidation induced by copper sulphate at 37°C with 
different conc. of polyphenolic content ranging from 0.2 to 2.0 pg/ml. 
Fig.3.4(a) for alcohol+polyphenol, Fig. 3.4(b) for polyphenol drink, and 
Fig. 3.4(c) for chocolate.
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3.1.4 Discussion
In the present study various substances containing an abundance of 
polyphenols were screened for their antioxidant potential in vitro. The antioxidant 
activity as measured by LDL oxidation, at a polyphenol concentration o f 0.2 pg/ml, 
varied for different compounds (see Table 3.3). When all the results were compared 
with the lag phase produced by red wine, red wine polyphenol powder and 
(anthocyanins) sefacal drink proved to be the most active compounds. These 
compounds increased the lag phase by 2.5 times compared to red wine. This result was 
in accordance with that o f Lanningham-Foster et al (1995), who demonstrated that 
grape extract can block the copper-induced oxidative modification o f LDL. In 
Lanningham-Foster et al study, LDL oxidation was assessed by conjugated diene 
formation at 234nm. Incubation of LDL (0.05mg protein/ml) with 1.66 pM cupric 
chloride produced a lag phase o f 130mins before the onset o f the propagation phase. 
However, the presence o f grape extract at a final concentration to an 8000-fold 
dilution, extended the lag phase to 185mins. A 4000-fold and 2000 fold dilution of 
grape extract produced lag phases o f 250 and 465 mins, respectively. LDL oxidation 
was essentially blocked entirely for at least lOh with al 000-fold dilution of grape 
extract. In the present study polyphenol powder produced lag phase of 35min (at 
0.2pg of polyphenols in assay), this was extended to more than 390 min (as soft ware 
can only read up to 6 V2 h) at 2.1pg of polyphenols in assay.
Waterhouse et al (1996) studied antioxidants in chocolate. They 
extracted chocolate with 95% aqueous methanol and hexane. The methanol extract 
was evaporated in a vacuum with the addition of water to eliminate the methanol and 
then centrifuged to give an aqueous solution. They found that cocoa powder extract 
was a potent antioxidant for LDL oxidation. At 5 pmol/i (GAE) gallic acid 
equivalents, cocoa phenols inhibited oxidation by 75%. In this study at 0.2pg of 
polyphenol in chocolate produced a 20 min increase in lag time compared to red wine 
at the same concentration (142.9% change see Table 3.3).
Endotelon capsules (proanthocyanidins), and polyphenon capsules (tea 
catechins) showed the inhibition in lag time over red wine with a 2.3 fold and 1.8 fold 
increase in lag phase. Extracted red wine polyphenols either in powder form, or as a 
drink or along with white wine, or with vodka gave an increase in lag time (see Table 
3.3) more than red wine. Polyphenol powder showed the greatest inhibition with a 2.5 
fold increase in lag phase compared to other red wine extracted polyphenols 
(polyphenol drink showed inhibition of 1.4 fold, white wine along with polyphenol 
powder showed inhibition o f 1.3 fold).
French paradox capsules showed an interesting result in vitro. These 
capsules are commercially available and made from grape skin residue after wine 
making, and claim to contain polyphenols equal to a half bottle of red wine. As such, a 
decrease in susceptibility o f LDL would be expected in vftro, (as judge by the 
polyphenolic content of the capsules), however a relative decrease in lag time, was 
observed at 0.2pg of phenolic content suggesting a potentially pro-oxidant effect for 
these capsules.
Evidence from a host o f recent studies suggests that the consumption of 
polyphenolic substances in red wine may oppose atherogenesis by protecting LDL 
against oxidative modification (Frankel et al 1993). In one study by Kanner et al 
(1994), when LDL was incubated with cupric ions in the presence of diluted red wine, 
levels of hexanal and conjugated dienes were reduced as compared to a control (no 
wine). Red wine equal to a 500-fold dilution was shown to completely block copper 
induced oxidation of LDL. Polyphenolic substances extracted from red wine were 
found to possess the potent antioxidant activity. It was concluded that these 
polyphenolic substances did not act by binding cupric ions, suggesting that they may 
act instead by donating hydrogen atoms to neutralise lipid free radicals. In support of 
this idea, plant polyphenols with antioxidant potential have been shown to react with 
aqueous peroxyl radicals (Laranjinha et al 1994).
In the present study levels of conjugated dienes were reduced in 
the presence of red wine and extracted red wine polyphenols in different forms either
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alone or when given in combination with white wine or alcohol. In contrast to this, 
levels o f conjugated dienes were increased in the presence of tea catechin, sefacal 
drink (anthocyanins), and grape skin residue (french paradox caps.), these result are 
consistent with that o f Kanner et al 1994.
Recently, Day et al (1997) studied the effect o f red grape juice 
concentrate (total antioxidant capacity 31,010pmol/l) and its quercetin concentration 
32.6mg/l (100pmol/l)on the susceptibility of LDL to peroxidation by ultraviolet light 
in vitro. The effects o f red grape juice concentrate at a dilution o f 1 in 2,500 on the 
electrophoretic mobility o f LDL was also studied by agrose gel electrophoresis under 
the same conditions. This study revealed that LDL oxidation by ultraviolet irradiation 
was inhibited in a concentration-dependent manner by red grape juice concentrate 
ranging in concentration from 1 in 250 to 1 in 25,000, which corresponded to a final 
concentration o f 4-400nmol/l o f quercetin in the LDL solution. These data were 
supported by an decrease in the REM indicating that the oxidation o f LDL had been 
inhibited by pre-incubation with red grape juice concentrate.
It was clear from the above results that all o f the compounds studied 
had some effect on extent of the lag phase (protection o f endogenous antioxidants) and 
could be selected on the basis o f this effect relative to red wine. An important issue in 
this respect is the absorption of such substances and their role in mediating the action 
o f low-molecular mass extracellular antioxidants. Therefore, various parameters were 
assessed in vivo, e.g.- lipid peroxides in plasma and LDL, total antioxidant status etc. 
(Chapter 5 & 6), to determine the antioxidant activity. Whether polyphenols are actual 
constituents o f LDL is unknown. Information concerning the bio-availability of 
polyphenols consumed in the diet is lacking, as highlighted by Halliwell et al (1993). 
On the other hand, there is evidence to suggest that a significant absorption of 
polyphenols must occur to account for their beneficial effects. Recently, Maxwell et al 
(1994) reported that the consumption of red wine results in enhanced serum 
antioxidant activity. Also, Kondo et al (1994) showed that the LDL isolated from red 
wine drinkers was found to be more resistant to oxidative modification in vitro. It 
would be of interest to determine if the consumption o f polyphenolic compounds in
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the diet can have similar effect as red wine in enhancing the resistance o f LDL to 
oxidation.
There is no doubt from the in vitro findings o f this study that red wine 
and substances which are abundant in polyphenol concentration are strong 
antioxidants and very powerful inhibitors of LDL oxidation, and that this is due to 
polyphenolic species.
CHAPTER 4 
Comparative investigation of methods for the 
deprotection of LDL (EDTA removal).
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4.1 Validation o f m ethods for the removal o f EDTA
LDL isolated by ultracentrifugation is relatively stable, but once 
desalted becomes prone to spontaneous oxidation. A likely explanation for the 
instability induced by the desalting process is the removal of trace amounts o f low 
molecular weight water-soluble antioxidants and EDTA. Therefore, it is important to 
establish optimal conditions for measuring the oxidative susceptibility o f LDL in 
vitro.
EDTA acts as a potent inhibitor of oxidation in the system, probably by 
chelating copper ions. Some peroxides probably form in lipoproteins during lengthy 
isolation procedures (Esterbauer et al 1992). It is also possible that circulating plasma 
lipoproteins contain traces o f lipid peroxides formed by endogenous peroxidation 
(Esterbauer et al 1992, Dowry et al 1992). There is evidence to suggest from the work 
of McDowell et al (1995) that residual EDTA may have marked effects on LDL 
oxidation measurement in vitro.
EDTA is often added to plasma and LDL to chelate trace quantities of 
copper or iron which could catalyse the oxidation of lipids (Lamb et al 1992). 
Esterbauer added both EDTA and the lipid soluble antioxidant BHT, with subsequent 
removal by dialysis (Esterbauer et al 1989). However, it is difficult to ensure that all 
antioxidants have been removed from the final preparation. The alternative approach 
is to add a known amount of EDTA and then excess of copper to over come the 
chelating effect of EDTA in the sample. This approach is likely to be critically 
dependent on any variation in the amount o f added EDTA. Some scientists prefer to 
desalt LDL and remove EDTA after its separation and employ either dialysis or an 
absorption column.
The procedure for the isolation of LDL described in Chapter 2 (section 
2.2) avoids the lengthy isolation procedure. To determine the importance o f the 
preparative method for LDL before oxidation measurements, this study compared 
three methods (Chapter 2, section No.2.2):-
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1 ) Final dialysis without EDTA
2) Continuous dialysis with EDTA, and
3) Column treatment.
Isolated LDL (without any preparative method i.e. dialysis or column) 
cannot be analysed because of the presence of Cu^^ oxidation-impairing EDTA in the 
blood collection tubes and the high ionic strength provided by sodium bromide. In this 
study this has been checked and this led to non measurable lag times (> 10hrs).
4 .2  S tu d y  p ro to co l
Volunteers were divided into groups o f between 6-9 and were given 
daily for 2 weeks one o f the following ;-
1) a black currant flavoured drink containing Ig red wine polyphenols {PD} [the drink 
was a commercially available drink powder containing sugar, citric acid, sodium 
citrate aspartame, and synthetic flavour (Corby company Ltd. UK) to which 330ml 
water was added immediately before consumption)(n=6).
2) capsules containing 2g red wine polyphenols (FT}(n=6),
3) Vitamin E (1000IU){VE}(n=4),
4) Vitamin E+lg extracted polyphenol powder (EP}(n=4).
4.3  R esu lts
4.3.1 Effect on copper diene determ ination (lag tim e)
When various methods for removing excess EDTA were compared (see 
Table 4.1) by omitting the EDTA from the final dialysis buffer, the consumption of 
red wine polyphenols either as drink (Ig/day) or capsules (2g/day) produced an 
increase in lag time of 30% and 21% respectively, and by the column method, of 12% 
and 22% respectively. The addition of EDTA to the dialysis buffer abolished the effect 
with Ig/day red wine polyphenols and gave only a small increase in lag time of 7% 
with 2g/day.
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Table 4.1: Copper catalysed peroxidation in minutes- using different methods for 
desalting LDL in volunteers consuming red wine polyphenols, vitamin 
E, or vitamin E + lg  polyphenol powder, results are mean ± SD
L a g  tim e  in m in u tes
Supplement No. LDL - dialysis LDL - dialysis LDL-
without EDTA with EDTA Column
Polyphenol Drink [PD]
Base line 6 60.0 ± 8.9 64.3 ± 7.7 54.2 ± 10.2
After 2 weeks 77.7 ± 20.5 64.5 ± 7.9 60.6 ± 10.4
Change 17.7 ± 12.9 0.3 ±3.3 6.4 ±2 .5
P-Value 0.02 0.9 0.005
Polyphenol Capsu les -2g [PT]
Base line 6 62.7 ±6.1 67.7 ±8 .7 54.0 ±5 .4
After 2 weeks 75.8 ± 6.9 72.2 ± 7.6 65.8 ± 5 .4
Change 13.2 ±0 .7 4.5 ± 1.2 11.8 ±0.25
P-Value 0.004 0.02 0.003
Vitamin E- 1000 in [VE]
Base line 4 65.5 ±5.5 74.0 ±5.1 59.0 ± 7.4
After 2 weeks 132.5 ± 13.0 133.8 ±24.4 125.0 ± 16.6
Change 67.0 ± 12.9 59.8 ±19.3 66.0 ± 9.2
P-Value 0.002 0.01 0.004
Vitamin E (1000 in) + Ig Polyphenol powder [EP]
Base line 4 60.8 ± 4.0 79.3 ±13.4 58.0 ±6 .2
After 2 weeks 129.0 ±9 .2 120.5 ±23.7 121.3 ±9 .8
Change 68.3 ± 5.2 41.3 ± 10.3 63.3 ± 3.6
P-Value 0.0004 0.04 0.003
There was no significant differences in the lag times between the 
dialysis without EDTA and the column method. Vitamin E and Vitamin E+lg 
polyphenol powder produced marked increases in lag time with the dialysis without 
EDTA and by the column method of 107% and 110% respectively. Inclusion of 
EDTA in the dialysis buffer gave an increase of 66% which was not significantly 
different from the other two methods. The increase in lag times with both of the above 
were 4-5 fold greater than with red wine polyphenols.
There was no significant difference between results o f three LDL separation methods.
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4.3.2 Effect on LDL polyphenols
Three different methods of desalting were compared in order to 
examine the effects of EDTA removal on changes in polyphenol concentration of 
LDL. Results are shown in Table 4.2
Table 4.2: LDL Polyphenols mg/g of LDL protein: using different methods for 
desalting LDL in volunteer’s consuming red wine polyphenols as a 
drink (PD), Vitamin E (VE), or Vitamin E + lg  polyphenol powder 
(EP), results are mean ± SD values at day 0 and after 2 weeks.
LDL polyphenols mg/g of protein
Supplement No.
sub.
LDL - dialysis 
without EDTA
LDL - dialysis 
with EDTA
LDL-
Column
Polyphenol Drink [PD]
Base line 
After 2 weeks 
Change 
P-Value
6 35.9 ±9.2 
42.4 ± 6.4 
6.5 ±4.2  
0.01
31.6 ± 4 .6
40.7 ±8 .5  
9.2 ± 6.6 
0.04
31.5 ±4.9
43.3 ±7.3 
11.9 ±4.6
0.005
Polyphenol Capsules -2g [PT]
Base line 
After 2 weeks 
Change 
P-Value
6 33.9 ±5.0
44.4 ±5.1
10.5 ± 1.8 
<0.0001
36.0 ±3.2
46.3 ± 3.4
10.4 ± 4 .6  
0.003
32.3 ±6.1 
40.7 ± 8.2
8.3 ±4 .7  
0.008
Vitamin E- 1000 in [VE]
Base line 
After 2 weeks 
Change
4 27.1 ±9.6  
39.5 ±6.9 
12.4 ± 7.6
24.8 ± 8.9
38.4 ± 10.5 
13.6 ±6.3
25.8 ± 10.4 
39.5 ± 6.0 
13.7 ± 8.6
P-Value 0.05 0.02 0.05
Vitamin E (1000 in) + Ig  Polyphenol powder [EP]
Base line 
After 2 weeks 
Change 
P-Value
4 26.4 ± 9.6
41.5 ±3.3 
15.1 ±6.8 
0.02
27.9 ±5 .6
40.3 ± 10.2
12.4 ± 7 .4  
0.04
26.4 ± 11.3 
38.7 ±8.3
12.3 ± 5 .2  
0.02
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An increase in LDL polyphenols was demonstrated in all four study f
groups using all three desalting methods.!
4.3.3 Effect on LDL lipid peroxides
To evaluate the effect of desalting LDL, either by dialysis without 
EDTA or by column, on LDL lipid peroxides, the concentration of lipid peroxides was 
measured within LDL prepared by both methods. The results obtained are shown in 
Table 4.3.
The LDL from subjects consuming the polyphenol drink showed a 
significant decrease in oxidative susceptibility (28% and 27%) by both methods. The 
decrease in oxidisability was similar for LDL desalted by either dialysis or column in 
the group consuming polyphenol capsules (28% and 31% respectively). Dialysis 
produced the greatest reduction in the vitamin E group (36% in their lipid peroxides) 
compared to the column method (23%). Similar results were obtained for vitamin E in 
combination with 1 g extracted polyphenols.
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Table 4.3 : Effects of dialysis without EDTA and column LDL desalting methods 
on LDL lipid peroxides (pmole/g of LDL protein:), in volunteers 
supplemented with red wine polyphenols as a drink (PD), 2g Capsules 
(PT)Vitamin E (VE), & Vitamin E +lg  polyphenol powder(EP).
LDL lipid peroxides pmole/g of Protein
Supplement No. LDL - dialysis LDL- Column
Polyphenol Drink [PD]
Base line 6 161.0 + 37.5 157.2 + 31.8
After 2 weeks 116.0 + 29.8 114.9 + 25.9
Change -45.0 + 26.9 -42.3 + 28.5
P-Value 0.009 0.02
Polyphenol Capsules-2g [PT]
Base line 6 219.5 + 76.6 197.8 + 68.2
After 2 weeks 162.1 + 53.1 136.6 + 41.8
Change -57.5 + 24.8 -61.2 + 43.9
P-Value 0.002 0.02
Vitamin E- 1000 in [VE]
Base line 4 242.3 + 54.2 221.4 + 20.9
After 2 weeks 156.1 +42.7 171.5 + 27.1
Change -86.2 + 41.9 -49.6+19.1
P-Value 0.03 0.01
Vitamin E (1000 in) + Ig Polyphenol powder [EP]
Base line 4 237.3 + 36.8 221.6 + 32.1
After 2 weeks 145.4 + 26.9 144.7 + 27.2
Change -91.9 + 47.8 -76.9 + 31.7
P-Value 0.03 0.02
4.3.4 Effect on LDL thiobarbituric acid reactive substances (TEA R S)
TEARS in LDL were determined on LDL desalted by dialysis (without 
EDTA) and by the column method. Results are summarised in Table 4.4.
As can be seen from Table 4.4,' 6 subjects consuming polyphenol 
drink showed a mean decrease in TEARS of 13% by dialysis and 18% by the column. 
Supplementation with polyphenol capsules (2g) was accompanied by a mean decrease 
in TEARS of 21% for dialysis, and 31% for the column method. The groups taking
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vitamin E, and vitamin E in combination with Ig o f polyphenol powder showed a 
similar inhibition o f LDL oxidation (change in TEARS) after both desalting methods.
Table 4.4: LDL TEARS (jiimoles/g of LDL Protein): using different methods for 
desalting LDL in volunteers consuming red wine polyphenols as a 
drink (PD), Vitamin E (VE), or Vitamin E +lg  polyphenol powder 
(EP), results are mean ± SD ,values at day 0 and after 2 weeks.
LDL - TEARS jiimole/g of Protein
Supplement No. LDL - dialysis LDL- Column
Polyphenol Drink [PD]
Base line 6 31.7 + 2.6 31.7 + 4.7
After 2 weeks 27.8 + 3.4 26.1 + 1.1
Change -3.9+ 2.9 -5.6 + 3.6
P-Value 0.02 0.03
Polyphenol Capsules-2g [PT]
Base line 6 34.8 + 5.8 35.0 + 6.5
After 2 weeks 28.1+7.2 2 4 .1+ 6 .4
Change -6.7 + 2.6 -10.9+1.1
P-Value 0.02 0.008
Vitamin E - 1000 in [VE]
Base line 4 28.5 + 4.2 29.5 + 2.9
After 2 weeks 23.6 + 3.6 23.9 + 3.7
Change -5.0+ 2.1 -5.6 +1.1
P-Value 0.02 0.03
Vitamin E (1000 lu) + Ig Polyphenol powder [EP]
Base line 4 28.9 + 4.1 28.3 + 4.2
After 2 weeks 23.9 + 3.2 23.5 + 4.1
Change -5.0+ 2.2 -5.1 + 1.1
P-Value 0.02 0.03
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Effect of dialysis and column for removing EDTA on 
antioxidative determinations.
Fig. 4 .1(a): Effect of dialysis without EDTA- polyphenol drink(PD)
EFFECT OF DIALYSIS WITHOUT EDTA ON ANTIOXIDANT PARAMETERS POLYPHENOL DRINK 
[PD]0 WEEK & AFTER 2 WEEKS
 h-
LAG TIMES LDL-POLYPHENOLS 'LDL LIPID PEROXIDES TEARS
Subjects
■PD08GH
■PD22EF
■PD32EF
PD21GH
■PD25EF
PD31EF
Fig. 4.1(b): Effect of column method-polyphenol drink (PD)
EFFECT OF COLUMN ON ANTIOXIDATIVE PARAMETERS 
POLYPHENOL DRINK [PD] 0 WEEK & AFTER 2 WEEKS.
Subjects
O-PD08GH80 -r
70 - 
60 - 
50 - 
40 - 
30 
20 
10
PD22EF
PD32EF
PD21GH
PD25EF
PD31EFTEARSLDL-POLYPHENOLS LDL LIPID PEROXIDESLAG TIMES
Fig. 4.1(c): Effect of dialysis without EDTA- polyphenol caps, 2g (PT)
EFFECT CD DIALYSIS WITHOUT EDTA ON ANTIOXIDATIVE PARAMETERS POLYPHENOL CAPS 2g [PT] 0
WEEK & AFTER 2 WEEKS.
 h-
LAG TIMES LDL-POLYPHENOLS *LDL LIPID PEROXIDES TEARS
Subjects
-PT28CD
-PT29EF
-PT48AE
PT30CD
-PT27CD
-PT12GH
Fig. 4.1(d): Effect of column method-polyphenol caps 2g (PT)
EFFECT OF COLUMN ON ANTIOXIDATIVE PARAMETERS 
POLYPHENOL CAPS 2G [PT] 0 WK& AFTER 2 WKS.
PT27CD60
PT28CD40 -
PT29EF20
PT30CD
P T 4 8 A B
Effect of EDTA on LDL oxidation: for lag time, polyphenol conc., lipid peroxides.
and TBARS. Comparison of dialysis without EDTA and column: 
4.1(a) for dialysis without EDTA polyphenol drink(PD),
4.1(b) for column method polyphenol drink (PD),
4.1(c) for dialysis without EDTApolyphenol Caps 2g(PT), and 
4.1(d) for column method polyphenol caps. 2g(PT).
** All LDL lipid peroxides results are divided by 10 for graph
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4.4 Discussion
EDTA is commonly added to plasma and LDL to chelate trace 
quantities of copper or iron which could catalyse the oxidation of lipids (Lamb et al 
1992). Some workers prefer to desalt LDL and remove EDTA after its separation and 
employ either dialysis or an absorption column. To determine the importance of the 
preparation o f LDL prior to oxidation, this study compared various methods i.e. 
dialysis with and without EDTA, and LcNo-pac desalting column methods. In the 
copper catalysed peroxidation of LDL, vitamin E is a sacrificial anti-oxidant and 
conjugated diene formation commences when all the vitamin L present has been 
oxidised. During dialysis without EDTA it is possible for antioxidants such as vitamin 
L in LDL to be oxidised by trace amounts o f metals present in buffer; this would lead 
to faster peroxidation of LDL and a reduced lag time. When extracted red wine 
polyphenols were given at a dose of Ig/day and 2g/day, the methods using dialysis 
without EDTA and column were comparable and gave increased lag times greater than 
6 minutes. Adding EDTA to the dialysis buffer had a pronounced effect. With Ig dose 
there was no increase in lag time and for the 2g dose the increase was only 4.5 minutes 
compared with 13.2 minutes for dialysis without EDTA and 11.8 minutes for the 
column method.
The mechanism by which polyphenols protect LDL from oxidation is 
unknown. There are several possibilities. It is known that red wine polyphenols 
function as metal chelators similar to EDTA in the ex vivo copper-catalysed 
peroxidation of LDL. Firstly, polyphenols could complex some o f the copper added in 
the catalysed peroxidation o f LDL. Secondly, it could protect vitamin E from 
oxidation by trace elements in the dialysing medium or by the trapping o f free- 
radicals. EDTA was shown to have no effect on LDL polyphenol concentration since 
its presence or absence during the dialysis did not affect the content phenolic 
substances and thereby alter oxidation parameters. The results obtained by the column 
method were similar. This finding demonstrates that even with an overnight dialysis 
procedure the polyphenol concentration remained the same in the LDL fraction and 
did not diffuse down the concentration gradient into the buffer. This may be due the
1 0 0
fact that the polyphenols act as chelators and hence form complexes. These results are 
consistent with the study of Fuhrman et al (1995), in which the amounts of 
polyphenols were shown to be similar in LDL which has been freshly prepared and 
dialysed overnight LDL (25.5mg and 24.7 mg polyphenols/g LDL protein before and 
after overnight dialysis, respectively).
However, this finding is at variance with the work of others such as 
Carbonneau et al 1997). In this study LDL was oxidised in vitro after pre-incubation 
with red wine polyphenol concentrate or phenolic acids (sinapic acid, caffeic acid and 
ferulic acid) present in red wine. Dialysis was either performed before oxidation and 
immediately after incubation, or was completely omitted. The results showed that 
these phenolic compounds without dialysis, readily increased the defence of the 
lipoprotein particle against oxidative stress. The higher protection provided by caffeic 
acid as compared with sinapic and ferulic acids underlies the negative effect of the 
presence of methoxyl group(s) on the aromatic ring near the phenyl hydroxyl group in 
preventing oxidation (Rafat et al 1987, Nardini et al 1995) as well as the positive 
effect of the orthodiphenol configuration. However, the antioxidative protection of 
phenolic compounds was totally lost after extensive LDL dialysis. This suggests that 
red wine polyphenol concentrate or phenolic acids are only loosely associated with 
the LDL particle, remaining at least partially by virtue of their mainly hydrophilic 
properties, at the surface o f the particle where they could achieve their antioxidant 
effects.
The levels of total phenols as determined by the Foilin-Ciocalteu 
method, do not provide an absolute measure o f the phenolic content o f plasma or LDL 
but are in fact based on their chemical reducing capacity relative to an equivalent 
reducing capacity of gallic acid. Phenolic compounds have been shown to give 
variable responses in this assay (Singleton et al 1965). The molar response o f this 
method is roughly proportional to the number of phenolic hydroxyl groups in a given 
substrate, but the reducing capacity is enhanced when two phenolic hydroxy groups 
are oriented orthro or para. Since these structural features of phenolic compounds are 
reportedly also responsible for antioxidant activity (Letan et al 1966), the
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measurement of total phenols in plasma and LDL may be related to their antioxidant 
activities.
Dialysis without EDTA and by the column method produced similar 
results in all four supplements for LDL lipid peroxides suggesting that there was no 
effect of the EDTA on the formation of lipid peroxides in LDL.
The four chosen groups, supplemented with polyphenol drink, 
polyphenol capsule^ 2g, vitamin E with and without Ig polyphenol powder, showed 
that there was no difference in TBARS formation in LDL. This would suggest that 
both methods were efficacious in desalting LDL. This result is consistent with the 
findings of Scheek et al (1995) who estimated the lipid peroxidation of 
polyunsaturated fatty acids during dialysis, by measuring the levels o f MDA 
equivalents in LDL before and after dialysis. They found that the value o f freshly 
isolated LDL (1.04 ± 0.3535nmoles MDA/ mg of protein) was virtually unchanged 
after 22 hours of dialysis (1.34 ± 0.17 35nmoles MDA/ mg of protein).
The measurement of TBARS provides only a crude estimate o f the 
extent of oxidation, and does not accurately describe the biochemical events taking 
place. Since, there is a great deal of variation in the amount of arachidonic acid in the 
LDL from different donors, the measurement of TBARS alone could be misleading. 
Hence, the direct iodometric measure o f the formation o f lipid peroxides has been 
used to evaluate lipoprotein oxidation and represents the formation o f peroxides from 
all the polyunsaturated fatty acids (Chapter 2, section 2.7.2).
In general, the measurement of TBARS in LDL provided results which 
were of a similar magnitude to that provided by the measurement o f LDL lipid 
peroxides. However, the measurement of conjugated dienes has been found to provide 
a particularly convenient measure o f peroxidation in lipoproteins, because o f the high 
intensity of the absorbance produced in the lipoproteins which are so rich in 
polyunsaturated fatty acids. In addition, the technique is a continuous measurement
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and facilitates the determination of a Tag phase’ which corresponds to the rate of 
consumption endogenous antioxidants.
In this study base line values for LDL lipid peroxides ranged from 
157.2 to 242.3 jimole/g o f LDL protein. This result is in accordance with a study by 
Fuhrman et al (1995), in their study base line values ranged from 175 to 275 pmole/g 
o f LDL protein.
CHAPTER 5 
Human Intervention Trial (I): Study design and 
effects of dietary polyphenol supplements on the 
polyphenolic content of plasma and LDL.
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5.0 Introduction
There are several studies in the literature to show that specific phenolic 
compounds such as flavonoids can protect LDL against oxidation (Laughton et al 
1989, Jessup et al 1990, Mangiapane et al 1992). Abu-Amsha et al (1996) 
demonstrated that phenolics in both alcoholic and non-alcoholic beverages can give 
dose-dependent protection against oxidation of isolated LDLs and serum in vitro. 
Polyphenols inhibit LDL oxidation since their inhibitory effects are ‘specific’ against 
LDL and removal o f polyphenols from beverages results in a loss o f antioxidant 
activity.
The number of different phenols already identified in red wines is well 
in excess o f 100 and includes both flavonoids and non-flavonoid phenols. In this study 
various wine and wine products were provided as dietary supplements and compared 
with the effects o f red and white wine.
1) Red wine polyphenol provided as a powder from Nutriproducts Ltd.
(Leeds,UK)and defined as -
Extracted red wine 
polyphenols
Powder form
(Ig)
Drink
(Ig)
Capsules
(2g)
2) The effects o f catechins and their gallic acid esters, proanthocyanidins, and 
anthocyanins, were tested by giving the following supplements :-
Supplem ents
Anthocyanins 
(grape skin extract 
Sefacal)
Grape skin residue 
(French paradox caps.)
Proanthocyanidins 
(grape seed, 
Endotelon tabs. )
No polyphenols 
(Alcohol)
Chocolate
Tea catechin 
(polyphenon caps.)
Vitamin E Vitamin E+lg polyphenol 
(Caps.) (Caps.)
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Grapes contain large amounts of polyphenols. Grape skins are rich in 
polyphenols, some of which are water soluble, but many only becoming so in the 
presence o f alcohol. So it was important to study the antioxidant effect o f various parts 
of grape (like skin, seeds). Grape seed contain proanthocyanidin which are reported to 
be present in a commercial product ‘Endotelon tablets’. After wine making, a residue 
is left. This contains most o f the skin. A commercial product on the market called 
‘French paradox’ which claims to contain polyphenols equal to half a bottle o f wine 
was used. Catechins are abundant in tea. To evaluate their effects another commercial 
product called ‘polyphenon capsules’ were used. To asses the effect o f alcohol alone 
(no polyphenols) vodka+lemonade was tested. Kondo et al (1996) demonstrated the 
effect of chocolate in prolonging the oxidation lag time in concentration-dependent 
manner. If  cocoa is an active in vivo antioxidant, then a diet that includes chocolate 
may afford some protection. Hence in this study chocolate was one of the compound 
which was tested. Also a known antioxidant Vitamin E was tested to confirm its 
antioxidant activity.
Polyphenols not examined included the flavonols (quercetin, 
kaempferol and myricetin), flavones (dihydroquercitin and dihydrokaempferol) and 
other phenolic compounds such as reseveratol and the hydroxy-benzoic acids, all of 
which occur in red and white wine.
5.1 Aims and objectives
To test the effects of selected compounds on the polyphenolic content 
of plasma and LDL in human volunteers before and after supplementation for 2 
weeks.
5.2 Study design.
5.2.1 Subject recruitment and Ethical approval.
Male subjects aged between 35-65 years of age were recruited.
They were non-smokers, normolipidaemic, non-obese, and had no history o f serious 
illness and were all consuming a normal (habitual) diets. All the volunteers were
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contacted by letter and asked to indicate on a return slip whether they would like to 
participate in the study. A stamped addressed envelope was provided for their reply. 
Initially every volunteer was contacted by telephone. The study design was explained 
and they were asked whether they would like to participate in the study. Between 
October 1995 and February 1997, those interested in participating were contacted over 
the telephone and a mutually suitable appointment was made, and confirmed by letter. 
All the volunteers were asked to abstain f f q m f^  Y ^4w o weeks prior to, and 
throughout the duration of the study, apart from that nominated as a test material. All 
the subjects were requested to maintain their habitual diet and life style. Ethical 
approval for the study was obtained from the Huntingdon health authority district 
medical ethics committee in February 1995.
At the first appointment the objectives and procedures o f the study 
were explained and the letter of consent was signed. The questionnaire (see appendix) 
was completed and height, weight, radial pulse and blood pressure were measured. 
Blood samples were drawn into K3EDTA (1 mmol/1) from an antecubital vein 12 hours 
after the evening meal for biochemical analyses. Total plasma cholesterol, HDL 
cholesterol, LDL cholesterol, and total triglycerides were analysed in the routine 
laboratory of Papworth hospital using conventional kits (Instrumentation Laboratories 
Ltd., Milan, Italy).
Volunteers with a plasma cholesterol level between 4.2 to 6.0 mmol/1 
were selected for the study. Blood samples were taken after an overnight fast and 
collected into K3EDTA (1 mmol/1). Volunteers were randomly assigned to different 
treatments and written instructions were provided indicating the time o f day and the 
frequency at which the treatment (dietary supplement) should be taken (twice daily: 
after lunch and evening meal). All the volunteers were then invited back after 14 days 
of treatment for a post-treatment blood sample. All the dietary supplements were 
provided. Each subject was studied on a single supplement (see section 5.2), or more.
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5.3 Protocol 
Dietary Supplements:
Subject numbers were limited because o f time and practical constraints, 
4-10 subjects were studied per group. The volunteers were divided into groups and 
given one of the following ,daily for two weeks
a) French Cabernet Sauvignon red wine. (1/2 bottle, 375 ml) (RW)
b) French vm white wine .(1/2 bottle, 375 ml) (WW)
c) French vin ordinaire white wine containing 1 g red wine polyphenols obtained
as described below. (1/2 bottle, 375mi) (WP)
d) Red wine polyphenols as a powder Ig in two gelatine capsules. (PP)
e) Red wine polyphenols as powder 2g in four gelatine capsules. (PT)
f i  Polyphenol drink: A blackcurrant flavoured drink containing 1 g red wine
polyphenols. The drink was commercially available drink powder {sugar, citric 
acid, sodium citrate aspartame, synthetic flavour; Cambridge Manufacturing 
Co. Ltd, Corby, UK}to which water 330ml was added immediately prior to 
consumption. (PD)
g) An alcoholic drink (10%v/v) as Vodka lemonade (400ml/day). (AL)
h) An alcoholic drink (10%v/v) as vodka lemonade+lg red wine polyphenol 
(400ml/day). (AP)
I) Anthocyanins as grape skin extract (Sefacal, St Julien de Peyrolas, France) in a
drink containing 50mg/day. (SD) 
j)  Red wine marc (French Paradox®, Arkopharma, Nice, France) in 3
capsules/day each capsule containing 250mg marc (grape skin residue after red 
wine making). (FP)
k) Grape seed proanthocyanidins as Endotelon® (Sanofi-Winthrop, France) in 3
capsules/day each capsule containing 150 mg proanthocyanidin. (EN)
I) Green tea extract as Polyphenon® (Mitsui Norin, Fujeda, Japan) 3
capsules/day each capsule containing lOOmg tea catechins comprising 1.6% 
gallo catechin, 19.3% epigallo catechin, 6.4% epi-catechins, 59.1% 
epigallocatechin gallate and 13.7% epicatechin gallate. (TC) 
m) Chocolate 500g bar/day. (Cadbury’s Bournville chocolate) (CH)
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n) Vitamin E capsules (Lane Health Products Ltd, Gloucester, UK) 1000 i.u/day.
(VE)
o) Vitamin E capsules 1000 i.u and red wine polyphenols as a powder Ig in two
gelatine capsule's together/day. (EP)
For practical reasons in groups with 6 or more subjects, 6 subjects were 
studied per week. They were randomly assigned to the various groups with a period of 
at least 4 weeks before they were on other supplementation trial. Each treatment lasted 
for two weeks. Subjects given vitamin E and vitamin E + lg  red wine polyphenols 
(group n and o) were left until the end of the study (as vitamin E could theoretically 
retained in the body for several weeks). All the treatment products were taken after 
lunch and dinner (1PM & 7PM). Each subject did not take all o f the supplements.
5.4 Preparation of red wine polyphenols (PP)
Red wine polyphenols were obtained from Nutriproducts Ltd 
(Grandview, N. Rigton, Leeds, LSI 7, ODW, UK). Their method o f manufacture 
involves the absorption and removal o f the polyphenols by an absorbent resin column 
from the same Cabernet Sauvignon red wine described above.
Red wine was filtered to remove sediment and then distilled under 
vacuum at 300millibar's pressure at 75^ to 80^C for 1 minute, then cooled and 
concentrated under vacuum at 55^C and then cooled down to 25^C quickly by 
refrigeration. The concentrated wine was passed through an absorbent polystyrene 
resin column (Diaion HP-20 Relite®, Supelco Poole, Dorset, UK) which was then 
washed with distilled water. The polyphenols were eluted with 45-50% ethanol. The 
eluate was concentrated to 35% dry matter under vacuum distillation at 55^C and 
spray dried under nitrogen to produce a powder with a moisture content between 3 to 
4%.
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The polyphenol powder had a dark red colour and was soluble in water 
and aqueous in alcohol. The powder was quite palatable but with an astringency 
similar to that of red wine.
5.5 Polyphenol content and intake
The total polyphenol content was determined by the Folin Ciocalteu 
method (Singleton et al 1965) the total polyphenols (in gallic equivalents) were:
Supplement Total polyphenols
Red wine 1.6g/l
White wine 0.2g/l
Red wine polyphenol powder 450mg/g
White wine containing red wine polyphenol powder 1.8g/l
Polyphenol drink 1.36g/l
Alcoholic drink O.Og/1
Alcoholic drink with red wine polyphenols 1.2g/l
Red wine marc (French paradox) 52.0 mg/capsule
Endotelon 107.0mg/tablet,
Green tea extract (Polyphenon tablets) 96.0mg/tablet,
Chocolate 4.9mg/g.
The red wine, and red wine polyphenol powder (from red wine) was 
analysed by ETS Laboratories (St. Helena, CA). Table 5.1 shows the actual phenolic 
content in red wine and extracted red wine polyphenols.
One gram of the powder was dissolved in 25 ml methanol and diluted 
1:1 with de-ionised water and centrifuged for 3 minutes and injected onto an HPLC 
column using the method o f Price et al (1995) which quantifies some of the major 
constituents present in wine. For the wine phenolic compounds present in 375ml of 
red wine 248mg, and Ig polyphenol powder 296 mg/g.
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The chief differences between the wine and extracted red wine 
polyphenol powder were as follows: '
1) The powder contained virtually no phenolic acids, because these were not 
extracted by the resin column used in its preparation.
2) The powder contained about 12 times the level anthocyanin glycosides 
(chiefly malvidin glycoside) than the wine. Presumably this was due to the 
precipitation of these compounds which occurs when red wine is aged.
Table 5.1: Actual phenolic content in compounds (mg/day) in red wine and red 
wine polyphenols.
Peak
No.
Wine Phenolic Compounds ^ Red wine 
mg/375ml
Polyphenol powder  ^
mg/g
1 Catechin 8 11
2 Epicatechin 6 7
3 Procyanidin dimers 18 12
4 Procyanidin polymers 170 190
5 Quercetin glycosides 3 1.7
6 Quercetin 0.4 1.8
7 Myrecetin glycosides 0.8 1.1
8 Myrecetin 0.4 0.4
9 Anthocyanin glycosides ^ 4.5 56
10 Polymeric anthocyanidins 8 9
11 Gallic acid 13 0.8
12 Other phenolic acids^ 13 2
13 trans Resveratrol 3 3
14 cis Resveratrol 0.8 0.3
a) Peaks 1 to 4 are quantified as catechin, 5 & 6 as quercetin, 7 & 8 as myricetin, 
9 & 10 as malvidin, 11 & 12 as gallic acid, 13 & 14 as trans resveratrol.
b) Vintage 1993 kept for two years
c) Prepared from the same red wine before bottling and kept at 5®C
d) Delphinidin, cyanidin, peonidin, petunidin and malvidin glucosides
e) Syringic, caftaric, p.coumaric acids
A qualitative example of
HPLC spectra for red wine and polyphenol powder (Capsule)
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X axis shows the retention time and y axis shows optical density in scan.
KEY: Peakl= Catechin, Peak2= Epicatechin, Peak3= Procyanidin dimers,
Peak4= Procyanidin polymers, Peak5= Quercetin glycosides, Peak6= Quercetin. 
Peak7= Myrecetin glycosides, Peak8= Myrecetin, Peak9= Anthocyanin glycosides. 
Peak 10= Polymeric anthocyanidins, Peakl 1= Gallic acid. Peak 12= Other phenolic 
acids, Peakl3= trans Resveratrol, Peak 14= cis Resveratrol.
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5.6 Separation o f  plasm a
Blood samples were obtained by venepuncture from fasted subjects (12 
hrs overnight fast), at the beginning of the study and after the two week treatment 
period. Blood was collected into K3EDTA (1 mmol/1) tubes and plasma was harvested 
by centrifugation at 2000 x g for 15 minutes at 4^C using MSE Mistral 30001 
refrigerated centrifuge. Aliquots of plasma prior to the analysis o f total antioxidant 
status and total growth factor-B (as described in chapter 6, section 6.4 & 6.5 
respectively) were stored at -70^C prior to analysis. All other analyses were carried out 
on the same day (within 12 hours) on fresh plasma which was stored at 4^C until 
processing.
5.7 Data Analyses
The computer software program Excel version 5 was used for the 
computations (Microsoft, USA) with the addition of Astute (DDU Software, Leeds, 
UK). All results are given as mean ± standard deviation. Evidence for statistical 
differences between pre and post-treatment values was obtained by the student paired 
t-test (2-tailed), having first established that the data fulfilled the following criteria .
1) The data was normal, or approximately normally distributed (descriptive statistic).
2) The number of groups to be compared was equal to two.
The purpose o f the t-test was to assess the significance o f the difference 
in the means of the two groups. If  one is using the pooled variance t-test then a 
preliminary F-test is required to ensure the homogeneity o f variances between the two 
groups otherwise a separate variance t-test can be calculated.
5.8 Total polyphenols in plasma and LDL
Total polyphenols were measured in total plasma and 
isolated LDL at the beginning o f the study and at the end o f 2 week study period
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using the method described in Chapter 2 (section No. 2.6). To 0.5ml o f sample 
(plasma or LDL or standard), 2.5 ml of diluted Folin reagent and 2 ml o f Na2C03 was 
added, incubated at room temperature for 190minutes, centrifuged at 2000g for 10 
minutes. The supernatant was aspirated and its optical density was measured at 
765nm. All test readings were made against the gallic acid standards so that results 
could be expressed in terms o f milligrams of gallic acid equivalent's (polyphenols)/g 
of plasma/LDL protein.
5.8.1 Results
Polyphenol concentration in plasma
The total concentration o f polyphenols in the plasma o f the subjects on 
each supplement, before and after two weeks is shown in Table 5.2. As can be seen, 
from Fig. 5.2(a) all the subjects in the red wine group showed a mean increase of 40% 
in the concentration o f plasma polyphenols after treatment (P=0.002) (16.2 ± 5.7 
versus 22.6 ± 2.7mg/g protein). There was also an increase in polyphenol 
concentration of 29% after supplementation with white wine+lg PP group (17.6 ± 4.2 
versus 22.6 ± 1.7) as shown in (Fig. 5.2(c)) and in the polyphenol powder group (Fig. 
5.2(d)) who showed a mean increase in plasma polyphenols of 28% (21.0 ± 3.0 versus 
26.9 ± 5.4). Subjects taking white wine supplements showed no change in their 
polyphenol concentration (Fig. 5.2(b)). The groups consuming red wine polyphenol 
extract, either in the form of drink or capsules, showed a significant differences in 
their polyphenolic content after supplementation period. Also, subjects in the 
alcohol+1 g PP group showed increase in their plasma polyphenol concentration o f 
27%. There was no significant change in plasma polyphenol concentration in the 
alcohol [post treatment values remained the same in all subjects], sefacal drink, 
endotelon caps.(l/3"^^ group showed an decrease), tea catechin (1/2 the group showed 
an increase which was abolished by the other 50% of the group) and french paradox 
groups. There was no significant differences in the baseline values o f all supplement 
groups before treatment (see Table 5.2).
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Table 5.2: Concentration of plasma polyphenols in volunteers consuming
different treatments for a period of two weeks (mg/g protein), results 
are mean ± SD , values at day 0 and day 14.
Polyphenols mg/g protein
Supplement NO 0 week After 2 
weeks
Diff. of 
mean+ SD
P-value
Red wine RW 9 16.2 ±5 .7 22.6 + 2.7 6.4 + 3.0 0.002
White wine WW 9 18.9 + 5.1 20.3 + 1.5 1.4+ 3.6 0.45
White w ine+lg 
PP
WP 6 17.6 + 4.2 22 .6+ 1 .7 5 .0+  2.4 0.02
Polyphenol 
Powder-1 g
PP 9 21.0 + 3.0 26.9 + 5.4 5 .8+  2.4 0.02
Alcohol AL 5 23 .9+ 1 .0 24 .0+ 1 .2 0 .9+  1.0 0.86
Alcohol + Ig 
PP
AP 4 18.7 + 0.7 23.8 + 0.4 5.1 + 0 .4 0.03
Sefacal drink SD 4 19.3 + 6.4 21.4 + 3.2 2.1 +3 .8 0J5
French paradox FP 6 22.7 + 0.7 23.4 + 0.5 0.8 + 1.1 0.16
Endotelon tabs. EN 6 20.6 + 0.8 21.3+2.1 0 .7+  2.3 0.51
Tea catechin TC 6 21.3 + 1.2 22.1 + 1.6 0.8 + 1.8 0.3
Chocolate CH 6 22.3 + 2.4 24 .2+ 1 .4 2 .0 + 2.0 0.04
Polyphenol
drink
PD 10 21.8 + 1.3 24.0+1.0 2.2 + 1.8 0.006
Polyphenol 
Capsules -2g
PT 6 22.1 + 1.8 23 .8+ 1 .0 1.6 + 1.0 0.01
Vitamin E VE 4 22.7 + 0.9 25.0 + 2.0 2.3 + 1.3 0.04
Vitamin E + lg  
PP
EP 4 22.8 + 0.9 25.3 + 1.8 2.6 + 1.4 0.04
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Effects of different supplements on plasma polyphenols: 
Selected individual responses of plasma polyphenols.
Fig. 5.2 (a): Individual results: Plasma polyphenols for red wine (RW),
PLASMA POLYPHENOLS - RED WINE [RW]
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Fig. 5.2(b) Individual results: Plasma polyphenols for white wine (WW)
PLASMA POLYPHENOLS - WHITE WINE [WW]
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Fig. 5.2(c): Individual results: Plasma polyphenols for 
white wine+lg polyphenol powder(WP)
PLASMA POLYPHENOLS-WHITE WINE+lg POLYPHENOL POWDER [WP]
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Fig. 5.2(d): Individual Results: Plasma polyphenols for Polyphenol powder Ig (PP
PLASMA POLYPHENOLS- POLYPHENOL POWDER Ig  [PP] Subjects
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Selected individual responses o f plasma polyphenols at day 0 and day 14, 
with individual subject code. 5.2(a) for red wine, 5.2(b) for white wine,
5.2(c) for white wine+lg polyphenol powder, 5.2(d) for Ig polyphenol powder.
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5.8.2 Polyphenol concentration in LDL
The total LDL polyphenol concentration o f each supplement tested 
before and after two weeks is shown in Table 5.3.
Table 5.3: Concentration of polyphenols in LDL from volunteers consuming
various treatments for a period of two weeks (mg/g of LDL protein), 
results are mean ±  SD, values at day 0 and day 14.
LDL Polyphenols m g/g protein
Supplement NO 0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. of
meant SD
P-
value
Red wine RW 9 33.6 ± 6.2 42.3 + 8.1 8.8 + 5.2 0.001
White wine WW 9 39.3 + 6.1 38.5 + 9.9 -0.7 + 9.4 0.8
White wine+lg 
PP
WP 6 31.1 ±2.5 45.8 ±3 .6 14.7 ±2.3 0.0001
Polyphenol 
Powder-1 g
PP 9 37.1 ±4 .6 47.6 ± 6.2 10.6 ± 6 .7 0.002
Alcohol AL 5 39.4 ±4.5 43.7 ± 1 .6 4.3 ±4 .2 0.08
Alcohol + Ig 
PP
AP 3 34.2 ± 6.5 41.3 ± 5 .2 7.1 ± 0 .9 0.006
Sefacal drink SD 4 39.9 ±5 .6 36.2 ± 5 .9 -3.7 ± 2 .0 0.52
French paradox FP 6 41.7 ± 3.6 38.4 ± 3 .4 -3.2 ± 3 .0 0.06
Endotelon tabs. EN 6 38.2 ±4 .8 40.7 ± 3 .6 2.5 ± 4.6 0.24
Tea catechin TC 6 36.9 ±6.1 37.3 ± 5.3 0.5 ± 1.2 0.8
Chocolate CH 6 25.6 ± 8.8 38.3 ±7 .5 12.7 ±1.3 0.02
Polyphenol
drink
PD 6 35.9 ±9.1 42.4 ± 6.4 6.5 ±4 .2 0.01
Polyphenol 
Capsules -2g
PT 6 33.9 ±5 .0 44.4 ±5.1 10.5 ±1 .8 0.0001
Vitamin E VE 4 27.1 ±9 .6 39.5 ± 6 .9 12.4 ±7 .5 0.05
Vitamin E + lg  
PP
EP 4 26.4 ± 9.6 41.5 ±3.3 15.2 ± 6.8 0.02
The changes in LDL polyphenols following the various 
supplementation were similar to that observed for total plasma of groups consuming
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red wine, white wine with Ig polyphenol powder, polyphenol capsules 2g. Groups 
(red wine, white wine with Ig polyphenol powder, polyphenol capsules 2g) showing a 
significant difference in LDL polyphenols (increase of 26%, 62% and 29% 
respectively), all showed consistent changes in measures of LDL antioxidant status 
i.e. increase in lag time, and decrease in lipid peroxides and TEARS. These changes 
in LDL were o f a similar magnitude to that seen in plasma. In the copper catalysed 
peroxidation assay, LDL susceptibility to oxidation was increased by 31% for red 
wine, 24% for white wine with Ig polyphenol powder, and 25% for polyphenol 
capsules 2g and the formation of TEARS was decreased by 22%, 24%, 25% 
respectively. Formation of total conjugated dienes was inhibited by 15% for red wine, 
11% for white wine with Ig polyphenol powder, 12% for polyphenol capsules 2g. 
However, in the group consuming alcohol alone there was no elevation in the 
concentration o f LDL polyphenols (See Chapter 6 for antioxidant results).
All subjects but one in the red wine group showed a positive 
polyphenol response in LDL concentration (33.6 ± 6.2 versus 42.3 ± 8.1 mg/g o f 
protein), with a mean increase of 26% after the treatment (Fig. 5.4(a)). In contrast, 
there was no significant difference in LDL polyphenols in the white wine group. The 
group consuming white wine+lg polyphenol powder supplement produced the 
greatest response with a mean rise in LDL polyphenols of 47% (Fig. 5.4(b)). As 
shown in Fig. 5.4(c), an increase of 28% in LDL polyphenol concentration was 
observed, in the group consuming polyphenol powder Ig. This increase in LDL 
polyphenols was 3% more than the red wine group. Furthermore, subjects in the 
chocolate group showed 50% increase in their LDL polyphenol concentration (Fig. 
5.4(d)). This result is in accordance with in vitro inhibition of LDL oxidation, and 
provides evidence to suggests that polyphenols in chocolate can be absorbed in blood.
A difference of 10% in LDL polyphenol concentration in the alcohol 
group was of baseline significance. In the sefacal drink group even though 3/4 '^’ o f the 
group showed a decrease after treatment, results were non-significant. Also results 
were insignificant in groups consuming endotelon tabs., and tea catechin (levels were 
unchanged (36.9 ± 5.6 mg/g protein versus 37.3 ± 5.3 mg/g protein (after 2 weeks)).
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Effects o f different supplem ents on LD L polyphenols;
Selected individual responses of LDL polyphenols.
Fig. 5.4(a): Individual results: LDL polyphenols for red wine (RW),
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Fig. 5.4(b): Individual results: LDL polyphenols for 
white wine+lg polyphenol powder (WP)
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Fig. 5.4(c): Individual results: LDL polyphenols for Polyphenol powder Ig (PP)
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Fig. 5.4(d): Individual results: LDL polyphenols for Chocolate (CH).
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Selected individual responses of LDL polyphenols at day o and day 14, 
with selected individual code. 5.4(a) for red wine, 5.4(b) for white wine+lg 
polyphenol powder, 5.4(c) for polyphenol powder, and 5.4(d) for chocolate.
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5.9 DISCUSSION
Red wine is known to contain substantially more polyphenols than 
white wine. At the beginning o f the study various wines were analysed for their 
polyphenolic content using the method described in Chapter 2 (section 2.6). Results 
obtained for both wines varied from the country o f origin, for white wine it was % 
0.2g/l and for red « 1.6g/l. Frankel et al (1993) showed previously that phenolic 
substances in red wine possess antioxidative properties directed against lipid 
peroxidation in LDL in vitro. To extend these observations we examined the 
relationship between the phenolic content o f LDL and (the oxidation status o f plasma) 
its susceptibility to oxidation in vitro in relation to the oxidation status o f plasma.
Whilst Furnham et al (1995) showed a 4-fold increase in total 
polyphenol concentration after 2 weeks of red wine consumption, in this study plasma 
polyphenols in red wine were elevated by 40%, and LDL polyphenols by 26% after 2 
weeks of supplementation. This discrepancy may be due to a difference in the 
polyphenol content o f the wines which originated from different countries. Furnham 
used Israeli wine whereas French wine was used in the present study. Frankel et al
(1995) studied 20 selected California wines by measuring their capacity to influence 
the copper catalysed oxidation of human LDL. The relative inhibition o f LDL 
oxidation varied from 46% to 100% with the red wines and from 3 to 6% with the 
white wines. When the phenolic content wine was standardised (compared at the same 
total phenol concentration), the inhibition of LDL oxidation varied from 37 to 65% 
with the red wine and from 27 to 46% with white wines.
Abu-Amsha et al (1996) carried out a study, in which they examined 
the nature of phenolic compounds in red wine. The red wine was analysed, after the 
hydrolysis of glycosides, for its major antioxidant components. Their results showed 
that caffeic acid and protocatechuic acid were two major components o f red wine. 
Although, much scientific interest has focused on flavonoids, Abu-Amsha suggested 
that the phenolic, non-flavonoid compounds may contribute significantly to the
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antioxidant capacity of red wine. Compounds with the catechol- type structure have 
been shown to be better than monoprotic phenols in inhibiting peroxyl-initiated 
oxidation in LDL. This phenomenon can probably be explained by the ability of the 
formed anti-oxidant radicals to be resonance stabilised. Catechol structures are also 
found in catechin, a major flavonoid component of red wine. The predominant 
mechanism for protection of LDL oxidation by caffeic acid appears to be free radical 
trapping, thus effectively sparing a-tocopherol from oxidation.
In the group consuming chocolate consuming, the 50% increase in 
LDL polyphenol concentration after 2 weeks of supplementation were consistent with 
Kondo et al (1996) findings. Waterhouse et al (1996) carried out a study, in which 
cocoa powder was extracted with 95% methanol and hexane. The methanol extract 
was evaporated in a vacuum with additions of water to eliminate the methanol and 
then centrifuged to give an aqueous solution. Total phenol levels were measured by 
the same method used in this study. Their result showed that cocoa powder or 
chocolate contains 20mg total phenol gallic acid equivalent (GAE). Using this 
information Kondo et al (1996) carried out a supplementation study and confirmed 
that cocoa increased the concentration o f polyphenols in LDL. Following these 
observations, the 50% increase in LDL polyphenols produced after 2 weeks of 
chocolate supplementation was an expected finding.
In the present study, 2 weeks of alcohol consumption produced no 
significant difference in plasma and LDL polyphenol concentration, whereas alcohol 
given with 1 g of polyphenol showed a significant difference in both plasma and LDL 
polyphenol concentrations. This would tend to confirm that polyphenols extracted 
from red wine, are another important factor in elevating plasma and LDL polyphenol 
concentrations. This result was in accord with that obtained by Abu-Amsha et al
(1996). In this study, regular beer drinkers consuming a high-alcohol beer showed an 
increase in the susceptibility o f LDL to oxidation as compared to those consuming a 
low-alcohol beer. Both high and low alcohol beers had the same phenolic content. 
These results and those of Furnham et al (1995) confirm that phenolics in alcoholic
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beverages counteract the potentially pro-oxidant effects o f ethanol, such that lo'w- 
phenolic beverages like white wine or beer may have a net pro-oxidant effect while 
red wine while red wine could have a net anti-oxidant influence.
The link between human cancer and the consumption o f green tea is of 
major interest. This relationship has been studied in different populations by many 
investigators, but no clear-cut conclusions have as yet, been drawn (Yang et al 1993). 
In the present study supplementation with tea catechin for 2 weeks produced no 
significant effects on plasma and LDL polyphenols. The effects of tea catechin on 
LDL polyphenols showed considerable variability between subjects. Two thirds of the 
group showed an increase in polyphenol concentration, whereas one third showed a 
decrease. This may be due to the fact that the tea catechin supplements were a 
commercially available product named as ‘polyphenon capsules’ claiming to contain 
mostly of tea catechins (lOOmg), and may be the absence o f bio-avalibility, thus 
compromising the results. Another explanation for this negative result may be due to 
the ihct that even though tea catechins are absorbed in the gut, they remain in 
circulation for a short time. The insignificant effects obtained for LDL polyphenols 
may be due to the fact that all tea catechins are excreted after 24h and none remain in 
circulation (Lee et al 1995). Nevertheless, there is still evidence to suggest that tea 
catechins are beneficial to health. The study of Yang et al (1993), investigated 
protection against tobacco-specific nitrosamine-induced lung tumorigenesis by green 
tea. They found that caffeine inhibited chemical carcinogenesis.
Some studies have shown a protective effect of green tea consumption 
against certain types o f cancers, other studies have indicated the opposite effect. 
Experimental studies have demonstrated inhibitory effects of green tea polyphenols 
against the formation and growth of tumours. This inhibitory activity is believed to be 
mainly due to the anti-oxidative and possible anti-proliferative effects o f polyphenolic 
compounds in green tea. Lagopoulos et a l { \9 9 \ )  also found that caffeine-induced 
effects on body weight were associated with decreased hepatocarcinogenesis by 
diethyl nitrosamine.
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There was no significant increase in polyphenol concentrations either
in plasma or in isolated LDL fractions after supplementation with french paradox
capsules containing grape skin residue (after wine making), or endotelon tablets
containing proanthocyanidines. After measuring the total polyphenol content in the
endotelon tablets (as described in Chapter 2), it was found to be 107.0mg/tablet, (three
tablets were given daily (321mg/day)). Therefore, even a very high dose of these
compounds for a period o f 2 weeks failed to influence polyphenol levels in plasma
and LDL concentrations. This finding might suggest that, if these substances are , 
then they
absorbed in the guf,\^  are excreted within short time and hence are not contributing 
to the protection o f LDL against oxidation.
The lack o f response to french paradox capsules was somewhat 
surprising given that this product was being marketed by the company, with the claim 
that each capsule contains ‘the same amount of polyphenols as in a half bottle of red 
wine’. When the polyphenolic content of capsules was determined using the method 
as described in Chapter 2 (section 2.6) it was 52mg/capsules (3 capsules were given 
daily (156mg/day) i.e. three times the dose indicated in the manufacturer's 
instructions). This study could show no effects of these capsules in any o f the 
volunteers. In vitro analysis o f the same capsules showed that polyphenol 
concentration 0.4pg, o f capsule was sufficient to inhibit the oxidation o f LDL within 
18 minutes, a result similar to the effects of chocolate (19minutes). This therefore 
confirms that the polyphenols present in french paradox capsules are not in the bio- 
available form. Nevertheless, extracted red wine polyphenols in capsules were shown 
to produce a marked increase in the content of polyphenols in plasma and LDL, 
suggesting that extracted wine polyphenols were in bio-avilable form.
The levels of total phenols as determined by the Foilin-Ciocalteu 
method, do not provide an absolute measure of the phenolic content o f plasma since 
this assay is based on the chemical reducing capacity o f phenols relative to an 
equivalent reducing capacity of gallic acid. Phenolic compounds have been shown to 
give variable responses in this assay (Singleton et al 1965). The response o f this
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assay in terms o f moles o f phenols is roughly proportional to the number o f phenolic 
hydroxyl groups in a given substrate, but the reducing capacity is enhanced when two 
phenolic hydroxy groups are oriented in either the orthro or para position. Since these 
structural features o f phenolic compounds are reportedly also responsible for their 
antioxidant activity (Letan et al 1966), measurement o f total phenols in plasma and 
LDL may be related to their antioxidant activities.
This study extends the findings o f previous workers to an in vivo 
situation, and demonstrates that total concentration o f polyphenols in plasma and LDL 
can be increased after dietary consumption o f wine and related products. This 
indicates that polyphenols extracted from red wine are absorbed from the gut into the 
circulation, in the absence o f alcohol and thus can then exert their antioxidant 
characteristics. This is consistent with previous studies which have provided evidence 
to show that intestinal absorption of quercetin, quercetin gluocosides and phenolic 
acids occurs in humans (Hollman et al 1995). In spite o f the known antioxidant 
potential o f polyphenols in LDL no association could be demonstrated between 
plasma and LDL total polyphenols using standard test o f correlation (Pearson)^ 
probably the group number was small.
CHAPTER 6 
Human Intervention trial (II) : Effects of dietary 
polyphenol supplements on antioxidant responses.
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6.0 Introduction
It is now widely accepted that the LDL which is oxidised in the 
subendothelial regions o f the artery originates from plasma. As LDL appears to pass 
readily across the endothelium, modified LDL may migrate back into plasma (Chirico 
et al 1993). The propensity of the LDL to oxidise may be determined, at least in part, 
by the properties and composition o f the lipoproteins as they are found in the plasma, 
even though the oxidation may not occur until it had passed into the arterial intima. 
Therefore, the interest in the effects of oxidation in vitro o f LDL which has been 
isolated from plasma seems rational.
The oxidation of LDL by transition metals like cupric ions is based on
the concept that LDL, like other lipoproteins, contain trace amounts o f endogenous
lipid hydroperoxides which are present in the lipid fractions; largely phospholipid or
cholesteryl ester hydroperoxides. When these are exposed to transition metal ions,
such as copper, the oxidative and reductive decomposition of the peroxides can occur
yielding peroxyl and alkoxyl radical species. This leads to the propagation of radical
attack on the polyunsaturated fatty acids and the formation of new lipid peroxides
I &tty acids
which pass through the cycle o f events until the polyunsaturated^re consumed. This 
process does not occur instaneously in most cases because of a ‘resistance’ to 
oxidation presumed to be due, at least in part, to the presence of antioxidants. The first 
event in this process appears to be the progressive disappearance o f the constituent 
antioxidants in an order which will be dependent on their reactivity taking into 
account their ability to recycle or be generated by other antioxidants.
When this so-called lag phase is completed the propagation phase 
begins with the acceleration of the oxidation o f the polyunsaturated fatty acids, and 
amplification of conjugated diene formation, the latter of which provides a real 
biomarker of this process. Afterwards there is the appearance of the major oxidation 
products of fatty acid oxidation, the lipid peroxides and also a variety o f aldehydes 
and hydroxyaldehydes, some of which are measurable. The appearance o f most of
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these products reaches a peak after a few hours and they degrade or react with the 
protein constituents of the LDL.
6.1 Determination of oxidative resistance in LDL (lag-phase-minutes)
The conjugated diene assay is a very convenient assay o f monitoring 
the oxidation process by ultra violet spectrophotometry. The measurement may be 
translated into a number o f parameters, the most important of which is the lag time.
An alternative is the lag time required to produce 50% of maximum oxidation which 
is helpful in samples that are very susceptible to oxidation. This continuous 
measurement allows the investigation o f the effects o f pro- and antioxidants in a 
quantitative and reproducible manner and has significant advantages in LDL oxidation 
studies.
6.1.2 Subjects and M ethods
As described in the study design (chapter 5, section 5.3), volunteers 
were given a single supplement from a range of 15 different polyphenol preparations 
over a 2 week period. All volunteers were asked to maintain their habitual diet and 
lifestyle. Plasma was separated from blood, and LDL was isolated as described in 
Chapter 2 (section 2.2).
LDL (0.05mg/ml) was incubated in the presence of copper sulphate 
(CuSo4 ) (5pmol/l) at 37°C for 6 h and the change in absorbance was monitored every 
5 minutes at 234nm. The lag time in minutes was calculated for each treatment and 
total conjugated dienes formed (pmol/g protein) were calculated for red wine, white 
wine, white wine+lg polyphenol powder. Polyphenol powder Ig, and alcoholic drink 
10% ethanol/day as described previously in Chapter 2 (section 2.5.1).
6.1.3 Results
6.1.3.1 Lag tim e
The time-course of conjugated diene formation was similar
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to that previously described by Esterbauer et al 1989. The lag time and maximal 
amount of conjugated diene formation were determined from the curve. The oxidative 
susceptibility of LDL for each supplement, before and after 2 weeks is listed in Table 
6.1. As can be seen from Fig. 6.2(a) all the subjects in the red wine group showed a 
mean increase in their lag phase after treatment o f 34%. Subjects taking white wine 
supplements showed no change in their lag phase (63.8 ± 18.5 min (control) versus
63.6 ± 9.9 min.) (Fig 6.2(b)).
Table 6.1: Copper catalysed oxidation lag times (minutes) in volunteers
consuming various treatments for a period of two weeks. Results are 
mean ± SD, values at day 0 and day 14.
Lag tim e in m inutes
Supplement NO 0 Week After 2 weeks Diff. of 
meant SD
P-
value
Mean ± SD Mean ± SD
Red wine RW 9 51.6 ± 7.6 69.3 ±18.4 17.8 ± 15.1 0.008
White wine WW 9 63.8 ± 18.5 63.6 ± 9.9 -0.22 ± 11.2 0.95
White wine+lg WP 6 54.8 ± 2.6 66.5 ± 5.2 11.7 ± 6.4 0.007
PP
Polyphenol PP 9 51.7 ± 5.6 65.9 ± 12.8 14.2 ± 11.6 0.006
Powder-1 g
Alcohol AL 5 54.0 ± 4.6 56.6 ±4 .2 2.6 ± 3 .2 0.14
Alcohol + Ig AP 3 56.3 ± 2.5 66.0 ±5.3 9.7 ±3 .5 0.04
PP
Sefacal drink SD 4 53.0 ± 4.4 51.5±3.1 -1.5 ± 5 .9 0.65
French paradox FP 6 62.0 ± 2.8 60.3 ± 5 .2 -1.7 ± 5 .6 0.5
Endotelon tabs. EN 6 69.5 + 2.4 62.8 ± 5.4 -6.7 ± 2.2 0.5
Tea catechin TC 6 66.2 + 4.4 59.3 ± 5.4 -6.8 ± 5.6 0.03
Chocolate CH 6 67.3 ± 5.5 77.5 ± 6.7 10.2 ±7.1 0.02
Polyphenol PD 10 68.6 ± 13.9 84.5 ±18.4 15.9 ±10.3 0.0009
drink
Polyphenol PT 6 62.7 ± 6.2 75.8 ± 6.9 13.2 ± 6 .4 0.004
Capsules -2g
Vitamin E VE 4 65.5 + 5.5 132.5 ±13.0 67.0 ± 12.9 0.002
Vitamin E + lg EP 4 60.8 + 4.0 129.0 ± 9.2 68.3 ±8.1 0.0004
PP
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Polyphenol powder (Fig. 6.2(c)) proved to be a potent compound by 
producing an increase in lag time of 28%, 51.7 ± 5.6 min (control) versus 65.9 ± 12.8 
min (after 2 weeks). All nine volunteers in the polyphenol powder group showed an 
increased resistance to oxidation of 28%. Fig. 6.2(d) shows an increment in lag phase 
of the vitamin E group of 100%. Supplementation with Vitamin E produced the 
greatest increase in lag phase (65.5 ± 5.5 min (control) versus 132.5 ± 13.0 min (after 
2 weeks)), which was quite prolific compared to white wine, which showed none (63.8 
± 18.5 min (control) versus 63.6 ± 9.9 min (after 2 weeks)). White wine containing 
added phenols produced an increase in the resistance o f LDL to oxidation which was 
of a similar magnitude to that seen with red wine.
The bio-avilability of extracted polyphenols in the present study was
similar when they were consumed either as cansules. drink or along with alcohol. The
. ! identical to vitamin E even
LDL susceptibility to oxidation was! _ . ' when extracted polyphenols
were given along with vitamin E (60.8 ± 4.0 min (control) versus 129.0 ± 9.2 min
(after 2 weeks)).
As seen from Table 6.1, shows that there was no inhibition in the lag 
phase in the groups consuming alcohol, sefacal drink, french paradox, endotelon, and 
tea catechin (P>0.05).
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Effects of different supplements on lag time: 
Selected individual responses in copper lag time.
Fig. 6.2(a): Individual results: Lag time for red wine (RW),
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Fig. 6.2 (b): Individual results: Lag time for white wine (WW)
LAG TIME IN MINUTES WHITE WINE (WW)
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Fig. 6.2 (c): Individual results: Lag time for polyphenol powder Ig (PP)
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Fig. 6.2 (d): Individual results: Lag time for vitamin E (VE)
LAG TIME VITAMIN E (VE) Subjects
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Selected individual responses of lag times at day 0 and day 14, with
individual subject code. 6.2(a) for red wine, 6.2(b) for white wine, 6.2(c) 
for white wine+lg polyphenol powder, 6.2(d) for Ig polyphenol powder.
131
6.1.3.2 T otal conjugated dienes.
Total conjugated dienes were decreased (see Table 6.2) in all 
volunteers consuming red wine (15.5%), polyphenol powder Ig groups (12%) and 
white wine with Ig polyphenol powder (11%). Whereas conjugated dienes were 
increased, 14% in the groups consuming white wine (7 subjects out o f 9 showed an 
increase), and 2 % in alcohol (1/2 the group showed increase & rest 1/2 decrease).
Table 6.2: LDL Copper catalysed peroxidation - Conjugated dienes in pmol/g
LDLprotein in volunteers consuming various supplements for period of 
2 week, results are mean ± SD, for day 0 and day 14.
Supplement NO 0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. of
M eant SD
P-
value
pmole/g LDL pro tein
Red wine RW 9 685 ± 75 579 ± 84 -106 + 57 0.0008
White wine WW 9 732 ± 126 833 ± 138 +101 ± 9 0 0.012
White
wine+lg PP
WP 6 809 ± 83 719 + 49 -90 ± 49 0.007
Polyphenol 
Powder-1 g
PP 9 803 ±71 709 ± 45 -93 ± 66 0.004
Alcohol AL 6 750 + 127 770 ± 76 20 ± 7 6 0.6
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Fig. 6.3: The effects o f 5 supplements on total conjugated dienes.
a) red wine (RW),
b) white wine (WW),
c) white wine + Ig polyphenol powder (WP),
d) polyphenol powder Ig (PP),
e) Alcohol (AL)
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Values represent the means o f 9 subjects for red wine, white wine, polyphenol 
powder and 6 subjects for white wine 1 g polyphenol powder, alcohol.
The data shows baseline value versus 2 weeks o f supplementation.
There was a statistically significant difference for 4 supplements (red wine, 
white wine, white wine + Ig polyphenol powder, polyphenol powder Ig, 
and alcohol) with the P value being less than 0.05 in each case. Alcohol 
showed no statistically significant difference (P=0.6 *).
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6.2 Lipid peroxides
Lipid peroxidation, defined as the oxidative deterioration of 
polyunsaturated fatty acids, is a free radical-mediated phenomenon. It occurs via a 
chain reaction mechanism and may be initiated enzymatically or non-enzymatically. 
Polyunsaturated fatty acids of cell membranes and lipoproteins are destroyed in the 
event o f peroxidation, leading to destabilisation and disintegration o f cell membranes. 
Several pathogenic conditions have been shown to involve lipid peroxidation.
Lipid peroxides in plasma were measured at baseline and after 2 weeks 
of supplementation using the method as described in Chapter 2 (section 2.7.1).
6.2.1 Plasm a lipid peroxides
All plasma lipids and lipoproteins were selectively removed by PHM- 
L-liposorb. Dry PHM-L-liposorb was suspended in 0.24 ml o f 150 mM sodium 
chloride containing 10 mM sodium citrate in a 2 ml micro centrifuge tube, the 
contents were mixed by stirring and allowed to equilibrate for 5 min. Plasma (0.5 ml) 
or saline (blank) was then added to the liposorb suspensions, stirred and the tubes 
placed in the horizontal shaker for 15 min. After centrifugation (12,000g for Imin), 
the supernatant was discarded and the liposob gel washed twice with 1.5ml saline 
followed by stirring and centrifugation. The washed liposorb gel was suspended in 
1.2ml of CHOD-iodide reagent and incubated for Ih at RT. After centrifugation 
optical density was measured at 405nm.
6.2.. 1.1 Results
Table 6.3 shows the concentrations of lipid peroxides in plasma 
(pmoles/1) in 15 groups o f volunteers consuming different supplements over a period 
o f 2 weeks. Statistically significant decreases in mean plasma lipid peroxides were 
recorded for 9 supplements. O f the total group, 9 supplements produced a significant 
decrease and 5 a non-significant decrease in plasma lipid peroxides. Only one group
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(white wine) showed a statistically significant increase in plasma lipid peroxides i.e. a 
potentially pro-oxidant effect.
Table 6.3: Concentration of lipid peroxides in plasma (pmoles/1) in volunteers
consuming RW, WW, WP, PP, AL, AP, SD, FP, EN, TC, CH, PD, PT, 
VE, EP for two weeks. Results are mean ± SD, for day 0 and day 14.
Plasma lipid peroxides (pmoles/1)
Supplement NO 0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. o f
mean± SD
P-
V alue
Red wine RW 8 2.21 ±0.70 1.42 ±0.34 -0.79 ±0.80 0.03
White wine WW 9 1.73 ±0.55 2.15 ±0.65 0.42 ±0.41 0.02
White wine+lg 
PP
WP 6 1.70 ±0.51 1.19±0.19 -0.51 ±0.32 0.01
Polyphenol 
Powder-1 g
PP 7 1.90± 0.52 1.37 ±0.38 -0.53 ±0.43 0 .0 2
Alcohol AL 5 1.60 ±0.25 1.47 ±0.40 -0.13 ±0.35 0.5
Alcohol + Ig 
PP
AP 3 2.21 ±0.41 1.48 ±0.11 -0.73 ±0.31 0.05
Sefacal drink SD 4 2.13 ±0.48 2.01 ±0.96 -0.12 ±0.64 0.73
French paradox FP 6 1.97 ±0.48 1.84 ±0.53 -0.14 ±0.75 0.7
Endotelon tabs. EN 6 1.69 ±0.13 1.46 ±0.47 -0.23 ± 0.52 0.3
Tea catechin TC 6 1.49 ±0.46 2.08 ± 1.05 0.59 ±0.80 0.1
Chocolate CH 7 1.82 ±0.33 1.31 ±0.26 -0.51 ±0.10 0.04
Polyphenol
drink
PD 6 1.67 ±0.36 1.43 ±0.32 -0.24 ±0.13 0.007
Polyphenol
Capsules-2g
PT 6 1.72±0.11 1.36 ±0.17 -0.37 ±0.11 0.005
Vitamin E VE 4 1.93 ±0.39 1.67 ±0.42 -0.26 ±0.10 0.01
Vitamin E + lg  
PP
EP 4 1.79 ±0.18 1.46 ±0.22 -0.33 ±0.15 0.02
When the 9 groups were taken together the mean decrease in plasma 
lipid peroxides was 25%. Figure 6.5(a) shows the effect of red wine on plasma lipid 
peroxides. All subjects showed a marked decrease in plasma lipid peroxides (mean 
decrease -36%) after 2 weeks of supplementation with red wine. This response was
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particularly evident in subjects with high baseline peroxide values in excess of 
2.5pmol/l. In contrast, supplementation with white wine produced a rharked increase 
in lipid peroxides (pro-oxidant effect) (36% increase) (Fig. 6.5(b)). White wine 
containing added phenols produced reductions in plasma lipids (Fig. 6.5(c)) which 
were of similar magnitude to that seen with red wine. As can be seen from Fig. 6.5(d) 
polyphenol powder alone proved to be the more efficacious by producing a fall in lipid 
peroxides of 28%. The remaining groups (alcohol with Ig of polyphenol powder, 
chocolate, polyphenol drink, polyphenol capsules 2g, vitamin E, and vitamin E with 
Ig o f polyphenol) produced consistent decreases in peroxides that were relatively 
similar.
There was no difference in base line values and after 2 weeks o f 
supplementation for the groups consuming: alcohol, sefacal drink, french paradox, 
endotelon tablets and tea catechins.
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Effects of different supplements on plasma lipid peroxides: 
Selected individual responses of plasma lipid peroxides.
Fig. 6.5(a): Individual results: Plasma lipid peroxides for red wine (RW),
PLASMA LIPID PEROXIDES-RED WINE
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Fig. 6.5(b): Individual results: Plasma lipid peroxides for White wine (WW),
PLASMA LIPID PEROXIDES-WHITE WINE[WW]
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Fig. 6.5(c): Individual results: Plasma lipid peroxides for 
White wine+Polyphenol powder (WP)
PLASMA LIPID PEROXIDES-WHITE WINE+lgPOLYPHENOL POWDER[WP]
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Fig. 6.5(d): Individual Results: Plasma lipid peroxides for
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Selected individual responses o f plasma lipid peroxides at day 0 & day 14, 
with individual subject code. 6.5(a) for red wine, 6.5(b) for white wine, 
6.5(c) for white wine polyphenol powder, 6.5(d) for polyphenol powder.
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6.2.2 LDL Lipid peroxides
Lipid peroxides in isolated LDL were measured at the beginning of the 
study (as base line) and after 2 weeks of supplementation, as described in Chapter 2 
(section 2.7.2). Purified and desalted (either by dialysis or by column), LDL 
(0.05mg/ml) was incubated in the presence of copper sulphate (final cone. 5pM) at 
37^C for 270 min. Oxidation was terminated by refrigeration at 4^C and by the 
addition o f EDTA (0.1 mmol/1). CHOD reagent was then added, and incubated at room 
temperature for 60 min, eentrifuged at 2500g for 8 minutes. The optical density of the 
supernatant was measured at 405nm.
6.2.2.1 Results
Table 6.4 shows the concentration of lipid peroxides in LDL, in 15 
different groups of volunteers each consuming one of 15 different supplements.
The results showed that signifieant decreases in mean LDL lipid peroxides were 
recorded for 9 supplements whilst 6 supplements showed no significant decrease in 
LDL lipid peroxides.
Red wine produced the most pronounced and consistent response 
(decrease in LDL peroxides o f 34%)(Fig. 6.7(a)). All the subjects in the group 
consuming white wine coupled with polyphenol powder showed mean decrease of 
41% (Fig. 6.7(b)) whilst those supplemented with polyphenol powder showed a mean 
31% decrease (216.3 ± 37.9 pmoles/g protein (control) versus 148.5 ± 45.4 pmoles/g 
protein (after 2 weeks)(Fig. 6.7(d)). Whereas white wine produced non-significant 
result (two thirds o f the group showing a decrease & one third increase)(Fig 6.7(c)).
In addition, a reduction in LDL lipid peroxides was recorded in the 
following groups, in decreasing order of magnitude relative to red wine were Vitamin 
E with 1 g o f polyphenol powder (39%), vitamin E (36%), chocolate (29%), 
polyphenol drink (28%), polyphenol capsules 2g (26%), and alcohol with Ig of 
polyphenols (24%). The remaining groups (alcohol, sefacal drink, french paradox, and
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tea catechin) showed no effect with the notable exception of endotelon, which showed 
an increasing trend (155.8 ± 61.9 pmoles/g protein (control) versus 182.7 ± 33.9 
pmoles/g protein (after 2 weeks)).
Table 6.4: Concentration of lipid peroxides in LDL (pmoles/g of LDL Protein) in 
volunteers consuming various treatments for a period of two weeks. 
Results are mean ± SD, for day 0 and day 14.
LDL lipid peroxides 
(pmoles/g of Protein)
Supplement NO 0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. of 
mean± SD
P-
Value
Red wine RW 8 236.1 +82.8 155.0 ±57.9 -81.1 ±46.0 0.008
White wine WW 9 170.4 ±47.9 187.7 ±58.2 17.3 ±39.4 0.2
White
w ine+lg PP
WP 6 216.5 + 73.6 127.9 ± 57.3 -88.6 ±45.0 0.005
Polyphenol 
Powder-1 g
PP 9 216.3 ±37.9 148.5 ±45.4 -67.7 ±51.8 0.004
Alcohol AL 5 137.6 ±45.7 173.9 ±43.6 36.4 ± 50.4 0.2
Alcohol + Ig 
PP
AP 3 168.0 ±46.9 127.1 ±62.4 -40.9 ± 54.7 0.01
Sefacal drink SD 4 150.0 ± 61.6 143.1 ±39.8 -6.9 ± 32.4 0.7
French
paradox
FP 6 136.3 ±47.9 128.5 ±25.6 -7.9 ± 70.6 0.8
Endotelon
tabs.
EN 6 155.8 ±61.9 182.7 ±33.9 26.8 ± 57.4 0.3
Tea catechin TC 7 205.3 ± 66.7 194.7 ±39.4 -10.7 ±85.5 0.8
Chocolate CH 7 200.9 ± 30.7 143.3 ±35.4 -57.6 ± 50.9 0.02
Polyphenol
drink
PD 6 161.0 ±37.5 116.1 ±29.8 -45.0 ±26 .9 0.009
Polyphenol
Capsules-2g
PT 6 219.5 ±76.6 162.1 ±53.1 -57.5 ± 24.8 0.002
Vitamin E VE 4 242.3 ± 54.2 156.1 ±42.7 -86.2 ±41.9 0.03
Vitamin E 
+ lg P P
EP 4 237.3 ± 36.8 145.4 ± 26.9 -91.9 ±47.8 0.03
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Effects of different supplements on LDL lipid peroxides; 
Selected individual responses of LDL lipid peroxides.
Fig. 6.7(a): Individual results: LDL lipid peroxides for red wine (RW),
LDL LIPID PEROXIDES-RED WINE [RW]
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Fig. 6.7(b): Individual results: LDL lipid peroxides for White wine (WW),
LDL LIPID PEROXIDES-WHITE WINE[WW]
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Fig. 6.7(c) Individual results: LDL lipid peroxides for White wine+lg polyphenol 
powder (WP)
LDL LIPID PEROXIDES-WHITE WINE+lg POLYPHENOL POWDER[WP]
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Fig. 6.7(d): Individual results: LDL lipid peroxides for Polyphenol powder (PP)
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Selected individual responses o f LDL lipid peroxides at day 0 and day 14. 
with individual subject code. 6.7(a) for red wine, 6.7(b) for white wine, 
6.7(c) for white wine+polyphenol powder, 6.7(d) for polyphenol powder.
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6.3 Thiobarbituric acid reactive substances (TEARS)
The majority of previous studies which have employed thiobarbituric 
acid (TEA) tests, have reported their results in terms of parts permillion of 
malonaldehyde. However, it is more accurate to use the expression “thiobarbituric 
reactive substances”(TBARS) because many more compounds than malonaldehyde 
react with TEA. The lipids of LDL contain large amounts o f both linoleic and 
arachidonic acid in the cholesterol esters and phospholipids which undergo oxidation. 
Disappearance of arachidonic acid and of linoleic acid can be measured with the 
appearance of oxidation intermediates (conjugated dienes), lipid peroxides and 
aldehydic oxidation products e.g. MDA, 4 hydroxynonenal and hexanal. The 
determination of thiobarbituric acid reactive substances (TEARS) primarily measures 
the release o f malonaldeyde which arises from the oxidation of archidonic acid rather 
than linoleic acid.
02, hydrolysis, heat 
Cyclic Endoperoxide ^  Malonaldehyde + alkenes etc.
The formation of lipid peroxides in LDL was measured by determining 
the amount o f TEARS as described in Chapter 2 (section No. 2.8), and expressed as 
malondialdehyde (MDA) equivalents per gram of LDL protein. The effect o f LDL 
oxidation on the formation of lipid peroxides was expressed by subtracting the amount 
present in native LDL from the amount in oxidised LDL.
TEARS were measured spectrophotometrically. To terminate the 
oxidation copper sulphate (5pmoles/l) buffer, containing EDTA was added (final 
conc. 0.1 mmol/1) to 1ml o f the post-incubated mixture containing 0.05mg/ml LDL 
protein. A further 2ml of TCA-TEA-HCL reagent was added to the mixture and the 
tubes were placed in a boiling water bath for 15minutes. After cooling, the tubes were 
centrifuged, and the absorbance of the supernatant was measured at 535nm.
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6.3.1 Results
The concentrations of TEARS in LDL (pmoles/g of LDL protein) 
before and after -oxidation in volunteers consuming 15 various supplements over 
a period of 2 weeks are summarised in Table 6.5.
Table 6.5: Conc. of TEARS in LDL (pmoles/g of LDL Protein) in volunteers
consuming various supplements for two weeks, results are mean ± SD, 
for day 0 and day 14.
LDL TEARS 
(pmoles/g of Protein)
Supplement N
O
0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. of 
m eant SD
P-
V alue
Red wine RW 9 34.7 ±5 .8 26.9 ±4 .9 -7.7 ± 1.1 0.0004
White wine WW 9 30.1 ±6 .0 36.5 ±7 .0 +6.5 ± 2.7 0.0001
White wine+lg 
PP
WP 6 39.9 ± 3 .9 30.5 ±2 .6 -9.3 ± 2.5 0.0003
Polyphenol 
Powder-1 g
PP 7 37.9 ± 8 .8 28.3 ±6 .8 -9.6 ± 2.4 0.02
Alcohol AL 4 36.5 ± 4 .7 29.3 ± 1.7 -7.2 ± 3.0 0.07
Alcohol + Ig 
PP
AP 3 33.6 ±4 .2 22.4 ± 1.1 -11 .2±3 .2 0.03
Sefacal drink SD 4 32.0 ± 3 .7 28.3 ± 8.2 -3.7 ± 5.7 0.5
French paradox FP 6 29.5 ± 5 .4 29.9 ±2.1 +0.4 ±3 .5 0.9
Endotelon tabs. EN 6 34.4 ± 7 .0 38.8 ±6 .9 +4.4 ± 1.7 0.2
Tea catechin TC 7 29.0 ±4 .8 29.9 ±4 .2 +0.9 ± 0.4 0.6
Chocolate CH 7 30.4 ±4 .2 26.3 ± 3.6 -4.2 ± 1.3 0.0001
Polyphenol
drink
PD 6 31 .7± 2 .6 27.8 ± 3.4 -3.9 ± 1.9 0.02
Polyphenol
Capsules-2g
PT 6 34.8 ±5.8 28.1 ±7 .2 -6.7 ± 2.6 0.02
Vitamin E VE 4 28.5 ±4 .2 23.6 ±3 .6 -5.0 ±2.1 0.02
Vitamin E + lg  
PP
EP 4 28.9 ±4.1 23.9 ±3 .2 -5.0 ± 2 .2 0.02
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Table 6.5 shows that approximately 66% of the supplements produced 
statistically significant decreases in mean LDL TEARS, whereas 33% o f the 
supplements produced non-significant effects.
Supplementation with red wine (Fig. 6.9(a)) was associated with a 22% 
decrease in TEARS, whereas, supplementation with white wine produced the opposite 
effect i.e. a pro-oxidant effect. The white wine group showed a mean increase of 22% 
(P=0.001) Fig. 6.9(b). However, LDL oxidation was inhibited by 24%, when subjects 
were supplemented with white wine in combination with polyphenol powder. 
Polyphenol powder produced the greatest fall in TEARS formations (Fig. 6.9(c)). In 
contrast, alcohol on its own had no effect on TEARS, though, inhibition o f LDL 
oxidation was significant when alcohol was coupled with Ig o f polyphenol powder 
(p=0.03). The base line plasma TEARS values for alcohol+lg polyphenol powder was
33.6 pmoles/g o f protein, similar to the red wine group (34.7 pmoles/g o f protein), 
however, the inhibition in LDL TEARS after 2 weeks o f supplementation by this 
group was 33% compared to red wine 22%, suggesting that polyphenol powder with 
alcohol can enhance the inhibition effect of TEARS.
The following supplements also showed a significant decrease in 
TEARS formation (P=0.02), in descending order of response: vitamin E, and vitamin 
with Ig of polyphenol powder chocolate, polyphenol drink, polyphenol capsules 2g,.
It was interesting to note that there was variation, but no significant 
change in LDL TEARS after supplementation by sefacal drink, french paradox, 
endotelon tablets, and tea catechin. Whereas grape skin residue (french paradox caps.), 
and tea catechin had no effect whatsoever.
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Effects of different supplements on LDL TEARS: 
Selected individual responses for LDL TEARS.
Fig. 6.9(a): Individual results: LDL TEARS for red wine (RW),
LDL TBARS-RED WINE[RW]
S .
I Ï
1 ‘
50
40
30
20
10
0
OWEEK AFTER 2 WEEKS
Subjects 
-*~RW05AB 
-»-RW 07AB  
-k-RW09AB  
RW14AB 
-*-RW 04CD  
-»-RW 06CD  
-4—RW08CD
 RW11CD
-4-RW 29CD
Fig. 6 .9(b); Individual results: LDL TEARS for White wine (WW),
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Fig. 6.9(c) Individual results: LDL TBARS for White wine+lg polyphenol
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Fig. 6.9(d): IndivWuAl results: LDL TBARS for Polyphenol powder Ig (PP)
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Selected individual responses o f TBARS at day 0 and day 14, with 
individual subject code. 6.9(a) for red wine, 6.9(b) for white wine,
6.9(c) for white wine+polyphenol powder, 6.9(d) for Ig polyphenol powder.
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6.4 Plasma total antioxidant status (TAS)
The published chemical methods of estimating antioxidant capacity of 
a solution in vitro all measure the inhibition of an artificially generated oxidative 
process (Rice-Evans et al 1994). A free radical species is generated in a solution 
containing an oxidation target; antioxidants in the added sample quench the target 
response by interaction with the reactive oxygen species. The current TAS method 
was developed for measuring the total antioxidant capacity of plasma, based on the 
absorbance of the ABTS’^  radical cation (Chapter 2, section 2.9.1).
The major antioxidant defences in plasma include ascorbate, protein 
thiols, bilibrubin, urate and a-tocopherol. The ‘chain-breaking’ or ‘radical- 
scavenging’ agents against oxidative stress are considered to act in the above sequence 
of events, thus conferring either on increased to decreased defence against free 
radicals generated in the plasma aqueous phase (Frei et al 1989). Plasma also contains 
the ‘preventive’ antioxidants, caeruloplasmin and transferring!
: (Stocker et al 1987).
Total antioxidant status was measured in plasma at the beginning of the 
study and after 2 weeks of supplementation, using the method described in Chapter 2 
(section 2.9.1). It took a longer time to establish and validate the modified method 
than was originally anticipated. Therefore, this part of the study examined the effects 
of 9 different supplements for plasma TAS to evaluate their antioxidant potential in 
relation to their phenolic content.
6.4.1 Results
The results obtained for plasma TAS at the beginning o f the study and 
at the end of 2 week period are represented in Table 6.6.
Fig. 6.11(a) illustrates that total antioxidant status was increased in all 
10 subjects consuming the polyphenol drink, (1.75 ± 0.32 (control)versus 1.91 ±
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0.29mmoles/l (after 2 weeks)). This result was similar to that found in the group 
supplemented with polyphenol capsules 2g (Fig. 6.11(b)). There was no significant 
change in the mean plasma TAS in the group consuming alcohol, although there was 
an upward trend.
Table 6.6: Concentration of plasma TAS (mmoles/1) in volunteers consuming 
various supplements for two weeks. Results are mean ± SD for day 0 
and day 14.
Plasma TAS (mmoIes/L)
Supplement NO 0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. of 
m eant SD
P -
V alue
Alcohol + Ig 
PP
AP 4 1.40 ±0.06 1.50 ±0.05 0.10 ±0.01 0.007
French paradox FP 6 1.60 ±0.16 1.46 ±0.13 -0.14 ±0.03 0.3
Chocolate CH 7 1.50 ±0.08 1.67 ±0.16 0.17 ±0.08 0.03
Polyphenol
drink
PD 10 1.75 ±0.32 1.91 ±0.29 0.16 ±0.03 0.0008
Polyphenol
Capsules-2g
PT 6 1.32 ±0.12 1.46 ±0.09 0.14 ±0.03 0.03
Vitamin E VE 4 1.57 ±0.05 1.67±0.07 0.11 ±0 .02 0.03
Polyphenol
powder
PP 5 1.82 ±0.07 2.04 ± 0.02 0.22 ± 0.07 0.04
Alcohol AL 5 1.86 ±0.03 1.94 ±0.05 0.08 ± 0.03 0.07
Vitamin E + lg  
PP
EP 4 1.44 ±0.14 1.55 ±0.12 0.11 ±0 .02 0.003
In contrast, subjects consuming alcohol along with Ig polyphenol 
powder showed a significant elevation in plasma TAS. Subjects consuming French 
paradox capsules showed variable effects, 30% of the group remained at same 
concentration, 30% showed a decrease, whereas remaining 30% showed an increase in 
plasma TAS, overall result was non-significant (Fig. 6.11(c)). Supplementation with 
chocolate (Fig. 6.11(d)), vitamin E alone or with polyphenol powder, was associated 
with a substantial elevation in plasma TAS after 2 weeks o f supplementation (P=0.03, 
P=0.03, P=0.04) respectively.
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E ffects o f different supplem ents on plasm a TAS:
Selected individual responses of plasma TAS
Fig. 6.11(a): Individual results: Plasma TAS for Polyphenol drink (PD),
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Fig. 6.11(b): Individual results: Plasma TAS for polyphenol capsules 2g (PT),
PLASMA TAS- POLYPHENOL CAPS.2g[PT]
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Fig. 6.11(c) Individual results: Plasma TAS for french paradox caps. (FP)
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Fig. 6.11(d): Individual results: Plasma TAS for Chocolate (CH)
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Individual responses of TAS at day 0 and day 14 with subject code. 
6.11(a) for polyphenol drink, 6.11(b) for polyphenol capsules ,
6.11(c) for french paradox capsules, and 6.11(d) for chocolate.
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6 .5  T ra n sfo rm in g  g ro w th  fa c to r  (T G F -B ) m ea su rem en t
6.5.1 Introduction
The abnormal proliferation of vascular smooth muscle cell (VSmC) 
makes a significant contribution to coronary heart disease, atherosclerosis, restenosis 
and stroke. TGF-B is one of the most potent growth inhibitors (Massague et al 1990) 
and inhibits VSMC proliferation. Human VSMC produce TGF-B in a latent inactive 
form which is activated proteolytically by the serine protease plasmin which in turn is 
obtained from plasminogen by tissue plasminogen activator (tPA). The formation of 
plasma TGF-B is inhibited by PAI-1 and Apoprotein (a). An increase in plasma TGF-B 
is considered effective in inhibiting the growth of VSMC, since the latent form is 
converted into the active form by plasmin (see Figure 1.12). The serum concentration 
of active TGF-B has been shown to be severely depressed, whereas total serum TGF-B 
was not greatly decreased in patients with coronary atherosclerosis compared with a 
control group (Grainger et al 1995). Several groups of scientists have developed 
methods for the estimation of the plasma level of TGF-B and to search for 
pharmaceutical compounds which may stimulate TGF-B production both in the latent 
and active form. The compound Tamoxifen (trans-2 {4 diphenyl-1 -butany 1} phenoxy- 
dimethyl ethylamine) is claimed as being effective. Tamoxifen stimulates the 
production of TGF-B, and increases the ratio of active to latent TGF-B in patients with 
CHD (Grainger et al 1995). Another compound showing activity is aspirin (Grainger 
et al 1995) which increases both total and active serum TGF-B in normal people but 
only total TGF-B in patients with CHD.
In this study, red wine, white wine and a preparation o f polyphenols 
obtained from red wine in the form of powder, drink, or capsules, and a range o f other 
supplements (see Chapter 5, section 5.4) were given by oral administration to human 
subjects to study the potential effects of these antioxidant compounds on plasma 
TGF-B. Plasma was analysed simultaneously by ‘Quantikine kit” for both the latent 
and active form by the method described in Chapter 2 (section 2.10.1), and by using 
BDA-19 antibody for active TGF-B, employing the method described in Chapter-2 
(section 2.10.2).
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6.5.2 Results
6.5.2.1 Total TGF-B (latent+active) by “Quantikine kit”
Total tgf-B in plasma was measured immediately before the study and 
after 2 weeks o f supplementation, using the “Quantikine” R&D systems kit, as 
described in Chapter 2 (section 2.10.1). The results are summarised in Table 6.7.
Table 6.7: Concentration of Plasma TGF-B (latent+active) using R&D kit
(ng/ml) in volunteers consuming various supplements over a period of 
two weeks. Results are mean ± SD for day 0 and day 14.
TGF-B (latent+active)ng/ml
Supplement NO 0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. of
m eant SD
P -
V alue
Red wine RW 8 6.6 ± 3.6 15.5 ±8 .8 8.9 ± 5 .2 0.04
White wine WW 8 9.7 ±7.1 11.9 ±9 .5 2.2 ± 2.4 0.6
White w ine+lg 
PP
WP 4 5.6 ± 3 .9 9.0 ± 4 .9 3.4 ± 1.2 0.02
Polyphenol 
Powder-1 g
PP 7 9.0 ± 6 .6 19.8 ± 10.9 10.8 ±4.3 0.002
Alcohol AL 5 16.4 ± 6.5 14.2 ±4.3 -2.3 ± 2.2 0.6
Alcohol + Ig 
PP
AP 3 12.9 ± 3 .9 15.1 ±3.3 2.2 ± 0.7 0.03
Sefacal drink SD 4 20.6 ± 10.2 10.9 ±6 .5 -9.7 ± 3 .7 0.3
French paradox FP 6 17.5 ±7.1 16.8 ± 6 .4 -0.7 ± 0.7 0.6
Endotelon tabs. EN 6 8.2 ±3.1 4.4 ± 3 .4 -3.8 ± 0.3 0.1
Tea catechin TC 6 10.6 ±5.1 12.4 ± 10.9 1.8 ± 5 .8 0.7
Chocolate CH 7 8.7 ± 3 .4 8.3 ± 3.3 -0.4 ± 0.3 0.7
Polyphenol
drink
PD 10 7.9 ±2 .8 12.3 ± 6 .2 4.4 ± 3 .4 0.007
Polyphenol
Capsules-2g
PT 6 15.3 ± 5 .4 19.0 ±7 .8 3.7 ± 2 .4 0.04
Vitamin E VE 4 22.3 ± 12.2 26.7 ± 20.2 4.4 ± 8.0 0.4
Vitamin E + lg  
PP
EP 4 13.0 ± 2 .6 16.2 ± 4 .4 2.2 ± 1 .8 0.02
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The results show that out of 15 different groups o f volunteers, 8 of the 
supplements produced a significant increase and 7 an non-significant increase in their 
total TGF-B . Subjects in the red wine group showed a two and half fold increase in 
their mean total TGF-B values (Fig. 6.13(a), 6.6 ± 3 .6  (base line) versus 15.5 ± 8.8 
ng/ml (after 2 weeks)). In contrast, the group consuming the white wine showed no 
significant difference, although 50% of the group showed an elevation in TGF-B (Fig. 
6.13(b)). As can be seen from Table 6.7, TGF-B production increased, markedly (61%) 
after supplementation white wine + lg  polyphenol powder (5.6 ± 3.9 (base line) versus
9.0 ± 4.9 ng/ml (after 2 weeks)). Subjects in the polyphenol powder (Ig) group 
showed a greater than two fold (2.2 fold) increase in their mean TGF-B values (Fig. 
6.13(c)). Supplementation with polyphenol drink resulted in a 56% increase in TGF-B 
(Fig. 6.13(d)) (7.9 ± 2.8 (base line) versus 12.3 ± 6.2 ng/ml (after 2 weeks)).
When subjects were supplemented with alcohol alone, no change in 
TGF-B concentration was observed, conversely, alcohol coupled with Ig of 
polyphenol powder showed a significant elevation in TGF-B concentration. This 
pattern was also observed in the group supplemented with vitamin E. Vitamin E by 
itself had no effect on production of TGF-B, where as when given in combination with 
Ig o f polyphenol powder produced a 25% increase.
In the tea catechin group, 50% of the subjects showed an inhibition in 
production of TGF-B, whereas half the group showed an elevation, producing overall 
no net change. There was no response in TGF-B levels to the sefacal drink, french 
paradox, endotelon tablets, and chocolate even after 2 weeks of supplementation.
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Effects of different supplementation on plasma TGF-B 
Selected individual responses of plasma TGF-B (latent+active) 
by Quantikine kit
Fig. 6.13(a): Individual results: Plasma TGF-6 (latent + active) for red wme (RW),
L A T E N T  & A C T IV E  T G F -B  [R & D  K IT ] F O R  R E D  W IN E  [R W ]
3 5  
3 0  
_  2 5
E 20
g  1 5  
10 
5  
0
O W E E K A F T E R  2  W E E K S .
Subjects 
- « - R W 4 C D  
- « - R W 5 A B  
- * - R W 6 C D  
-W - R W 7 A B  
R W 9 A B  
- * - R W 1 1 C D  
- I — R W 1 4 A B  
 R W 2 9 C D
Fig. 6.13(b): Individual results: Plasma TGF-B (latent + active) for White wine 
( W W ) , ___________________________________________
L A T E N T  & A C T IV E  T G F -B  [R & D  K IT] F O R  W H IT E  W IN E [W W ]
O W E E K A F T E R  2  W E E K S .
► -W W 4 A B  
" - W W 5 C D  
& -W W 6 A B  
» * -W W 7 C D  
W W 8 A B  
« - W W 9 C D  
4 - W W 1 1 A B  
— W W 1 4 C D
Fig. 6.13(c): Individual results: Plasma TGF-B (latent 4- active) for Polyphenol 
powder Ig (PP) ________ ____________ _________ __________ _
L A T E N T  & A C T IV E  T G F -B  [R & D  K IT] F O R  P O L Y P H E N O L  P O W D E R [P P ]
4 0
3 0
Ë  20 
^10 
0
OWEEK A F T E R  2 W E E K S .
Subjects 
- * - P P 0 4 E F  
- " - P P 0 6 E F  
- * - P P 1 0 C D  
- W - P P 1 3 C D  
- * - P P 1 6 A B  
P P 1 7 A B  
- P - P P 1 8 A B  
 P P 3 2 A B
Fig. 6.13(d): Individual results: Plasma TGF-6 (latent + active) for Polyphenol 
drink (PD) _________________ _ ________________ _
L A T E N T  & A C T IV E  T G F -B  [ R & D  K IT] F O R  P O L Y P H E N O L  D R IN K  [P D ]
2 5  
20 
1 15O)
C 10
5
0
O W E E K A F T E R  2  W E E K S .
Subjects
- P D 0 8 G H
- P D 2 1 G H
r - P D 2 2 E F
> - P D 2 5 E F
P D 3 1 E F
- P D 3 2 E F
—  P D 5 0 A B
—  P D 4 7 C D  
« - P D 0 7 I J  
► -P D 3 8 C D
Selected individual responses of plasma TGF-6 (latent + active) at day 0 & day 1 , 
with individual subject code. 6.13(a) for red wine, 6.13(b) for white wine,
6.13(c) for Ig polyphenol powder, and 6.13(d)polyphenol drink.
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6.S.2.2 Active TGF-B using BDA-19 antibody
In addition to total TGF-B (latent & active) active plasma TGF-B was 
also measured at the beginning of the study and after 2 weeks o f supplementation, 
using BDA-19 antibody, employing the method described in Chapter 2 (section 
2.10.2). Results are summarised in Table 6.8.
Table 6.8: Concentration of Plasma TGF-B (active) ng/ml using BDA-19
antibody in volunteers consuming dietary supplements over a period 
of 2 weeks, results are mean ± SD for day 0 and day 14.
TGF-B (active) ng/ml
Supplement NO 0 Week 
Mean ± SD
After 2 weeks 
Mean ± SD
Diff. of
meant SD
P-
Value
Red wine RW 8 5.0 ± 1.0 6.5 ± 1.5 1.5 ± 0.5 0.002
White wine WW 8 5.6 ± 1.8 5.3 ± 1.7 -0.3 ± 0.3 0.7
White w ine+lg 
PP
WP 4 5.0 ± 4.6 10.0 ±6 .2 5.0 ± 1 .6 0.05
Polyphenol 
Powder-1 g
PP 8 6.0 ± 1.9 8.5 ± 2 .4 2.5 ± 0 .5 0.003
Alcohol AL 5 8.9 ±8 .7 8.2 ± 6 .0 -0.8 ± 2 .7 0.6
Alcohol + Ig 
PP
AP 3 4.5 ± 0.9 6.8 ± 0.6 2.3 ± 0.3 0.01
Sefacal drink SD 4 5.2 ± 1.3 4.7 ± 0.8 -0.5 ± 0.5 0.3
French paradox FP 6 4.3 ± 1.4 4.5 ±1.3 0.2 ± 0.7 0.6
Endotelon tabs. EN 6 4.5 ± 1.4 4.8 ± 1.7 0.3 ± 0.3 0.7
Tea catechin TC 6 2.6 ±3.1 1.9± 1.6 -0.7 ± 1.5 0.7
Chocolate CH 7 3.2 ± 3.3 2.4 ± 2.0 -0.8 ± 1.3 0.2
Polyphenol
drink
PD 10 3.7 ±3 .2 8.1 ± 3 .2 4.4 ± 2 .6 0.0005
Polyphenol
Capsules-2g
PT 6 7.6 ± 5 .4 9.8 ± 5 .2 2.2 ± 1.2 0.007
Vitamin E YE 4 3.6 ±1 .4 3.5 ± 1.0 -0.1 ± 0 .4 0.9
Vitamin E + lg  
PP
EP 4 5.7 ±4 .0 9.5 ± 5 .7 3.7 ± 1.7 0.04
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To examine the effects o f dietary compounds with anti-oxidant activity 
on active TGF-6 concentration, a total of 15 dietary supplements were examined. 
Nearly 50% of the chosen supplements (7) were associated with an elevation in TGF-6 
production, whilst the rest showed no effect.
As can be seen from the Fig. 6.15(a), red wine supplementation was 
accompanied by an increase of 30% in the concentration of active TGF-6. In contrast, 
white wine showed no change in mean active TGF-6 (P=0.7, Fig. 6.15(b)). Whereas, 
the group consuming white wine with 1 g polyphenol powder showed a 2 fold increase 
in their mean active TGF-6 values (5.0 ± 4.6 versus 10.0 ± 6.2 ng/ml). The group 
supplemented with polyphenol drink showed the greatest overall increment (2.2 fold) 
of active TGF-6 (Fig. 6.15(d)).The relative increase in TGF-6 following polyphenol 
drink supplementation was even greater when compared to red wine. When subjects 
were supplemented with alcohol alone, there was no change in TGF-6 concentration,. 
However, this effect was reversed when Ig o f polyphenol powder was given along 
with the alcohol, resulting in a 51% elevation in the concentration o f the active TGF-6.
An effect of polyphenol powder on active TGF-6 was also observed 
when the group consuming vitamin E alone showed no change, whereas when coupled 
with Ig polyphenol powder showed an increase of 67 % in active TGF-6. 
Supplementation o f polyphenol powder on its own was accompanied by a 32% 
increase in active TGF-6 values (Fig. 6.15(c). In view of the previous results, it was 
surprising to see that chocolate supplementation produce no effect on active TGF-6,
(as the base line value was on lower side 8.7 ng/ml), 50% of the group showed an 
increase whilst the rest showed a decrease, giving no effect overall. The groups 
supplemented with Sefacal drink, French paradox, and Endotelon tablets showed no 
significant change in their mean levels of active TGF-6 values, and small decreases of 
10%, 7%, 7% respectively.
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Effects of different supplementation on plasma TGF-B 
Selected individual responses of plasma TGF-B (active) 
using BDA-19 antibody.
Fig.6.15(a): Individual results: Plasma TGF-B (active) for red wine (RW),
TGF-6 ACTIVE-RED WINE[RW]
9.0 j
8.0
7.0
E 6.0
g 5.0
4.0 -
3.0
2.0
Qi iKiû/«4’e
~»-RW 4CD 
-"-R W 5A B  
-*-R W 6C D  
RW7AB 
H»-RW9AB 
■ ^ R W IIC D  
-*-R W 14A B  
 RW29CD
OWEEK AFTER 2 WEEKS.
Fig. 6.15(b): Individual results: Plasma TGF-B (active) for White wine (WW)
TGF-B ACTIVE- WHITE WINE[WW]
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8.5
7.5
6.5
5.5
4.5
3.5
2.5
1.5
Subjects
^W W 4A B  
*-W W 5C D  
^WWSAB 
^ W W 7C D  
WW8AB 
*-W W 9C D  
■+-WW11AB 
— WW14CD
OWEEK AFTER 2 WEEKS.
Fig. 6.15(c): Individual results: Plasma TGF-B (active) for Polyphenol powder(PP)
TGF-B ACTIVE POLYPHENOL POWDER[PP]
15.5
13.5
11.5
9.5
7.5
5.5
3.5
1.5
OWEEK AFTER 2 WEEKS.
Subjects
+ -P P 0 4 E F  
PP06EF 
-*-PP10CD  
4*-PP13CD 
4W-PP16AB 
—-PP17A B  
-4-PP18A B 
— PP32AB
Fig. 6.15(d): Individual results: Plasma TGF-B (active) for Polyphenol drink (PD)
TGF-B ACTIVE POLYPHENOL DRINK[PD]
14 
12 
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1 8 
c 6 
4 
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0
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-PD 08G H
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'-PD 38C D
Selected individual responses o f plasma TGF-6 (active) at day 0 & day 14, 
with individual subject code.6.15(a) for red wine, 6.15(b) for white wine, 
6.15(c) for white wine+lg polyphenol powder, 6.15(d) for polyphenol drink.
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6.6 D iscussion
The overall outcome of the LDL oxidation experiments indicates that 
phenolic compounds may protect LDL from oxidation as measured by the extension of 
the conjugated diene lag phase, plasma and LDL lipid peroxides, LDL TEARS plasma 
TAS, and plasma TGF-6 in vitro.
The observation that the red wine and the polyphenol powder (derived 
from red wine) phenolics appear to be more effective at inhibiting copper induced 
oxidation is not surprising, given that phenolic compounds can actively bind copper 
ions as well as trap free radicals. As there is some evidence that redox-reactive copper 
ions may exist in atherosclerotic lesions in vivo.
The consumption of red wine was shown to be associated with a 
significant decrease in lag phase which was prolonged by 18 min. In contrast, white 
wine consumption had no effect. Plasma lipid peroxides were decreased by red wine 
36%, and LDL lipid peroxides by 34%. This result is in accordance with a study by 
Fuhrman et al (1995) who showed that a consumption o f red wine reduces the 
susceptibility o f LDL to lipid peroxidation. In their study, 17 healthy men were 
divided into two groups; 8 received 400ml red wine/day for two weeks, and 9 received 
a similar amount o f white wine. Red wine consumption for 2 weeks resulted in a 
prolonged lag phase by 130 min (which represents the resistance o f LDL to undergo 
lipid peroxidation), a 2.3 fold decrease in LDL lipid peroxides (P<0.01), and up to 
80% reduction in TEAR formation in the presence o f AAPH (lOOmmol/1). The results 
of the present study are thus consistent with those o f Fuhrman et al showing that red 
wine clearly reduces LDL oxidation. Conversely, the consumption o f white wine 
resulted in the susceptibility of LDL to oxidation. Since white wine consumption 
actually reduced the time of the lag phase by 20 min. Eecause white wine contains 
only minimal amounts o f polyphenols (0.2g/L) compared with red wine (1.6g/L), this 
may underlie the inability o f white wine to act as an antioxidant. The pro-oxidant 
activity of white wine consumption toward LDL may thus be related to the
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pro-oxidative properties of alcohol consumption (Femandez-Checa et al 1991).
These findings conflict with those o f a study by de Rijke et al (1996) 
who showed that red wine consumption does not affect oxidisability o f LDL in 
volunteers. In their study they gave 13 healthy volunteers 550ml o f red wine and 
another 11 volunteers white wine for 4 weeks in a randomised double-blind trial. 
Interference by alcoholic components o f wine was eliminated by reducing the alcohol 
content to 3.5%. Red wine did not affect the susceptibility of LDL to copper mediated 
oxidative modification (lag time before and after red wine drinking 61.8 ± 7.7; after 
62.7 ± 11.8 mins. respectively; lag time before and after white wine drinking :64.5 ± 
10.4 and 63.3 ±  10.8 min. respectively). The discrepancy between this present study 
and that of de Rijke et al (1996) may be explained by a major difference in 
methodology used for measuring LDL oxidisability, essentially the omission of the 
dialysis step to prevent early oxidative modification of LDL. They also showed that 
low-alcohol white wine with added colourants, known as anthocyanins, failed to 
inhibit the AAPH-induced lipid peroxidation when added to plasma in vitro. This 
study's findings were also similar, in that subjects consuming sefacal drink 
(anthocyanin) showed a no-significant reduction in the formation o f LDL TEARS.
The effects of vitamin E on LDL lag phase were predictable on the 
basis of existing evidence for the benefits of vitamin E supplementation. Duthie et al 
(1993) demonstrated that chronic vitamin E administration decreases the concentration 
o f plasma conjugated dienes, which were highly and directly co-related with LDL 
oxidation and plasma total triglyceride concentrations. The results obtained in this 
study were consistent with Duthie et al, vitamin E supplementation was associated 
with prolonged lag phase by 67min, in addition to this Vitamin E+lg polyphenol gave 
a prolonged lag phase 69 min. These results are also similar to those produced by 
Stampfer et al (1993) and Dieber-Rotheneder et a / (1991). Studies by Dieber- 
Rotheneder, showed that the effect of oral supplementation with D -a- tocopherol on 
the vitamin E content o f human LDL decreased the particles resistance to oxidation. In 
their study 12 clinically healthy subjects participated in a vitamin E supplementation 
trial. 8 were given daily dosages o f 150, 225, 800, or 1200 lU RRR-a- tocopherol for
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21 days (2 persons per dose) and 4 receive placebo. The resistance o f LDL against 
copper-mediated oxidation was significantly higher during vitamin E supplementation. 
The oxidative resistance of LDL increased in all participants, though there was 
considerable individual variation in the response. Paolisso et al (1995) also showed 
that a chronic intake of pharmacological doses of vitamin E contributed towards the 
lowering of plasma lipid concentrations. This present study showed that vitamin E 
decreases plasma lipid peroxidation levels by 21%^ ;
This effect
has been linked to a decline in the concentration of oxygen free radical in plasma, 
which may, in part, explain the protective role of vitamin E.. The present data also 
suggests that the efficacy of vitamin E in protecting LDL against oxidation shows 
individual variations between subjects.
Vitamin E, and vitamin E along with Ig polyphenol powder showed 
the similar : reduction in LDL lipid peroxides. This result was similar to that formed 
by Croft et al (1995) who showed that the rate o f LDL oxidation was positively 
correlated with vitamin E content of LDL. While this may appear to be incongruefeS 
with respect to the role o f vitamin E as an antioxidant, recent studies have clearly 
shown that in several in vitro model systems vitamin E can act as a pro-oxidant 
(Bowry et al 1992, Maiorino et al 1993). Once vitamin E is oxidised, the tocopherol 
radical can act as a chain-transfer agent rather than as a radical trap, particularly in 
absence o f other antioxidants such as ascorbate or ubiquinol, which may act to 
regenerate vitamin E from its radical (Ingold et al 1993).
Vitamin E is quantitatively the most important lipophilic antioxidant in 
LDL in vivo. The importance of vitamin E is confirmed in the present study, since 
vitamin E and vitamin E with Ig of polyphenol powder produced a marked decrease in 
LDL lipid peroxides, with Vitamin E coupled with 1 g o f polyphenol powder showing 
the greatest antioxidant activity, and plasma TAS was significantly increased by both.
Negre-Salvayre et a/ (1991), showed that the cytoprotectivfe effect of 
vitamin E was associated with a complete inhibition o f cellular TEARS formation
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induced by ultra-violet treated of LDL. The results o f this study werei similar to 
the above study, Vitamin E either alone or in combination with Ig of polyphenol 
produced 21% inhibition o f LDL TEARS formation.
The polyphenol drink which consisted of red wine polyphenols reduced 
the susceptibility o f LDL to oxidation by 23% (lag phase). This provided evidence to 
suggest that by isolating the polyphenols from red wine without an alcohol content, 
polyphenols can give significant results o f a similar magnitude as red wine. This was 
confirmed when alcohol on its own gave no significant results for lag time after 2 
weeks of supplementation. In other words, extracted red wine polyphenols in water 
without any alcohol content consumed for 2 weeks, prevented the formation of 
conjugated dines. In addition plasma and LDL lipid peroxides were decreased 
significantly (P=0.007, P=0.009 respectively) whilst plasma TAS was significantly 
elevated (P=0.0008).
A study by Seigneur et al (1990) showed that components o f red wine 
such as tannins, have specific actions and play an important role in the protective 
effects of a moderate consumption of alcohol against heart disease. In their study they 
compared alcohol and wine, and their results showed that pure alcohol led to enhanced 
adrenaline-induced platelet aggregation, a reduction in LDL-cholesterol and an 
increase in apo-protein AI levels in serum. In contrast, the ingestion o f red wine for 15 
days reduced ADP-induced platelet aggregation and increased HDL-cholesterol. As 
seen in this study alcohol alone produced a non-significant change in plasma lipid 
peroxides (P=0.5), and showed a potentially pro-oxidant effect on LDL lipid peroxides 
with 60% of the subjects showing an increase in LDL lipid peroxides, yet when 
coupled together with Ig o f polyphenol produced highly significant results for plasma 
and LDL lipid peroxides (P=0.05, and P=0.01 respectively). This, implicates the 
added polyphenol extract in the ‘cardioprotective’ effects, since alcohol alone is 
associated with pro-oxidant effects. In addition, a recent study by R uf et al (1995) in 
rats reported that the oral administration of low-alcohol red wine decreased alcohol- 
induced lipid peroxidation in plasma and reduced platelet aggregation in vivo. It was 
suggested that alcohol may promote the absorption o f polyphenols in the intestine.
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Before this present study, few data were available on the absorption and metabolism 
of individual flavonoids after consumption.
Evidence for the pro-oxidative effect of ethanol has been provided by 
Bjomeboe et al (1993). It is generally accepted that ethanol induces an increase in 
NADH-dependent production of reactive oxygen intermediates (Dicker et al 1992) or 
iron mobilisation favouring free radical generation (Shaw et al 1990). Despite this 
Abu-Amsha et al (1996), showed that ethanol up to a final concentration o f 0.05% by 
volume had no effect on isolated LDL oxidation in vitro.
Whilst, alcohol supplementation in this study produced a non­
significant result in TEARS (P=0.07), 75% of volunteers still showed some inhibition 
of TEARS formation in LDL. This result is at variance with the work o f Miyagi et al 
(1997) who showed that in the presence o f ethanol, the copper catalysed formation of 
TEARS in LDL increased significantly (P<0.01). In a previous study. Seigneur et al 
(1990) showed that alcohol consumption influenced platelet function. Overall, 
ingestion o f alcohol compared with water led to an enhancement o f ADP and 
adrenaline-induced platelet aggregation associated with a fall in LDL-cholesterol and 
a rise in apo-protein A-I level.
White wine supplemented with Ig o f polyphenols was associated with 
increased lag time o f 1 Imin. This result is extremely significant as white wine on its 
own produced a non-significant result even after 2 weeks o f supplementation. This 
difference again highlights the action o f polyphenol as antioxidants. These results 
were similar to Whitehead and Day (1995).
Whitehead et al (\ 995), demonstrated the effects in normal individuals 
o f ingesting red or white wine, and high doses o f vitamin C on the antioxidant 
capacity o f serum, by means of a chemiluminescent reaction. In subjects who ingested 
300ml of red wine, the mean serum antioxidant capacity was increased by 18% after 1 
hour and by 11% at 2 hour. The same amount o f white wine produced 4% and 7% 
increases in serum TAS, respectively. This result was similar to a previous finding of
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Maxwell et al (1994). In their study healthy students (5 males, and 5 females, mean 
age 22 years, and mean weight 67.3 kg) consumed a standard meal either alone or with 
red wine (5.7 ml Bordeaux/kg) over 30 min. After ingestion of red wine serum 
antioxidant capacity rose rapidly to reach a peak at 90 minutes. Day et al (1997) also 
demonstrated the antioxidant effect with concentrated red grape juice, serum total 
antioxidant capacity was increased by grape juice (P<0.05).
Recently, Kondo et al (1996) published a paper on the inhibition of 
LDL oxidation by cocoa. In their study they used 12 male volunteers (mean aged
39.0 (SE 4.0) years) to consume 35g of delipidated cocoa. LDL was isolated before, 
and after 2 hours after consuming the cocoa. The LDL oxidation lag time before 
ingesting 35g of cocoa was 61.2 (SE 6.4) min, but was prolonged at 2 hours after 
cocoa (70.3 (6.1) min). In this study, chocolate produced an significant change in lag 
time (67.3 ± 5.5min (control) versus 77.5 ± 6.7 min (after 2 weeks)). The present 
findings thus confirm that cocoa in chocolate also inhibits LDL oxidation after 2 
weeks consumption. Furthermore, these data are also consistent with that of 
Waterhouse et al (1996) who showed that cocoa powder extract was a potent 
antioxidant for LDL oxidation.
Tea catechins and endotelon tablets produced surprising little effect on 
all antioxidant responses. When compounds were screened, in vitro experiments, both 
showed LDL inhibition, at 0.26pg and 0.25 pg of the polyphenols in assay o f copper 
diene test, they showed a lag time of 41 mins. and 32 mins. respectively. This 
difference between the two experiments may be due to the absorption o f tea catechins 
and proanthocyanidins during metabolism. Thus, resulting in a decrease in availability 
of tea catechins and pro-anthocyanidines. Another explanation for the discrepancy 
between the two experiments may be that the supplements were commercially 
available products and during the process of manufacturing the chemical structure may 
have altered, subsequently altering the function or bio-availibilty o f the compound.
This finding was supported by non-significant results for plasma and LDL lipid 
peroxides levels(plasma P=0.1, LDL P=0.8 lipid peroxides for tea catechin, and 
plasma P=0.3, LDL P=0.3 lipid peroxides for endotelon tabs.). The individual results
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for the endotelon group indicate considerable variability in the intensity o f the lipid 
peroxide response. Furthermore, LDL TEARS were also non-significant (P=0.6 for 
tea catechin and P=0.2 for endotelon tabs).
Although the phenolic compounds have similar chemical properties, 
their antioxidant capacity cannot be predicted on the basis of their chemical reducing 
potential. In the LDL oxidation assay for antioxidant activity, the system is typically 
heterogeneous and physical properties, such as lipophilicity, solubility, and 
partitioning between the aqueous and lipid phases o f LDL can become important in 
determining as major determinants o f the antioxidant activity (Frankel et al 1993,
1994).
Sefacal drink (anthocyanins) and french paradox (grape skin residue) 
showed non-significant results for lag time, plasma and LDL lipid peroxides and LDL 
TEARS. These results would suggest that grape skin residue (proanthocyanin) is not 
the main contributing factor in the LDL oxidative process, but that other factors are 
involved. Therefore, this treatment shows that the antioxidant activity o f different food 
supplements towards LDL oxidation may not be the property of a single phenolic 
compound and this activity is widely distributed among the phenolic phytochemical 
constituents.
A previous study by Ratty and Das (1988) demonstrated that ferrous 
sulphate-induced lipid peroxidation had a structure-activity relationship between 
flavonoids on non-enzymatic lipid peroxidation. Quercetin, qercetrin, myricetin, 
myricitrin, phloretin, morin, fistin, and catechin were found to be the most potent anti- 
peroxidative agents. Therefore, as red wine and polyphenols contain anthocyanins, 
procyanidin, catechin, quercetin, phenolic acid and tannins they have the capacity 
to act as potent inhibitors of LDL lipid peroxidation.
A more recent study by Hayek et al (1997) showed that the 
consumption o f red wine or its polyphenolic flavonoids quercetin and, to a lesser 
extent, catechin in apolipoprotein deficient (E°) mice, led to the attenuation in the
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development of the atherosclerotic lesion, and that this effect was associated with 
reduced susceptibility of their LDL to oxidation and aggregation. In vitro enrichment 
o f LDL, with polyphenols in non treated E° mice at the age of 2 months; (18-hour 
incubation o f the LDL at 37^ C with 50 pmol/1 catechin or quercetin or 10% red wine), 
followed by extensive dialysis to remove non-bound materials, resulted in a 
remarkable delay in the onset o f LDL oxidation (up to 360 minutes after LDL 
enrichment with quercetin or red wine and 90 minutes after LDL enrichment with 
catechin). When LDL oxidation was measured, a 95% inhibition was obtained after 
enrichment o f the LDL with red wine or quercetin, whereas LDL enrichment with 
catechin showed no significant inhibition in LDL oxidation under their experimental 
conditions. These data also suggest that red wine possesses the capacity to directly 
inhibit LDL oxidation. However, catechin possesses a relatively lower antioxidant 
capacity than quercetin.
Natural flavonoids are able to donate hydrogen or react with super 
oxide anions, hydroxide radicals, and lipid peroxyl radicals, all o f which can cause 
lipid peroxidation in vivo. One mechanism may involve complexation o f natural 
polyphenolic components with Cu^^ to reduce it to Cu^ complex, which in turn may 
reduce hydroperoxides. Alternatively during LDL lipid peroxidation the natural 
polyphenols in wine or other food supplements may act as self regenerating reducing 
components.
A number of mechanisms have already been identified which result in 
the suppression of TGF-B activity. A study by Grainger et al (1995) showed that low 
levels of precursor latent TGF-B complexes can account for the reduced TGF-B 
activity in the circulation in 30-40% of the individuals with atherosclerosis. Also 
studies by Kojima et a / (1991), Lyons et al (1990), and Grainger et al (1993) 
demonstrated that reduced TGF-B activation was attributed to the action o f lipoprotein 
(a) and plasminogen (PAH), all o f which are known to be independent inhibitors of 
TGF-B activation in vitro.
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In this study one of the aims was to examine the influence of phenolic 
compounds in red wine and other supplements on total and active TGF-B levels. Red 
wine and white wine coupled with extracted polyphenols elevated the TGF-B 
production by 2.2 fold. Although, the base line concentrations o f TGF-B (red wine 6.6 
ng/ml and white wine+lg polyphenols 9.0 ng/ml), were different for both 
supplements, the elevations in TGF-B production were o f the same magnitude, 
suggesting that TGF-B production can still be increased, even though TGF-B is present 
in circulation in a high concentration. This finding was substantiated by the effects of 
alcohol which on its own had no effect at all, either on total or active TGF-B 
concentration, but when combined with polyphenol powder produced a 51% 
increment in both TGF-B values. Non-significant results were obtained for vitamin E 
and chocolate were surprising, but may be due to the huge individual variation in 
TGF-B levels and response. Hence, this suggests that there is no correlation between 
antioxidant response and TGF-B activity.
The variety of compounds occurring in red wine (phenolics, flavanols, 
flavonoids, and phytoalexins) all have different redox potential and as a result interact 
in a synergistic manner, and at low concentration levels to provide protection against 
lipid pro-oxidation, and conceivably retard pathophysiological reactions. There has 
been much interest in whether wine-red or white contains antioxidants in sufficient 
quantity to affect antioxidant capacity, and whether this is the basis o f its alleged 
effectiveness in decreasing the risk of atherosclerosis. In this study all polyphenol rich 
supplements increased the resistance of LDL to oxidation after only 2 weeks. An 
important issue is the absorption o f such substances like polyphenols and their role in 
the action o f low-molecular-mass extracelluar antioxidants. Although this could be a 
direct consequence of absorption o f polyphenolic compounds, since the identity o f the 
antioxidant factors present is unknown or at best speculative, it is not possible to 
determine whether the doses given of extracted red wine polyphenols were equivalent 
to those normally ingested as red wine. However, the results obtained in this study 
supports the suggestion that the red wine may be contributory factor to the “French 
paradox”.
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The precise mechanism by which antioxidant activity in LDL is 
achieved, and the particular polyphenols involved, cannot be specifically identified by 
this investigation. There is, however, great scope for further research into the 
usefulness of determining antioxidant capacity in various stages o f disease or 
treatment of diseases such as heart disease, stroke, diabetes. In conclusion, polyphenol 
rich supplements increased the resistance of LDL to oxidation after only 2 weeks. It 
might, therefore, be interesting to try and isolate specific components o f wine such as 
phenolic compounds.
CHAPTER 7 
General discussion and Conclusions
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The first aim of this study was to establish optimal conditions for 
measuring the oxidation susceptibility o f LDL in vitro; i.e. to validate methods for the 
removal o f excess EDTA. This was achieved by comparing three different techniques; 
membrane dialysis with and without EDTA by using dialysis cassette and a EcNO-pac 
1ODG desalting column. The second aim of this study was to investigate influence of 
dietary polyphenol for their antioxidant potential. This was achieved by screening the 
compounds (wine and related food products) in vitro, by using the copper induced 
oxidation, and calculating the lag time. The third aim o f this study was to evaluate the 
influence of dietary polyphenols on the composition and chemical properties of 
plasma lipids and LDL with a focus on their effects on lipid and lipoprotein 
oxidisability. This was achieved by examining a wide range of biomarkers 
undertaking intervention trial in human volunteers:
a) by measuring polyphenolic content in plasma and LDL before and after 
supplementation, and
b) by determining the indices o f oxidative stress/antioxidant activity in plasma 
and LDL; by measuring lag time, lipid peroxides (plasma and LDL), TEARS, 
plasma TAS, and plasma TGF-B (total and active form).
The purpose of this study was to examine the in vivo ‘functional’ 
effects o f an alcoholic-free phenolic supplementation in human volunteers. The 
question was whether extracted red wine polyphenols ingestion over a long period (2 
weeks) is sufficient to protect LDL and/or plasma from oxidation in vivo.
It can be concluded from this study that LDL, in its own right, does 
gain increased protection against oxidation after a 2 week period o f wine and 
extracted red wine polyphenol supplementation. A dose of Ig may be sufficient to 
produce this effect. This effect is in agreement with other results (Kondo et al 1994, 
Fuhrman et al 1995), where the action of red or white wine consumption was analysed 
using a similar preparative procedure. However, the result was not in accordance with 
De Rijke (1996), who reported no difference in LDL protecting effects o f red wine as 
compared with white wine in the particular case o f lower alcohol content (3.5%).
There were some major differences in protocols (Table 7.1).
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Furhman et al studied the effect of red and white wine on LDL. Their 
data shows that red and white wine consumption for 2 weeks resulted in a 20% 
reduction and 34% increase in the susceptibility of plasma lipids to undergo oxidation. 
In contrast, De Rijke et al (1996) could not reproduce these results by using the de- 
alcoholised wine. The difference, however, may be explained by the supply o f an 
integrate wine. Wine is a complex biological liquid that alters appreciably with 
vintage, age, and exposure to oxygen. All these variables must have effect on 
antioxidant activity. In different wines one must consider the possible effects of 
synergism and antagonism in complex mixtures of phenolic compounds. On the basis 
of previous studies by Pryor et al (1988 and 1993) both the physical and chemical 
properties of individual phenolic antioxidants strongly affect their potency. More 
research is needed to evaluate individual components from different wines and from 
different vintages to gain a better understanding of the interactions o f phenolic 
compounds and their changes on ageing. Furthermore, the difference between these 
two studies (Fuhrman and De-Rijke) may be due to either the de-alcoholising process 
that is purely a distillation o f alcohol off the wine under vacuum, polyphenols which 
may have been destroyed, or may be the technique for the analysis was different. LDL 
isolated from the ultracentrifuge is relatively stable, but once desalted is prone to 
spontaneous oxidation if  processing is delayed for more than 60 min (McDowell et al
1995). A likely explanation for the instability induced by the desalting process is the 
removal of trace amounts o f low molecular weight water soluble antioxidants such as 
ascorbate or urate from the ‘crude’ ultracentrifuge LDL preparation. In the study by 
De-Rijke et al LDL was not dialysed. Instead, more copper was added to the assay to 
compensate for the EDTA. This approach will obviously be critically dependent on 
any variation in the amount of added EDTA.
In the present study a comparison was made of desalting techniques, 
results obtained by dialysis against PBS method produced substantially similar results 
to that obtained by an EcNo-pac desalting column (method by Leonhardt et al (1996). 
In addition, the consumption of red wine in volunteers showed an increase in plasma 
and LDL polyphenols, lag time, plasma TAS, and decrease in plasma and LDL lipid 
peroxides, along with TEARS.
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Table 7.1: Differences in protocols between the (Israeli) Fuhrman, (Dutch) De 
Rijke, and this study.
Parameter
Investigated
Israeli group 
(Fuhrman)
Dutch group 
(De Rijke)
This study
Product Red and white 
Israeli wines
Dealcoholised 
Italian wines
French wines
mount
given/day
400ml 550ml 375ml
Study period 1,2 wk 4 wk 2 wk
Pre Diet No change Low flavonoid diet 
2wk white wine
without wine 2 
wk
Plasma storage 4"C -80“C with 
daccharose
4*^ C analysis 
same day
Plasma
estimations
Polyphenols, 
TEARS with 
AAPH, Lipids
Lipids Polyphenols, 
Lipid peroxides, 
TAS, TGF-B
Subsequent 
preparations o f 
LDL after ultra 
centrifugation
Dialysis against 
PES, No EDTA in 
final dialysis buffer
EDTA added and 
not removed
Comparison 
Dialysis against 
PES, With and 
without EDTA, 
& column
LDL estimations Polyphenols Not done polyphenols,
TGF-B
Copper used for 
peroxidations
lOpmol/1 38pmol/l 5pmol/l
Estimations-with
copper
peroxidation
Lag time. 
Conjugated dienes, 
TEARS, Lipid 
peroxides
Lag time.
Conjugated dienes. 
Oxidation rate
Lag time. 
Conjugated 
dienes, TEARS, 
Lipid peroxides
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When results obtained in this were compared to Fuhrman et al, the 
antioxidant activity with red wine was much less (see table 7.2).
Table 7.2: Comparison of red wine results with Fuhrman et at group.
Test parameter This study (Israeli) Fuhrman
Lag time 31% 3809&
TEARS -2294 -4496
Conjugated dienes -1594 -4894
Lipid peroxides -3094 -4094
Polyphenols 26% 400%
This could be explained by significantly greater enrichment in total 
polyphenol concentration in LDL obtained by the Fuhrman et al (This study 26%, 
versus Israeli 400%). The Folin-Ciocalteu method for the determination of 
polyphenols is not an absolute measure of the amounts of phenolic materials but is in 
fact based on their chemical reducing capacity relative to an equivalent reducing 
capacity o f gallic acid. Hence, any substance containing a phenolic group could 
interfere. Indeed, the absence of sufficiently reliable and sensitive method for 
assessing wine phenolic or wine phenolic-deriving products in plasma and LDL, 
makes it difficult to explain the difference in the both studies. Future research should 
employ HPLC for the analysis which is currently developed by those working in this 
field. Analysis of the polyphenol composition of LDL after polyphenol intake should 
provide further information on which polyphenols are absorbed and incorporated into 
LDL and have potential antioxidant activity.
Fuhrman et al also showed that the consumption of white wine had a
pro-oxidant effectl while no effect was seen in i the present study (lag time: this study 
0%, versus Fuhrman et al -33%). The exact reason for this is not clear.
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A significant increase in plasma TAS was found, when the effect of 
extracted red wine polyphenols; isolated by resin column alone or coupled with 
alcohol, on the total plasma, of treated volunteers. This finding is in line with that of 
others (Whitehead et al 1992, & 1995, Lissi et al 1995, Maxwell et al 1994), all of 
whom reported the changes in TAS by using a different system of chemiluminescence 
produetion. The question raised was whether the ingestion of extracted red wine 
polyphenols over a long period i.e. for 2 weeks, was sufficient to prevent LDL and/or 
plasma from oxidation in vivo. In this respect, this study provides new and important 
information since the enhanced antioxidant activity status was achieved by ingesting a 
phenolic extract and not red wine itself. Thus, the results obtained in this study 
suggests that red wine but not white wine has antioxidant activity when given to 
volunteers and this difference is most likely due to the content o f wine polyphenols 
which are abundant in red wine but not in white wine. A polyphenol extract of red 
wine obtained as an alcohol-free powder produced similar results to red wine and had 
equivalent antioxidant activity both in plasma and in LDL. The difference between 
these studies o f Fuhmam’s and De-Rijke could not be explained by the use of de­
alcoholised wine in the latter. Fuhrman’s group suggested that the effect o f white wine 
could be due to the pro-oxidative properties o f alcohol (Femandwez-Checa et al 
1991). This pro-antioxidant effect is in variance with the results obtained in this study. 
Since there was no change in plasma or LDL in the group consuming alcohol 
supplement alone.
Whether phenolic compounds are readily absorbed in the gut in the 
absence of alcohol is questionable. Nevertheless, the results obtained in this study 
confirm that the wine phenolics are absorbed even in the absence o f alcohol, and do 
not have to be in a liquid form. However, it should be kept in mind that only some of 
the red wine polyphenol components, (specifically the low molecular weight 
polyphenols), have the capacity to pass through the intestinal wall and enter the 
circulation. The process o f absorption is obviously crucial to the understanding of 
wine polyphenol action and requires further investigation.
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The present findings, provides indirect but still persuasive evidence 
that at least one part of the antioxidant components in red wine phenolic extracts can 
be absorbed and enter the plasma in the absence of alcohol. This idea is supported by 
other studies which have demonstrated the intestinal absorption o f quercetin, quercetin 
glycosides and phenolic acids present in wine and possibly derived from flavonoids 
through the action of intestinal microflora which is known to occur in humans 
(Hollman et al 1995).
In the present study, supplementation with other red wine and grape 
products provided no real evidence of antioxidant activity. Anthocyanins, red wine 
marc, (grape skin residue i.e. french paradox caps), grape seed proanthocyanidines, 
and green tea catechins were inactive and caused no increase in plasma or LDL 
polyphenol content and showed no antioxidant effects. The results from green tea were 
interesting in that they differed from that obtained by Serafmi et al (1994). In the latter 
study 10 volunteers consumed 300ml o f green tea and black tea. The tea was prepared 
by a 2 minute infusion at lOO^C of 2g of dried tea leaves per 100ml of water. The 
antioxidant potential of plasma was measured by TRAP, based on the peroxyl radical 
induced decay of a fluorescence probe. Plasma TRAP was increased 41-48% over 
basal values, reaching a peak after 30 min in subjects consuming green tea and after 
50 min in those who drank black tea. It returned to normal in both groups after 80min. 
The earlier peak of plasma TRAP after green tea could be explained by the abundance 
of smaller, and therefore, more easily absorbed polyphenols. This would suggest that 
the insignificant effects obtained for green tea in this study resulted from levels 
returning to normal after 2 weeks. As there were no interim results during the present 
study there is no information on the earlier impact and this ‘acute’ effects of 
supplementation. The results obtained for chocolate were in accordance with Kondo et 
al (1996) indicating that cocoa inhibits LDL oxidation. The results obtained in this 
study show that the catechins and their gallic acid esters, the proanthocyanidins, or 
anthocyanins are inactive in vivo although all the polyphenol compounds studied were 
active in vitro (see Chapter 3).
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Substances other than flavonoids and non-flavonoid phenolic 
compounds in wine may have an antioxidant effect. However, wine essentially lacks 
antioxidant vitamins (vitamin C and E) (Miyagi et al 1997), although it contains 
vitamin B groups. Sodium sulphites are usually added to wine as an antioxidant, 
though the inhibitory effects on LDL oxidation in this case are unlikely to arise from 
sodium sulphite since this compound is added equally to both red and white wine.
Some o f the polyphenols present in wine, which are not evaluated for 
antioxidant activity include flavonols (quetcetin, kempferol, and myricetin), flavones 
(dihydroquercetin and dihydrokempferol) and other phenolic compounds such as 
resveratrol and hydroxy-benzoic acids. Much attention has been focused on 
resveratrol, since it is an active ingredient of the oriental folk medicine kojokon, 
which is reported to have a multitude of therapeutic effects (Kimura et al 1985). Even 
so, Frankel et al (1993) found that resveratrol was less potent than either epicatechin 
or quercetin as an antioxidant in inhibiting human LDL. Since resveratrol constitutes 
approximately 0.1% of the phenolic material in a typical red wine, the oxidation o f 
LDL would not be expected to be signiflcantly affected by this compound. Therefore, 
the health signiflcance o f resveratrol relative to the other antioxidants remains 
controversial. All phenolic compounds that are absorbed could have a potential impact 
on health. Hackett et al (1983) showed that large doses of catechin are absorbed from 
the gut, but the catechin found in blood is largely transformed into glucuronides. On 
the other hand, quercetin is reported to be absorbed by humans (Gugler et al 1975).
This study showed that the antioxidant activity o f red wine and 
extracted polyphenols from red wine toward LDL oxidation may not be a property of a 
single phenolic compound and that this activity is widely distributed among the 
phenolic photochemical constituents. This wide distribution of activity suggests that it 
will be important to determine the antioxidant potential o f individual phenolic 
constituents in order to better understand the chemical and physical factors which 
determine the overall potency. Other studies have shown that the consumption o f other 
polyphenol-rich constituents of the diet are also associated with increased plasma
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antioxidant potential and a decreased susceptibility of LDL to oxidation, and might 
therefore contribute to the protection against oxidative stress. These data provide 
indirect evidence for the bioavailability of physiological amounts of polyphenols.
A number of other independent factors need to be considered as 
important determinants o f the susceptibility of LDL to oxidation. These include 
particle size and density of LDL particle, with the general observation that the small 
dense LDL subtractions are more susceptible to oxidation. Frei and Gazino (1993), on 
the other hand found that LDL’s with an increased lipid-to-protein ratio (i.e. less 
dense) were more susceptible to oxidation. Another factor which these workers 
investigated was the level of preformed lipid peroxides in LDL which was found to 
explain about 15% of the LDL’s susceptibility to oxidation. It is likely, then, that the 
overall susceptibility o f LDL to oxidation is determined by a number o f both 
compositional and structural factors. Given the wide spread use of the in vitro C u ^ - 
induced LDL oxidation model to study LDL oxidative susceptibility in a number of 
clinical studies, it is essential that we develop a clearer understanding o f this process 
and how it relates to the possible mechanism of LDL oxidation in vivo. A measure of 
the human absorption o f these compounds is also necessary to asses their potential 
health effects.
The characterisation of at least some of the specific constituents of red 
wine responsible for its antioxidant effect will enable us to target the absorption of 
these compounds and their possible association with lipoproteins in vivo. 
Furthermore, studies are also needed to establish whether substances in red wine 
which confer antioxidant protection are the same compounds responsible for the 
observed inhibition o f platelet function. The possibility that plant phenolics may be 
absorbed and contribute to the antioxidant protection o f LDL as well as influencing 
platelet and vascular function (Demrow et al 1995, R uf et al 1995, Fitzpatric et al 
1993) has major implications for the role of theses substances in human nutrition and 
disease. The beneficial effects o f antioxidants nutrients are now supported by many 
studies, including those associated with (Harman 1995), lowered disease incidence 
and longevity.
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Most studies which have addresed the effects o f alcohol on CHD have 
shown equivocal results. Moderate intake of alcohol (5-lOg/day) appears to provide 
some positive benefits in men, women, the elderly and tobacco smokers. The positive 
effects are related to elevated high-density lipoprotein, a reduction in the atherogenic 
lipoproteins, reduced stress, and possibly to a reduction in platelet activity i.e. reduced 
thrombotic tendency (Renaud et al 1992).
Fuhrman et al (1995) found an increase in HDL cholesterol with red 
wine but not with white wine. However, there were no significant changes either with 
red wine or with extracted red wine polyphenols in this study. It is well known that 
alcohol intake increases HDL cholesterol (Hartung et al 1990). In this study plasma 
lipids were measured by routine Papworth laboratory (see Table B.1.1 in Appendix) 
by conventional methods. The results for alcohol on its own and white wine along 
with added Ig polyphenols showed an increase HDL cholesterol but the results were 
insignificant. Hence, it can be concluded that 2 weeks supplementation was 
insufficient to observe a significant effect. As can be expected De-Rijke et al (1996) 
did not find any lipid changes since their wine had a reduced alcohol content.
In the last two decades there has been a considerable increase in our 
knowledge and understanding of the mechanisms involved in development and 
progression of atherosclerosis, which has naturally led to the implementation of 
guidelines for the prevention and treatment o f atherosclerosis. However, despite 
considerable progress in this area of research, there is little doubt that conventional 
cardiovascular risk factors explain only a small fraction of an individual's 
predisposition to disease. Consequently, attention is focusing on a range of novel, 
potential cardio- vascular risk factors in an attempt to explain the development of 
atherosclerosis in individuals without apparent risk factors. One such factor is TGF-fi. 
TGF-fi has been proposed as a lesion-suppresser protein in part because reduced 
plasma TGF-fi activity has been correlated with advanced atherosclerosis in man 
(Grainger et al 1995). In biochemical terms this is a cytokine that circulates in plasma 
as a latent complex and an activated form.
179
Regulation of active TGF-fi levels is poorly understood. Active TGF-fi 
is generated by cleavage of the latency associated peptide from the latent complex and 
production of active TGF-fi may play an important role in maintenance of normal 
blood vessel structure (Grainger et al 1995). As only 40% of the variation in plasma 
active TGF-fi levels is attributable to regulation o f TGF-fi gene (Grainger et al 1995), 
it is important to determine if environmental factors mediate any influence on the 
remaining of 60% of variation in levels, because behavioural or supplementation may 
provide a simple method of increasing active TGF-fi concentration.
In the present study, significant increases in TGF-fi (total and active) 
were observed in the group consuming red wine and extracted red wine polyphenols. 
Whilst the effect o f polyphenols on TGF-fi is novel, aspirin a derivative o f a phenolic 
acid has a similar effect (Grainger et al 1995). It could be hypothesised that the 
phenolic groups in one or more of the polyphenols may underlie the similarity.
Because of the high level o f commitment and compliance required for 
such a study, it was not possible to recruit a large numbers of subjects for each 
intervention. However, to obtain statistical significance (i.e. probability value using 
the t-test) usually requires a minimum of 6 subjects. At the outset of the human 
investigations each study group contained 9 subjects. However, as the study 
progressed, it seemed necessary and important to include additional supplements to 
provide a wider overview. These include chocolate, vitamin E, sefacal drink, french 
paradox caps., tea catechin. Further combinations o f various treatments were included 
to investigate which underlying factor was responsible for LDL peroxidation. As the 
number of treatments increased to 15, it became practically impossible to achieve the 
required number o f volunteers for each treatment.
Lipid peroxidation is considered as an important step in the 
development of atherosclerosis, but not a phenomenon which explains the whole 
process. It is probable that the use of dietary and synthetic antioxidants will play a role 
in cardioprotective therapy. To date, most o f the evidence rests on techniques in cell
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biology in vitro based assays with serious methodological draw backs, and will need 
more human studies to reveal the efficacy o f such an approach.
It has been suggested (Shahidi et al 1992) that an ideal, food grade, 
antioxidant, should be safe, not impart colour, odour or flavour; be effective at low 
concentrations; be easy to incorporate; survive after processing; and be stable in the 
finished product (carry through) as well as being available at a low cost.
Growing awareness of the epidemiological link between red wine 
consumption and low incidence of CHD and evidence that this effect is not due to 
alcohol consumption (Gronbeak et al 1995, Day et al 1995), has led to an interest in 
the possibility o f developing drugs containing the putative cardioprotective 
polyphenolic species present in red wine few o f which were used in this study (french 
paradox caps., polyphenon caps.(tea catechin)). Several commercial preparations 
containing red wine extract are already on the market. Since the exact identity o f these 
protective compounds, and their mode of action, is still unknown, (Goldberg et al 
1995, Leake et al 1995) it is not possible to derive a rational strategy for drug 
development, and the value of the existing ‘health food’ medication is questionable. It 
is uncertain whether the manufacturing process extracts the relevant compounds from 
the grape, and whether they are represented in a bioavailable form. It has been 
proposed that whilst a normal diet containing fruit and vegetables is moderately rich in 
polyphenolics they may be relatively unavailable in the absence o f ethanol (Gronbaek 
et al 1995). Notwithstanding this concern, recently Knekt et al (1996) demonstrated 
an association between low intakes of flavonoids and higher risk o f CHD. There is 
little doubt from this study that red wine and extracted red wine polyphenols are 
strong antioxidants and very powerful inhibitors o f LDL oxidation, and that this could 
be mediated through polyphenolic species. The present study has demonstrated that 
consumption of extracted red wine polyphenols and red wine increases in vivo 
protection of LDL from oxidation. It remains to be seen whether this truly indicates 
protection from atherogenesis, but it provides a rationale basis for the further study of 
the benefits of grape derived products. It is essential, however, that the underlying
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biochemical and physiological mechanisms, and potential toxicity, are fully 
understood before their use by the general population.
7.1 Conclusion
CHD has a multi-factorial aetiology. LDL plays an important role in 
atherogenesis as demonstrated by experimental and clinical studies. Lipid peroxidation 
products contained in oxidised LDL are cytotoxic and could be involved in the genesis 
o f necrotic lesions and endothelial cell injury. Theoretically, LDL cytotoxicity can be 
blocked (at least) at two levels: by increasing the resistance of LDL to oxidation or by 
inhibiting oxidation and by preventing (at the cellular level) the cytotoxicity of lipid 
peroxides contained in oxidised LDL. Thus, it is of interest to discover dietary or 
pharmacological compounds which can increase the resistance o f cells to injurious 
effect of oxidised LDL.
This study presents evidence to suggest that dietary polyphenols can be 
absorbed into the blood and may have potentially beneficial cardio-protective effects. 
Since, red wine polyphenols can inhibit LDL oxidation, increase plasma antioxidant 
activity, raise the level of plasma TGF-fi an inhibitor of vascular smooth muscle cell 
proliferation. All these factors are known to be important in the aetiology of 
atherosclerosis. If  the increased antioxidant capacity produced by red wine 
polyphenols has any clinical benefit especially in the prevention o f CHD the use of 
wine polyphenols as a food ingredient could be advantageous. The value o f wine 
polyphenols can only be established by primary or secondary prevention trials in 
relatively large populations or patients with CHD. In view of the biochemical 
evidence of their activity in vivo, such clinical trials would seem worthwhile.
This work has shed new light on the role of polyphenols as antioxidants 
and as potential therapeutic agents. In addition, it has shown that it is possible to 
obtain the antioxidant effects o f red wine using an extract of polyphenols derived from 
red wine. The advantages of red wine polyphenols in a dry form is that they have a 
therapeutic benefit without the possible deleterious effects o f alcohol in causing liver
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damage. People who are prohibited to consume alcohol because o f religious believes, 
can consume and achieve the same effect as red wine. Moreover, developing countries 
where wine is not easily available or expensive could also benefit.
In spite of the emerging relationship between flavonoids and 
antioxidative protection, further investigations are still required to determine which 
forms of flavonoid-derived products in vivo would be effective in humans in 
preventing oxidative and deleterious alterations in lipids and lipoproteins, and thus 
atherogenesis. Further work on the analysis o f the polyphenol composition o f LDL 
after red wine consumption will provide a much needed insight into which further 
information on which polyphenols are absorbed and incorporated into LDL. As Saint 
Leger et al (1979) has pointed out “if wine is ever found to contain a constituent 
protective against IHD, then we consider it almost a sacrilege that this constituent 
should be isolated. The medicine is already in a highly palatable form”.
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Appendix Afi]
WRITTEN EXPLANATION GIVEN TO EACH PARTICIPATING INDIVIDUAL
Title o f  the Study: '‘The influence o f Certain Natural Dietary 
Polyphenols on the Resistance o f Plasma Lipoprotein to oxidation in 
Healthy Volunteers. ”
This study is designed to measure the effects o f  some natural components 
o f  certain foods related to tea, wine, and fruit in respect o f  their ability to 
provide protection from coronary heart disease.
I f  you agree to participate we would ask you to have a sample o f  blood 
(30 to 50ml) taken for testing in the laboratory before taking a food  
extract daily, for two weeks. We will then ask you to return to our 
laboratory for another two blood samples, before and after taking the 
same extract. You will then be given a second extract and the blood 
sampling and dosing procedure will be repeated after the next two weeks. 
There will be a total offive, two-week periods totalling ten weeks. We 
will measure factors in the blood associated with the risk o f  heart 
disease, and find out whether each o f the food extracts has affected 
theses. The study will be performed in a blind fashion, so that two o f  the 
five treatments will be inactive. We shall take a total o f  eleven blood 
samples over the ten week period. One o f  the food components given 
could be alcoholic (red or white wine).
The study will have no adverse effect on your health and no information 
about you will be divulged to any unauthorised person. You are advised 
not to donate blood whilst taking part in this study.
Needless to say, although we hope you will agree to participate in this 
study you are completely free to decline to do so. You may also withdraw 
from the study at any stage. Your treatment and the attitude o f  the 
doctors looking after you will not be prejudiced whatsoever by your 
decision. You will be reimbursed for the time that you have given to the 
study on its completion.
I f  you have any questions regarding this study, please contact Dr.
Norman Williams at Papworth Hospital (tel: 01480 830541 ext. 4691).
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Appendix A[ii]
HUNTINGDON HEALTH A UTHORÏTY
CONSENT BY PATIENT OR VOLUNTEER TO PARTICIPATE IN A CUNICAL 
TRIAL OF THERAPEUTIC PROCEDURE/DRUG OR OTHER CLINICAL 
RESEARCH
/  :...........................................................................
hereby fu lly  and freely consent to participate in the Investigation entitled:
 The influence of Certain Natural Dietary Polyphenols on the Resistance of .............................
.............................Plasma Lipoproteins to Oxidation in Healthy Volunters ....................................
I understand and acknowledge that the Investigation is designed to add to medical 
knowledge. I note that I may withdraw my consent at any stage in the Investigation 
and I acknowledge that the purpose of the Investigation, the risks involved from drugs 
or other procedures, and the nature and purpose of such procedures have been 
explained to me by
and that I have had an opportunity to discuss these matters with him/her.
I consent to the disclosure of personal information Tunder the Data Protection 
ActI in relation to this research project.
I have received a written explanation of these matters, a copy of which is on the 
reverse of this form.
Signed................................................... Date.....................................................
Witness to the fact that he/she read the document and freely given his/her consent.
Address...........................................................................................................................
Occupation....................................................................................................................
Signed........................................................Date..................................................
(Witness must not be a member of project team).
I confirm that I have explained to the patient/volunteer the nature and effect of 
these procedures and handed him/her a duplicate copy of this form.
Signed...................................................  Date............................................................
(Member of project team acting on behalf of Physician/Surgeon responsible for 
Investigation).
Name of researcher responsible for investigation......................................................
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Q uestionnaire for the wine study
Study N um ber:........................................  D ate:.........
Surnam e:..................................................  Forenames:
Address:............................................................................ .
Postcode.............................................................................................................................
Tel. N o .:........................................ (day)....................................................... (evening)
Date of B irth :......................................GP Name........................................................
GPs A ddress:...................................................................................................................
Do you smoke   If yes how long & how many...................................
Do you drink wine...................red..........................white............................. ..........
How often do you drink wine...................................................................................
Do you take Aspirin..................................  How often..................................
When was the last time you took Aspirin...................... .......................................
Are you taking any medication (including HRT or vitamin supplements)? 
YES/NO   If YES, please give details:.......................................................
Have you suffered from any serious illness (e.g. Diabetes, heart disease, etc.)
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Appendix A[iv]
V O L U N T E E R S  M E D IC A T . S H E E T  
SUBJECT NAME: ...............................................................................
D A T E :.......................................................................................................
SUBJECT:...............................................................................................
FASTED:................................................... ..............................................
W EIG H T:.............................................................................................
H EIG H T:.................................................................................................
CARBON MONOXIDE M ETER:.....................................................
BLO O DS:......................................................................................... .......
BLOOD PRESSURE & PU LSE:.......................................................
ASPIR IN :.................................................................................................
OTHER M EDICATION:.....................................................................
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WTNE STUDY
DATE:
TREATMENT:
NAME: 
SUBJECT NO.
BLEEDING
TIME
DRINKING
TIME
SAMPLES
COLLECTED
BLOOD 
PRESSURE 
& PULSE
COMMENTS
TART FINISH
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APPENDIX B : Biochemical measurements
Table B l.l :  Conecentration o f total cholesterol, HDL cholesterol, LDL cholesterol, 
and triglycerides in plasma. Before [day 0] and after [day 14] 
supplementation, results are MEAN ± SD, paired t-test.
Supplement Cholesterol HDL cholesterol LDL cholesterol Triglycerides
mmol/1
Red wine (n = 9)
Baseline 
After 2 wk 
Change 
P-value
5.69 ±1.41 
5.76 ± 0.93 
0.07 ± 0.84 
0.82
0.94 ± 0.27 
0.96 ±0.15 
0.01 ±0.18 
0.87
3.82 ± 1.20 2.03 ± 0.75
3.84 ±0.99 2.06 ± 0.90
0.02 ± 0.63 0.02 ± 1.20
0.92 0.96
White wine (n = 9)
Baseline 
After 2 wk 
Change 
P-value
5.76 ± 1.20 
5.70 ± 1.35 
-0.06 ± 0.57 
0.78
0.99 ±0.21 
1.02 ±0.21 
0.03 ± 0.06 
0.081
3.76 ±0.99 
3.71 ± 1.14 
-0.04 ± 0.45 
0.78
2.29 ± 0.75 
2.09 ± 0.72 
-0.20 ± 0.33 
0.11
White wine + Ig polyphenol powder (n = 9)
Baseline 
After 2 wk 
Change 
P-value
6.03 ± 1.37 
6.08 ± 1.13 
0.05 ± 0.49 
0.82
1.18±0.12 
1.25 ±0.15 
0.07 ± 0.05 
0.025
4.13 ± 1.05 
4.22 ± 0.96 
0.08 ± 0.25 
0.46
1.63 ± 1.20 
1.35 ±0.76 
-0.28 ± 0.49 
0.21
Polyphenol powder Ig (n = 9)
Baseline 
After 2 wk 
Change 
P-value
5.79 ± 1.05 
5.71 ± 0.99 
-0.08 ± 0.36 
0.54
0.97 ±0.21 
1.00 ±0.30 
0.03 ±0.12 
0.40
3.85 ± 0.90 
3.78 ± 0.66 
-0.07 ± 0.33 
0.56
2.38 ±2.40  
2.08 ± 1.77 
-0.30 ±0 .69  
0.23
Alcohol (n = 6)
Baseline 
After 2 wk 
Change 
P-value
4.14 ±0.71 
4.56 ±0.83 
0.42 ±0.71 
0.22
0.82 ± 0.25 
0.98 ± 0.29 
0.16 ±0.12  
0.035
3.00 ±0.56  
3.18 ±0 .69  
0.18 ±0 .59  
0.50
0.70 ±0.12 
0.88 ± 0.29 
0.18 ±0.22  
0.10
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Effects o f  different supplem ents on plasm a polyphenols:
Individual responses of plasma polyphenols.
Fig.B.l.l(a): Individual results: Plasma polyphenols for sefaeal drink (SD),
PLASMA PO LYPH EN O LS-SEf ACAL DRINK[SD]
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Fig. B .l.l(b): Individual Results: Plasma polyphenols for french paradox (FP),
PLASMA POLYPHENOLS-PRENCH  PARADOX CAPS.[FP]
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Fig. B. 1.1(c): Individual Results: Plasma polyphenols for alcohol (AL),
PLASMA POLYPHENOLS-ALCOHOL ONLY[AL]
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Fig. B. 1.1(d): Individual Results: Plasma polyphenols 
for alcohol+polyphenol powder (AP),
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Individual responses o f plasma polyphenols (mg/g o f protein) at day 0 & 
day 14, with individual subject code.B .l.l(a) for sefaeal drink, B. 1.1(b) for 
french paradox, B.1.1 (c) for alcohol, and B.1.1 (d) for 
alcohol+lg polyphenol powder.
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E ffects o f different supplem ents on plasma polyphenols
Individual responses of plasma polyphenols.
Fig.B. 1.2(a): Individual results: Plasma polyphenols for polyphenol drink (PD),
PLASMA POLYPHENOLS-POLYPHEHOL  DRINK[PD]
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Fig.B. 1.2(b): Individual results: Plasma polyphenols for polyphenol capsules (PT),
PLASMA POLYPHENOLS - POLYPHENOL CAPS-2g [PT]
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Fig.B. 1.2(c): Individual Results: Plasma polyphenols for vitamin E (VE),
PLASMA  POLYPHENOLS-VITAMIN E [VE]
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Fig.B. 1.2(d): Individual Results: Plasma polyphenols for 
vitamin E+polyphenol powder (EP),
PLASMA  POLYPHENOLS-VITAMIN E+1g PP [EP]
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Individual responses o f plasma polyphenols (mg/g o f protein) at day 0 and 
day 14, with individual subject code. B. 1.2(a) for polyphenol drink,
B. 1.2(b) for polyphenol caps., B. 1.2(c) for vitamin E, and 
B.1.2(d) for vitamin El+1 g polyphenol powder.
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Effects o f different supplem ents on plasm a polyphenols
Individual responses o f  plasm a polyphenols.
Fig.B, 1.3(a); Individual results: Plasma polyphenols for endotelon tabs. (EN),
PLASMA POLYPHENOLS-ENDOJELOH  TABS. [EN]
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Fig.B. 1.3(b): Individual Results: Plasma polyphenols for tea catecbin.(TC),
PLASMA PO LYPHENOLS-TEA CATECHIN [TO]
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Fig.B. 1.3(c): Individual Results: Plasma polyphenols for chocolate.(CH),
PLASMA POLYPHENOLS- CHOCOLATE [CH]
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Individual responses o f plasma polyphenols (mg/g o f protein) at day 0 and 
day 14, with individual subject code. B. 1.3(a) for endotelon tabs.,
B. 1.3(b) for tea catechin, B. 1.3(c) for chocolate.
211
E ffects o f different supplem ents on LD L polyphenols;
Individual responses on LDL polyphenols.
Fig. B. 1.4(a): Individual results: LDL polyphenols for white wine (WW),
LDL POLYPHENOLS - WHITE WINE [WW] 0 0  WEEK
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Fig. B. 1.4(b): Individual results: LDL polyphenols for polyphenol drink (PD),
LDL POLYPHENOLS-POLYPHENOL DRINK[PD]
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Fig. B.1.4(c): Individual results: LDL polyphenols for polyphenol caps.2g (PT),
LDL POLYPHENOLS-POLYPHENOL P0WDER2g [PT]
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Fig. B. 1.4(d): Individual results: LDL polyphenols for vitamin E (VE),
LDL POLYPHENOLS-VITAMIN E [VE]
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Selected individual responses o f LDL polyphenols (mg/g o f LDL protein) 
at day o and day 14, with individual subject code B. 1.4(a) for white wine, 
B. 1.4(b) for polyphenol drink, B. 1.4(c) for polyphenol caps., 
and B. 1.4(d) for vitamin E.
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Effects o f d ifferent supplem ents on LDL polyphenols:
Individual responses on LD L polyphenols.
Fig. B. 1.5(a): Individual results: LDL polyphenols for sefaeal drink (SD),
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Fig. B. 1.5(b): Individual results: LDL polyphenols for french paradox (FP),
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Fig. B. 1.5(c): Individual results: LDL polyphenols for alcohol (AL),
LDL POLYPHENOLS-ALCOHOL [AL]
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Fig. B. 1.5(d): Individual results: LDL polyphenols for
alcohol+polyphenol powder (AP),
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Selected individual responses of LDL polyphenols (mg/g of LDL protein) 
at day o and day 14, with individual subject code B. 1.5(a) for sefaeal 
drink, B. 1.5(b) for french paradox, B. 1.5(c) for alcohol, and 
B. 1.5(d) for alcohol+polyphenol powder.
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Effects o f d ifferent supplem ents on LDL polyphenols:
Individual responses on LD L polyphenols.
Fig. B. 1.6(a): Individual results: LDL polyphenols for endotelon tabs.
ra 10
LDL POLYPHENOLS-ENDOTELON  TABS. [EN]
i I
10 WEEK
QAFTER 2 
WEEKS
SUBJECTS
EN12CD EN21CD EN31AB EN30AB EN07EF EN09EF
Fig. B.1.6[b]: Individual results: LDL polyphenols for tea catechin.(TC),
LDL POLYPHENOLS-TEA  CATECHIN [TC]
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Fig. B. 1.6(c): Individual results: LDL polyphenols for 
vitamin E+polyphenol powder.(EP),
LDL POLYPHENOLS- VITAMIN E+1g PP [EP]
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Selected individual responses of LDL polyphenols (mg/g of LDL protein) 
at day o and day,with individual subject code 14. B. 1.6(a) for endotelon 
tabs.,B. 1.6(b) for tea catechin, B. 1.6(c) for vitamin E+ polyphenol powder
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Effects of different supplements on lag time: 
Individual responses in copper lag time.
Fig. B. 1.7(a): Individual results: Lag time for white 
wine+lg polyphenol powder (WP),
LAG TIME WHITE WINE+1g POLYPHENOL POWDER (WP)
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Fig. B. 1.7(b): Individual results: Lag time for tea cateehin (TC),
LAG TIME-TEA CATECHIN [TC]
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Fig. B. 1.7(c): Individual results: Lag time for chocolate (CH),
LAG TIME-CHOCOLATE [CH]
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Fig. B. 1.7(d): Individual results: Lag time for endotelon tabs. (EN),
LAG TIME- ENDOTELON TABS. [EN]
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Individual responses o f lag time (minutes) at day 0 and day 14, with 
individual subject code. B. 1.7(a) for white wine+polyphenol powder,
B. 1.7(b) for tea catechin, B. 1.7(e) for chocolate, B. 1.7(d) for endotelon tabs.
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Effects o f different supplem ents on lag time:
Individual responses in copper lag time.
Fig. B. 1.8(a): Individual results: Lag time for sefaeal drink (SD),
LAG TIME SEFACAL DRINK (SD)
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Fig. B. 1.8(b): Individual results: Lag time for french paradox (FP),
LAG TIME FRENCH PARADOX (FP)
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Fig. B. 1.8(c): Individual results: Lag time for alcohol (AL),
LAG TIME ALCOHOL ONLY (AL)
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Fig. B. 1.8(d): Individual results: Lag time for alcohol+polyphenol powder (AP),
LAG TIME ALC0H0L+1g POLYPHENOL POWDER
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Individual responses of lag time (minutes) at day 0 and day 14, with 
individual subject code.B. 1.8(a) for sefaeal drink, B. 1.8(b) for french 
paradox, B. 1.8(c) for alcohol, B. 1.8(d) for alcohol+polyphenol powder.
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Effects o f different supplem ents on lag time:
Individual responses in copper lag time.
Fig. B. 1.9(a): Individual results: Lag time for polyphenol drink (PD),
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Fig. B. 1.9(b) Individual results: Lag time for polyphenol caps.2g (PT),
LAGTIME POLYPHENOL P0WDER2g. (PT)
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Fig. B. 1.9(c): Individual results: Lag time for vitamin E+polyphenol powder(E).
LAG TIME VITAMIN E +lg POLYPHENOL POWDER (EP)
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Individual responses o f lag time (minutes) at day 0 and day 14, with 
individual subject code.B. 1.9(a) for polyphenol drink, B. 1.9(b) for 
polyphenol caps.2g, B. 1.9(c) for vitamin E+polyphenol powder.
217
Effects o f different supplem ents on plasm a lipid peroxides:
Individual responses of plasma lipid peroxides.
Fig.B. 1.10(a): Individual results: Plasma lipid peroxides for sefaeal drink
PLASMA LIPID PEROXIDES-SEFACAL DRINK [SD]
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Fig.B. 1.10(b): Individual results: Plasma lipid peroxides for french 
paradox (FP),
PLASMA LIPID PEROXIDES-FRENCH PARADOX [FP]
3.0 
2.5
2.0 
| l . 5
l,.o
0.5
0.0
BO WEEK
aAFTER 2 
WEEKS
FP04GH FP07GH FP14GH FP19CD FP41AB FP45AB SUBJECTS
Fig.B. 1.10(c): Individual results: Plasma lipid peroxides for alcohol (AL),
PLASMA LIPID PEROXIDES ALCOHOL ONLY [AL]
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Fig.B. 1.10(d): Individual results: Plasma lipid peroxides for 
alcohol+polyphenol powder (AP),
PLASMA LIPID PEROXIDES- ALCOHOL+1 g POLYPHENOL POWDER [AP]
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Selected individual responses o f plasma lipid peroxides (pmoles/1) at day 
0 and day 14, with individual subject code. B. 1.10(a) for sefaeal drink, 
B.1.10(b) for french paradox, B.1.10(c) for alcohol, and B.1.10(d) for 
alcohol+polyphenol powder.
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E ffects o f different supplem ents on plasm a lipid peroxides:
Individual responses of plasma lipid peroxides.
Fig.B. 1.11(a): Individual results: Plasma lipid peroxides for polyphenol drink (PD),
PLASMA LIPID PEROXIDES- POLYPHENOL DRINK [PD]
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Fig.B. 1.11(b): Individual results: Plasma lipid peroxides for polyphenol caps. (PT),
PLASMA LIPID PEROXIDES- POLYPHENOL CAPS.-2g [PT]
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Fig.B. 1.11(c): Individual results: Plasma lipid peroxides for vitamin E (VE),
PLASMA LIPID PEROXIDES-VITAMIN E [VE]
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Fig.B. 1.11(d): Individual results: Plasma hpid peroxides for vitamin E+polyphenol
powder (EP),
PLASMA LIPID PEROXIDES-VITAMIN E +lg PP [EP]
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Selected individual responses of plasma lipid peroxides (pmoles/1) at day 
0 and day 14, with individual subject code. B.1.11(a) for polyphenol drink, 
B.l.11(b) for polyphenol caps., B.l.11(c) for vitamin E, and 
B.1.11(d) for vitamin E+polyphenol powder.
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Effects o f different supplem ents on plasm a lipid peroxides:
Individual responses of plasma lipid peroxides.
Fig.B. 1.12(a): Individual results: Plasma lipid peroxides for endotelon tabs. (EN),
PLASMA LIPID PEROXIDES-ENDOTELON TABS. [EN]
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Fig.B. 1.12(b): Individual results: Plasma lipid peroxides for tea catechin (TC),
PLASMA LIPID PEROXIDES-TEA CATECHIN [TC]
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Fig.B. 1.12(c): Individual results: Plasma lipid peroxides for chocolate (CH).
PLASMA LIPID PEROXIDES-CHOCOLATE [CH]
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Selected individual responses o f plasma lipid peroxides (pmoles/1) at day 
0 and day 14, with individual subject code. B .l. 12(a) for endotelon tabs., 
B .l. 12(b) for tea catechin., B .l. 12(c) for chocolate.
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E ffects o f d ifferent supplem ents on LDL lipid peroxides:
Individual responses of LDL lipid peroxides.
Fig.l.l3.(a): Individual results: LDL lipid peroxides for sefaeal drink (SD),
LDL LIPID PEROXIDES-SEFACAL DRINK [SD]
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Fig .L I3.(b): Individual results: LDL lipid peroxides for french paradox (FP),
LDL LIPID PEROXIDES -FRENCH PARADOX [FP]
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Fig. 1.13.(c): Individual results: LDL lipid peroxides for alcohol (AL),
LDL LIPID PEROXIDES - ALCOHOL ONLY [AL]
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Fig. 1.13.(d): Individual results: LDL Hpid peroxides for alcohol+polyphenol 
___________powder (AP), ____________________________________ __
LDL LIPID PEROXIDES- ALC 0H 0L+1g POLYPHENOL POWDER [AP]
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Individual responses of LDL lipid peroxides (pmoles/g LDL protein) at day 
0 and day 14 with individual subject code. B .l. 13(a) for sefaeal drink,
B.L 13(b) for french paradox, B.L 13(c) for alcohol, and B.L 13(d) for 
alcohol+polyphenol powder.
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Effects o f different supplem ents on LD L lipid peroxides:
Individual responses o f LD L lipid peroxides.
Fig. 1.14.(a): Individual results: LDL lipid peroxides for polyphenol drink (PD),
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Fig.l.l4.(b): Individual results: LDL lipid peroxides for polyphenol caps. (PT),
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Fig.l .14.(c): Individual results: LDL lipid peroxides for vitamin E (VE),
LDL LIPID PEROXIDES-VITAMIN E [VE]
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Fig.l.l4.(d): Individual results: LDL lipid peroxides for vitamin E+polyphenol 
powder (EP),
LDL LIPID PEROXIDES- VITAMIN E+1gPP[EP]
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Individual responses o f LDL lipid peroxides (pmoles/g LDL protein) at day 0 
and day 14 with individual subject code. B .l. 14(a) for polyphenol drink,
B .l. 14(b) for polyphenol caps., B .l. 14(c) for vitamin E, B .l. 14(d) for 
vitamin E+polyphenol powder.
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Effects o f different supplem ents on LD L lipid peroxides:
Individual responses o f LD L lipid peroxides.
Fig. 1.15.(a): Individual results: LDL lipid peroxides for endotelon tabs. (EN),
LDL LIPID PEROXIDES-ENDOTELON TABS. [EN]
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Fig. 1.15.(b): Individual results: LDL lipid peroxides for tea catechin (TC),
LDL LIPID PEROXIDES- TEA CATECHIN [TC]
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Fig. 1.15.(c): Individual results: LDL lipid peroxides for chocolate (CH).
LDL LIPID PEROXIDES- CHOCOLATE [CH]
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Individual responses o f LDL lipid peroxides (pmoles/g LDL protein) at 
day Oand day 14 with individual subject code. B .l. 15(a) for endotelon 
tabs., B.1.15(b) for tea catechin, B.1.15(c) for chocolate.
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Effects o f different supplem ents on LD L TEARS:
Individual responses for LD L TEARS.
Fig. B.l. 16(a): Individual results: LDL TEARS for sefaeal drink (SD),
LDL TBARS- SEFACAL DRINK [SD]
HOWEEK
40
BARTER 2 
WEEKS30 I
Ô 0.
SUBJECTSSD15ASD12A SD13ASD10A
Fig. B.L 16(b): Individual Results: LDL TBARS for french paradox (FP),
LDL TBARS- FRENCH PARADOX [FP]
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Fig. B.l .16(c): Individual Results: LDL TBARS for alcohol (AL),
LDL TBARS- ALCOHOL [AL]
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Fig. B.L 16(d): Individual Results: LDL TBARS for alcohol+polyphenol 
powder (AP),
LDL TBARS- A LC 0H 0L+1g POLYPHENOL POWDER [AP]
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Individual responses o f TBARS (pmoles/g LDL protein) at day 0 and 
day 14 with individual subject code. B.1.16(a)for sefaeal drink,
B.1.16(b) for french paradox, B.1.16(c) for alcohol, and 
B.1.16(d) for alcohol+polyphenol powder.
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Effects of different supplements on LDL TBARS: 
Individual responses for LDL TBARS.
Fig. B .l. 17(a): Individual results: LDL TBARS for polyphenol drink (PD),
LDL TBARS-POLYPHENOL DRINK[PD]
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Fig. B .l. 17(b): Individual results: LDL TBARS for polyphenol caps.(PT),
LDL TBARS- POLYPHENOL CAPS.2g [PT]
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Fig. B.1.17(c): Individual Results: LDL TBARS for vitamin E (VE),
LDL TBARS- VITAMIN E [VE]
35
30
25 1
c 20 +
1 15 'Q. 10 i
5 +
0 -
VE25GH VE28EF VE29GH VE30EF
HOWEEK
□  AFTER 2 
WEEKS.
SUBJECTS
Fig. B.L 17(d): Individual Results: LDL TBARS for vitamin E+polyphenol 
powder (EP),
LDL TBARS- VITAMIN E +lg PP [EP]
Q
c
O) ÔJ
Ô Û. 
E
40
30
20
10
0
□  OWEEK
□  AFTER 2 
WEEKS.
EP19EF EP37CD EP41CD EP46CD SUBJECTS
Individual responses o f TBARS (pmoles/g LDL protein) at day 0 and 
day 14 with individual subject code. B .l. 17(a) for polyphenol drink, 
B.L 17(b) for polyphenol caps., B.L 17(c) for vitamin E, and 
B.1.17(d) for vitamin E+polyphenol powder.
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Effects o f d ifferent supplem ents on LD L TBARS:
Individual responses for LD L TBARS.
Fig. B.l .  18(a): Individual results: LDL TBARS for endotelon tabs. (EN),
50
I  40
Q
_ i
5 » 20
i  10 I
EN12CD
LDL TBARS-ENDOTELON TABS. [ENJ
m
EN21CD EN30AB EN31AB EN07EF
HOWEEK
HAFTER 2 
WEEKS
SUBJECTS
EN09EF
Fig. B .L  18(b): Individual Results: LDL TBARS for tea catechin (TC),
LDL TBARS- TEA CATECHIN [TC]
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Fig. B. l .  18(c): Individual Results: LDL TBARS for chocolate (CH),
LDL TBARS- CHOCOLATE[CH]
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Individual responses o f TBARS (pmoles/g LDL protein) at day 0 
and day 14 with individual subject code.B. 1.18(a) for endotelon 
tabs., B.1.18(b) for tea catechin, B.1.18(c) for chocolate.
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E ffects o f different supplem ents on plasm a TAS:
Individual responses o f plasm a TAS
Fig. 6.19(a): Individual results: Plasma TAS for alcohol (AL),
PLASMA TAS-ALCOHOL ONLY [AL]
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Fig. 6.19(b): Individual results: Plasma TAS for alcohol+polyphenol 
powder (AP), ______________ ____________
PLASMA TAS- A LC 0H 0L+1g POLYPHENOL POWDER [AP]
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Fig. 6 .19(c): Individual results: Plasma TAS for vitamin E (VE),
PLASMA TAS- VITAMIN E ONLY [VE]
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Fig. 6.19(d): Individual results: Plasma TAS for vitamin E+polyphenol 
powder (EP),
PLASMA TAS- VITAMIN E+1g PP [EP]
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Individual responses of TEARS (mmoFl) at day 0 and day 14 with subject
code. B. 1.19(a) for alcohol, B. 1.19(b) for alcohol+ polyphenol powder,
B. 1.19(c) for vitamin E, B. 1.19(d) for vitamin E+polyphenol powder.
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Effects of different supplements on plasma TAS: 
Individual responses of plasma TAS
Fig.B. 1.20(a): Individual results: Plasma TAS for chocolate (CH),
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Individual response of TBARS (mmoFl) at day 0 and day 14 
with subject code. B. 1.20(a) for chocolate.
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Effects of different supplementation on plasma TGF-B 
Individual responses of plasma TGF-B (latent+active) 
by Quantikine kit
Fig.B. 1.21(a): Idividual results: Plasma TGF-B (latent + active) for 
white wine+polyphenol powder (WP),
TGF-B LATENT & ACTIVE [R&D KIT]- 
WHITE WINE+1g POLYPHENOL POWDER[WP]
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Fig.B.1.21(b): Idividual results: Plasma TGF-B (latent + active) for polyphenol 
powder2g (PT),
TGF-BLATENT & ACTIVE (R&D KIT)- POLYPHENOL CAPS 2g [PT]
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Fig.B.1.21(c): Idividual results: Plasma TGF-B (latent + active) for vitamin E (VE
TGF-B LATENT & ACTIVE (R&D KIT)- 
VITAMIN E [VE]
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Fig. B.1.21(d): Idividual results: Plasma TGF-B (latent + active) for 
vitamin E+polyphenol powder (EP)
TGF-B LATENT & ACTIVE (R&D KIT)- 
VITAMIN E+lgPP [EP]
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Individual responses o f Plasma TGF-B (latent + active) in ng/ml at day 0 
and day 14, with subject code. B. 1.21(a) for white wine+polyphenol powder, 
B. 1.21(b) for polyphenol caps., B. 1.21(c) for vitamin E, and 
B. 1.21(d) for vitamin E+polyphenol powder.
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Effects of different supplementation on plasma TGF-B 
Individual responses of plasma TGF-B (latent+active) 
by Quantikine kit
Fig.B. 1.22(a): Individual results: Plasma TGF-B (latent + aetive) for sefaeal 
drink (SD), ______________________________________ ___
TGF-B LATENT & ACTIVE (R&D KIT)- 
SEFACAL DRINK [SD]
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Fig.B. 1.22(b): Individual results: Plasma TGF-B (latent + aetive) for french 
paradox (FP),
TGF-B LATENT & ACTIVE (R&D KIT)- 
FRENCH PARADOX CAPS.[FP]
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Fig.B. 1.22(c): Individual results: Plasma TGF-B (latent + active)for alcohol (AL),
TGF-B LATENT & ACTIVE (R&D) KIT- 
ALCOHOL ONLY[AL]
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Fig.B. 1.22(d): Individual results: Plasma TGF-B (latent + active) for 
alcohol+polyphenol powder (AP),
TGF-B LATENT & ACTIVE (R&D KIT)- ALC0H0L+1g PP [AP]
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Individual responses of plasma TGF-B (latent + active) in ng/ml at day 0 and
day 14 with subject code. B. 1.22(a) for sefaeal drink, B. 1.22(b) for french
paradox, B. 1.22(c) for alcohol, B. 1.22(d) for alcohol+polyphenol powder.
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Effects of different supplementation on plasma TGF-B 
Individual responses of plasma TGF-B (latent+active) 
by Quantikine kit
Fig.B. 1.23(a): Individual results: Plasma TGF-B (latent + active) for 
endotelon tabs. (EN),_________________________
TGF-B LATENT & ACTIVE (R&D KIT)- 
ENDOTELON TABS. [EN]
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Fig.B. 1.23(b): Individual results: Plasma TGF-B (latent + active) for 
tea cateehin (TC),
TGF-B LATENT & ACTIVE (R&D KIT)- 
TEA CATECHIN [TC]
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Fig.B. 1.23(e): Individual results: Plasma TGF-B (latent + active) for chocolate (CH
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Individual responses of plasma TGF-B (latent + active) in ng/ml at day 0 and 
day 14 with subject code. B. 1.23(a) for endotelon tabs., B. 1.23(b) for tea 
cateehin, and B. 1.23(c) for chocolate.
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Effects of different supplementation on plasma TGF-B 
Individual responses of plasma TGF-B (active) using 
BDA-19 antibody.
Fig B. 1.24(a): Individual results: Plasma TGF-B (aetive) for 
white wine+polyphenol powder (WP),
TGF-a ACTIVE- WHITE WINE+1a POLYPHENOL POWDERfWP]
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Fig B. 1.24(b): Individual results: Plasma TGF-B (active) for polyphenol caps. 
(PT),________________________________
TGF-a ACTIVE- POLYPHENOL CAPS.2a IPTl
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Fig B. 1.24(c): Individual results: Plasma TGF-B (active)or vitamin E (VE),
TGF-a ACTIVE- VITAMIN E fVEl
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Fig B. 1.24(d): Individual results: Plasma TGF-B (active) for 
vitamin E+polyphenol powder (EP).
TGF-a ACTIVE-VITAMIN E+1aPP FEP1
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Individual responses o f plasma TGF-B (active) in ng/ml at day 0 and day 14 
with subject code.B. 1.24(a) for white wine+polyphenol powder, B. 1.24(b) for 
polyphenoleaps., B. 1.24(c) for vitamin E and B. 1.24(d) for 
vitamin E+polyphenol powder.
232
Effects of different supplementation on plasma TGF-B 
Individual responses of plasma TGF-B (active) using 
BDA-19 antibody.
Fig.B. 1.25(a): Individual results: Plasma TGF-B (aetive) for sefaeal drink (SD),
TGF-a ACTIVE-SEFACAL DRINK fSD l
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Fig.B. 1.25(b): Individual results: Plasma TGF-B (active) for polyphenol eaps.(PT]
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Fig.B. 1.25(c): Individual results: Plasma TGF-B (active) for alcohol (AL),
TGF-a ACTIVE-ALCOHOL ONLYfALI
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Fig.B. 1.25(d): Individual results: PlasmaTGF-B (active) for 
alcohol+polyphenol powder (AP).
TGF-a ACTIVE- ALC 0H 0L+1a PP FAPl
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Individual responses of plasma TGF-B (active) in ng/ml at day 0 and day 14
with subject code.B. 1.25(a) for sefaeal drink, B. 1.25(b) for french paradox,
B. 1.25(c) for alcohol, and B. 1.25(d) for alcohol+polyphenol powder.
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Effects of different supplementation on plasma TGF-B 
Individual responses of plasma TGF-B (active) using 
BDA-19 antibody.
Fig.B. 1.26(a): Individual results: Plasma TGF-B (active) for endotelon tabs. (EN),
TGF-R ACTIVE- ENDOTELON TABS. fENl
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Fig.B.1.26(b): Individual results: Plasma TGF-B (active) for tea cateehin (TC),
TGF-B ACTIVE- TEA CATECHIN FTCl
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Fig.B. 1.26(c): Individual results: Plasma TGF-B (active) for chocolate (CH).
TGF-B ACTIVE- CHOCOLATE fCHI
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Individual responses of plasma TGF-B (active) in ng/ml at day 0 and 
day 14 with subject code.B. 1.26(a) for endotelon tabs., B. 1.26(b) for 
tea cateehin, B. 1.26(c) for chocolate.
